<SEC-DOCUMENT>0001104659-20-027472.txt : 20200302
<SEC-HEADER>0001104659-20-027472.hdr.sgml : 20200302
<ACCEPTANCE-DATETIME>20200302070737
ACCESSION NUMBER:		0001104659-20-027472
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200301
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200302
DATE AS OF CHANGE:		20200302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		20674188

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2011253d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:gild="http://gilead.com/20200301">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_gild_gilead.com_20200301 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20200229_20200301 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityCentralIndexKey">0000882095</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="gild-20200301.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-02-29to2020-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-29</xbrli:startDate>
        <xbrli:endDate>2020-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: none; font-size: 14pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20200229__20200301_zjLzMMaEj5Fl"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>of the
Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of  Earliest
Event Reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20200229__20200301_zcq6x7oj2dR"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 1,
2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span><b>&#160;</b></span></p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--EntityRegistrantName_c20200229__20200301_zrlLLTHKJgY2"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityRegistrantName"><b>Gilead
Sciences, Inc.</b></ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in its Charter)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 34%; font-size: 10pt; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20200229__20200301_zpTKIxQBdCo6"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b><br />
    <b>(State or Other <br />
    Jurisdiction<br />
    of Incorporation)</b></td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_90D_edei--EntityFileNumber_c20200229__20200301_zIRWR8JmXgTf"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityFileNumber">0-19731</ix:nonNumeric></span></b><br />
    <b>(Commission File Number)</b></td>
    <td style="white-space: nowrap; width: 34%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20200229__20200301_zOB2n5gB5x2f"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityTaxIdentificationNumber">94-3047598</ix:nonNumeric></span></b><br />
        <b>(I.R.S. Employer</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20200229__20200301_zCD9q4l4mQi4" style="font-size: 10pt"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityAddressAddressLine1">333
    Lakeside Drive</ix:nonNumeric></span></b><br />
<b><span style="font-size: 10pt"> <span id="xdx_90D_edei--EntityAddressCityOrTown_c20200229__20200301_ztweApsK5BBj"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityAddressCityOrTown">Foster
    City</ix:nonNumeric></span></span></b><b><span style="font-size: 10pt">, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20200229__20200301_zdq0szQgI3hg"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></span></b></td>
    <td style="text-align: center; width: 50%"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20200229__20200301_zpK4oCNKebIf" style="font-size: 10pt"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:EntityAddressPostalZipCode">94404</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>(Address of Principal
    Executive Offices)</b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90F_edei--CityAreaCode_c20200229__20200301_zNQr6sT9Wbp"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:CityAreaCode">650</ix:nonNumeric></span></b><b>) <span id="xdx_906_edei--LocalPhoneNumber_c20200229__20200301_zbl6q4Bj5rT6"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:LocalPhoneNumber">574-3000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Not Applicable</b><br />
<b>(Former Name or Former Address, if Changed Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20200229__20200301_zs0UllhYZ2Gb"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>                                                                                                                                                                                                                                                                                                       <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20200229__20200301_zsNBeMlzLFRi"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>                                                                                                                                                                                                                                                                                                     <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20200229__20200301_zXFS7JLHEK3d"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:booleantrue" name="dei:PreCommencementTenderOffer">&#120;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20200229__20200301_zvgAwDkhJ0V2"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding: 2pt; width: 34%; text-align: center; vertical-align: bottom">Title of each class</td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; width: 32%; text-align: center; vertical-align: bottom">Trading Symbol(s)</td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; width: 34%; text-align: center; vertical-align: bottom">Name of each exchange on which<br />
 registered</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt; text-align: center"><span id="xdx_900_edei--Security12bTitle_c20200229__20200301_zl6bA6mRahpb"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; text-align: center"><span id="xdx_90D_edei--TradingSymbol_c20200229__20200301_zMKwqAv4MCbb"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" name="dei:TradingSymbol">GILD</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt; text-align: center"><span id="xdx_90B_edei--SecurityExchangeName_c20200229__20200301_zAnZ3nG7kg7g"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20200229__20200301_z4sGf671hYei"><ix:nonNumeric contextRef="From2020-02-29to2020-03-01" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font-size: 10pt; vertical-align: top">
    <td style="width: 1.25in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item&#160;1.01.</b></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 1, 2020, Gilead Sciences, Inc., a Delaware corporation
(&#8220;<span style="text-decoration: underline">Parent</span>&#8221; or &#8220;<span style="text-decoration: underline">Gilead</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger
Agreement</span>&#8221;), among Parent, Forty Seven, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Forty Seven</span>&#8221;), and Toro Merger
Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Merger Agreement, and upon the terms and subject
to the conditions thereof, Purchaser will commence a tender offer (the &#8220;<span style="text-decoration: underline">Offer</span>&#8221;), to purchase all of the issued
and outstanding shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of common stock, par value $0.0001 per share, of Forty Seven other than
any Shares held immediately prior to the effective time of the Merger by Forty Seven (or held in Forty Seven&#8217;s treasury)
and any Shares held immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or indirect
wholly owned subsidiary of Parent at a price of $95.50 per Share (the &#8220;<span style="text-decoration: underline">Offer Price</span>&#8221;), net to the seller in cash,
without interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offer will initially remain open for a minimum of 20 business
days from the date of commencement of the Offer. If at the scheduled expiration time of the Offer any of the conditions to the
Offer have not been satisfied (unless such condition is waivable by Purchaser or Parent and has been waived), Purchaser will, and
Parent will cause Purchaser to, extend the Offer to permit the satisfaction of all Offer conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The obligation of Purchaser to consummate the Offer is subject
to the satisfaction or waiver of customary conditions, including, among others, (i)&#160;there being validly tendered and not validly
withdrawn prior to the expiration of the Offer a number of Shares that, considered together with all other Shares (if any) owned
by Parent and its affiliates, comprise one more Share than 50% of the sum of the then-outstanding Shares plus Shares issuable upon
conversion of all vested and outstanding options at the expiration of the Offer, (ii)&#160;the expiration or termination of the
waiting period (or any extension thereof) applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended (the &#8220;<span style="text-decoration: underline">HSR Act</span>&#8221;), (iii)&#160;the absence of any law or order prohibiting the consummation of the Offer
or the Merger and other customary conditions set forth in Annex I to the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the consummation of the Offer and subject to the terms
and conditions of the Merger Agreement, Purchaser will merge with and into Forty Seven pursuant to Section 251(h) of the General
Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;), with Forty Seven being the surviving corporation (the
&#8220;<span style="text-decoration: underline">Merger</span>&#8221;). At the effective time of the Merger, each Share, including any Shares subject to vesting or employment
based forfeiture conditions (other than (i) Shares held by Forty Seven (or held in Forty Seven&#8217;s treasury), (ii) Shares held
by Parent, Purchaser, or any other direct or indirect wholly owned subsidiary of Parent and (iii) Shares held by stockholders who
have properly exercised and perfected their demands for appraisal of such Shares in accordance with the DGCL and have neither withdrawn
nor lost such rights prior to the effective time) will be converted into the right to receive an amount in cash equal to the Offer
Price, without interest, without regard to any applicable vesting or employment based forfeiture conditions, and subject to any
required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement includes customary representations, warranties
and covenants of Forty Seven, Parent and Purchaser.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forty Seven has agreed to customary &#8220;no-shop&#8221; restrictions
on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations with third
parties regarding alternative acquisition proposals. Notwithstanding these restrictions, Forty Seven may under certain circumstances
provide information to and participate in discussions or negotiations with third parties with respect to a bona fide written alternative
acquisition proposal that the board of directors of Forty Seven has determined constitutes or would reasonably be expected to result
in a Superior Offer (as defined in the Merger Agreement), if failing to do so would be inconsistent with the board&#8217;s fiduciary
duties under applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement also provides that, in connection with
the termination of the Merger Agreement under specified circumstances, including termination by Forty Seven to accept and enter
into an agreement with respect to a Superior Offer (as defined in the Merger Agreement), Forty Seven will pay Parent a termination
fee of $160 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Merger Agreement and the transactions
contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which
is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed to provide information
to investors regarding its terms. It is not intended to provide any other factual information about Parent, Purchaser or Forty
Seven, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation
of the Offer, the Merger or the other transactions contemplated by the Merger Agreement. The Merger Agreement and this summary
should not be relied upon as disclosure about Parent or Forty Seven. None of Forty Seven&#8217;s stockholders or any other third
parties should rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual
state of facts or conditions of Parent, Purchaser, Forty Seven or any of their respective subsidiaries or affiliates. The Merger
Agreement contains representations and warranties that are the product of negotiations among the parties thereto and that the parties
made to, and solely for the benefit of, each other as of specified dates. The assertions embodied in those representations and
warranties are subject to qualifications and limitations agreed to by the respective parties and are also qualified in important
part by confidential disclosure schedules delivered in connection with the Merger Agreement. The representations and warranties
may have been made for the purpose of allocating contractual risk between the parties to the agreements instead of establishing
these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those
applicable to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1.25in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item&#160;8.01.</b></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other Events.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 2, 2020, Parent and Forty Seven issued a joint press
release announcing their entry into the Merger Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report on
Form 8-K and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1.25in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item&#160;9.01.</b></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Exhibits.</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(d) Exhibits</span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Exhibit Number</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Description</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left"><a href="tm2011253d2_ex2-1.htm">2.1*</a></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: left"><a href="tm2011253d2_ex2-1.htm">Agreement and Plan of Merger, dated March 1, 2020, among Forty Seven, Inc., Gilead Sciences, Inc. and Toro Merger Sub, Inc.</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="tm2011253d2_ex99-1.htm">99.1</a></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="tm2011253d2_ex99-1.htm">Joint Press Release, dated March 2, 2020.</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">104</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1.5%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="width: 98.5%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Schedules omitted pursuant to Item&#160;601(b)(2) of Regulation S-K. Gilead agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Forward-Looking Statements </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K contains forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition
of Forty Seven by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements of historical
fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or
current expectation of the companies&#8217; and members of their senior management team. Forward-looking statements include, without
limitation, statements regarding the business combination and related matters, prospective performance and opportunities, post-closing
operations and the outlook for the companies&#8217; businesses, including, without limitation, the ability of Gilead to advance
Forty Seven&#8217;s product pipeline, including magrolimab, FSI-174 and FSI-189; regulatory approval of magrolimab, FSI-174 and
FSI-189 on a timely basis; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials;
filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete
the transaction considering the various closing conditions; difficulties or unanticipated expenses in connection with integrating
the companies; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on
these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks
and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking
statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Forty Seven&#8217;s
stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various
closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay
or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees,
other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions,
if any; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or
political conditions outside of the companies&#8217; control; transaction costs; actual or contingent liabilities; and other risks
and uncertainties detailed from time to time in the companies&#8217; periodic reports filed with the U.S. Securities and Exchange
Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports
on Form 10-K, as well as the Schedule 14D-9 to be filed by Forty Seven and the Schedule TO and related tender offer documents
to be filed by Gilead and Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based
on information currently available to Gilead and Forty Seven, and Gilead and Forty Seven assume no obligation and disclaim any
intent to update any such forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Additional Information and Where to Find It</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tender offer described in this Current Report on
Form 8-K has not yet
commenced. This Current Report on
Form 8-K is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer
to sell shares of Forty Seven, nor is it a substitute for any tender offer materials that Gilead, its acquisition company or Forty
Seven will file with the SEC. A solicitation and an offer to buy shares of Forty Seven will be made only pursuant to an offer to
purchase and related materials that Gilead intends to file with the SEC. At the time the tender offer is commenced, Gilead will
file a Tender Offer Statement on Schedule TO with the SEC, and Forty Seven will file a Solicitation/Recommendation Statement on
Schedule 14D-9 with the SEC with respect to the tender offer. FORTY SEVEN&#8217;S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO
READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER
DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY
BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain
other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Forty Seven
at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free
at the SEC's web site at www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Forty Seven. Free copies
of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing
requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Copies of
the documents filed with the SEC by Forty Seven will be available free of charge under the &#8220;Investors&#8221; section of Forty
Seven&#8217;s internet website at ir.fortyseveninc.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the Offer to Purchase, the related Letter of
Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Forty Seven
file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead&#8217;s and Forty Seven&#8217;s
filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained
by the SEC at www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0.5in; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0.5in; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0.5in; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">
<tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td colspan="3" style="font-size: 10pt"><span style="font-size: 10pt">GILEAD SCIENCES, INC.</span></td></tr>
<tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; width: 42%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">By:</span><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">/s/ Daniel P. O&#8217;Day</span></td></tr>
<tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Name:</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Daniel P. O&#8217;Day</span></td></tr>
<tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;<span style="font-size: 10pt"> </span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left">Title:</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: March 2, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LpqWKto3LSpiFSkivka7SrDNlk38O5K3NLaIy8KyzHwzQoRiQXNdIcNhWuSww7qplEMo8IyM5oTekS1XKfhb4EVbx8q49v2BGXkGPTPoyePJC631ri2WKchRP0760RjkMB0kMFmL4KtnZM66ROO0qkCZErZMDWt0il9dwk49yVD9aqv2yFaTSSHqyU5+QyyjGDZ0Vw/iq4U8z0QQthOIBdOt+dbcrKMaZhXWvst26H+DDzhySXg= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2011253d2_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 2.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>CONFIDENTIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>EXECUTION COPY</U></P>



<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">among:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORTY SEVEN,&nbsp;INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">a Delaware corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GILEAD SCIENCES,&nbsp;INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">a Delaware corporation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TORO MERGER SUB,&nbsp;INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">a Delaware corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of March&nbsp;1, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE OFFER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">1.1</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">The Offer</FONT></TD><TD STYLE="width: 10%">2</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">1.2</TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt"></FONT><FONT STYLE="font-size: 10pt">Company Actions</FONT></TD><TD STYLE="width: 10%">4</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MERGER TRANSACTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.1</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Merger of Purchaser into the Company</FONT></TD><TD STYLE="width: 10%">6</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.2</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Effect of the Merger</FONT></TD><TD STYLE="width: 10%">6</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.3</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Closing; Effective Time</FONT></TD><TD STYLE="width: 10%">6</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.4</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Certificate of Incorporation and Bylaws; Directors and Officers</FONT></TD><TD STYLE="width: 10%">6</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.5</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Conversion of Shares</FONT></TD><TD STYLE="width: 10%">7</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.6</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Surrender of Certificates; Stock Transfer Books</FONT></TD><TD STYLE="width: 10%">8</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.7</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Dissenters&rsquo; Rights</FONT></TD><TD STYLE="width: 10%">10</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.8</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Treatment of Company Options</FONT></TD><TD STYLE="width: 10%">11</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">2.9</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Further Action</FONT></TD><TD STYLE="width: 10%">11</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.1</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Due Organization; Subsidiaries, Etc.</FONT></TD><TD STYLE="width: 10%">12</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.2</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></TD><TD STYLE="width: 10%">12</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.3</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Capitalization, Etc.</FONT></TD><TD STYLE="width: 10%">12</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.4</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Authority; Binding Nature of Agreement</FONT></TD><TD STYLE="width: 10%">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.5</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">SEC Filings; Financial Statements</FONT></TD><TD STYLE="width: 10%">14</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.6</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Absence of Changes; No Material Adverse Effect</FONT></TD><TD STYLE="width: 10%">16</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.7</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Title to Assets</FONT></TD><TD STYLE="width: 10%">17</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.8</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Real Property</FONT></TD><TD STYLE="width: 10%">17</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.9</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Intellectual Property</FONT></TD><TD STYLE="width: 10%">17</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.10</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Contracts</FONT></TD><TD STYLE="width: 10%">19</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.11</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Liabilities</FONT></TD><TD STYLE="width: 10%">21</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.12</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Compliance with Legal Requirements</FONT></TD><TD STYLE="width: 10%">22</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.13</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Regulatory Matters</FONT></TD><TD STYLE="width: 10%">22</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.14</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Certain Business Practices</FONT></TD><TD STYLE="width: 10%">25</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.15</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Governmental Authorizations</FONT></TD><TD STYLE="width: 10%">25</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.16</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Tax Matters</FONT></TD><TD STYLE="width: 10%">25</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.17</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Employee Matters; Benefit Plans</FONT></TD><TD STYLE="width: 10%">27</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.18</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Environmental Matters</FONT></TD><TD STYLE="width: 10%">29</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.19</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Insurance</FONT></TD><TD STYLE="width: 10%">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.20</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Legal Proceedings; Orders</FONT></TD><TD STYLE="width: 10%">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.21</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Takeover Laws</FONT></TD><TD STYLE="width: 10%">30</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.22</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Non-Contravention; Consents</FONT></TD><TD STYLE="width: 10%">31</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.23</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Opinion of Financial Advisor</FONT></TD><TD STYLE="width: 10%">31</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">3.24</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Brokers and Other Advisors</FONT></TD><TD STYLE="width: 10%">31</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPRESENTATIONS AND WARRANTIES OF PARENT
AND PURCHASER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.1</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Due Organization</FONT></TD><TD STYLE="width: 10%">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.2</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Purchaser</FONT></TD><TD STYLE="width: 10%">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.3</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Authority; Binding Nature of Agreement</FONT></TD><TD STYLE="width: 10%">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.4</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Non-Contravention; Consents</FONT></TD><TD STYLE="width: 10%">32</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.5</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Disclosure</FONT></TD><TD STYLE="width: 10%">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.6</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Absence of Litigation</FONT></TD><TD STYLE="width: 10%">33</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.7</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Funds</FONT></TD><TD STYLE="width: 10%">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.8</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Ownership of Shares</FONT></TD><TD STYLE="width: 10%">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.9</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Acknowledgement by Parent and Purchaser</FONT></TD><TD STYLE="width: 10%">34</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">4.10</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Brokers and Other Advisors</FONT></TD><TD STYLE="width: 10%">35</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTAIN COVENANTS OF THE COMPANY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">5.1</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Access and Investigation</FONT></TD><TD STYLE="width: 10%">35</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">5.2</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Operation of the Company&rsquo;s Business</FONT></TD><TD STYLE="width: 10%">36</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">5.3</FONT></TD><TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">No Solicitation</FONT></TD><TD STYLE="width: 10%">40</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ADDITIONAL COVENANTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.1</TD><TD STYLE="width: 80%">Company Board Recommendation</TD><TD STYLE="width: 10%">41</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.2</TD><TD STYLE="width: 80%">Filings, Consents and Approvals</TD><TD STYLE="width: 10%">44</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.3</TD><TD STYLE="width: 80%">Employee Benefits</TD><TD STYLE="width: 10%">46</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.4</TD><TD STYLE="width: 80%">ESPP</TD><TD STYLE="width: 10%">47</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.5</TD><TD STYLE="width: 80%">Indemnification of Officers and Directors</TD><TD STYLE="width: 10%">48</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.6</TD><TD STYLE="width: 80%">Stockholder Litigation</TD><TD STYLE="width: 10%">50</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.7</TD><TD STYLE="width: 80%">Additional Agreements</TD><TD STYLE="width: 10%">50</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.8</TD><TD STYLE="width: 80%">Disclosure</TD><TD STYLE="width: 10%">51</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.9</TD><TD STYLE="width: 80%">Takeover Laws</TD><TD STYLE="width: 10%">51</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.10</TD><TD STYLE="width: 80%">Section&nbsp;16 Matters</TD><TD STYLE="width: 10%">51</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.11</TD><TD STYLE="width: 80%">Rule&nbsp;14d-10 Matters</TD><TD STYLE="width: 10%">52</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.12</TD><TD STYLE="width: 80%">Stock Exchange Delisting; Deregistration</TD><TD STYLE="width: 10%">52</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">6.13</TD><TD STYLE="width: 80%">401(k)&nbsp;Plan</TD><TD STYLE="width: 10%">52</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDITIONS PRECEDENT TO THE MERGER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">7.1</TD><TD STYLE="width: 80%">No Restraints</TD><TD STYLE="width: 10%">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">7.2</TD><TD STYLE="width: 80%">Consummation of Offer</TD><TD STYLE="width: 10%">53</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TERMINATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">8.1</TD><TD STYLE="width: 80%">Termination</TD><TD STYLE="width: 10%">53</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">8.2</TD><TD STYLE="width: 80%">Effect of Termination</TD><TD STYLE="width: 10%">54</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">8.3</TD><TD STYLE="width: 80%">Expenses; Termination Fees</TD><TD STYLE="width: 10%">55</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Section&nbsp;9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MISCELLANEOUS PROVISIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.1</TD><TD STYLE="width: 80%">Amendment</TD><TD STYLE="width: 10%">56</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.2</TD><TD STYLE="width: 80%">Waiver</TD><TD STYLE="width: 10%">57</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.3</TD><TD STYLE="width: 80%">No Survival of Representations and Warranties</TD><TD STYLE="width: 10%">57</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.4</TD><TD STYLE="width: 80%">Entire Agreement; Counterparts</TD><TD STYLE="width: 10%">57</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.5</TD><TD STYLE="width: 80%">Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</TD><TD STYLE="width: 10%">58</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.6</TD><TD STYLE="width: 80%">Assignability</TD><TD STYLE="width: 10%">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.7</TD><TD STYLE="width: 80%">No Third Party Beneficiaries</TD><TD STYLE="width: 10%">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.8</TD><TD STYLE="width: 80%">Transfer Taxes</TD><TD STYLE="width: 10%">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.9</TD><TD STYLE="width: 80%">Notices</TD><TD STYLE="width: 10%">59</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.10</TD><TD STYLE="width: 80%">Severability</TD><TD STYLE="width: 10%">60</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.11</TD><TD STYLE="width: 80%">Obligation of Parent</TD><TD STYLE="width: 10%">61</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%">9.12</TD><TD STYLE="width: 80%">Construction</TD><TD STYLE="width: 10%">61</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Exhibits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: left">Exhibit&nbsp;A</TD>
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: left">Certain Definitions</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Annexes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: left">Annex I</TD>
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: left">Conditions to Offer</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: left">Annex II</TD>
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: left">Form&nbsp;of Certificate of Incorporation of the Surviving Corporation</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THIS AGREEMENT AND PLAN OF MERGER</B>
(&ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of March&nbsp;1, 2020, by and among: Gilead Sciences,&nbsp;Inc., a
Delaware corporation (&ldquo;<U>Parent</U>&rdquo;); Toro Merger Sub,&nbsp;Inc., a Delaware corporation and a wholly owned subsidiary
of Parent (&ldquo;<U>Purchaser</U>&rdquo;); and Forty Seven,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;).
Certain capitalized terms used in this Agreement are defined in <U>Exhibit&nbsp;A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(A)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Parent
has agreed to cause Purchaser to commence a tender offer (as it may be amended from time to time as permitted under this Agreement,
the &ldquo;<U>Offer</U>&rdquo;) to acquire all of the outstanding shares of Company Common Stock (the &ldquo;<U>Shares</U>&rdquo;),
other than the Excluded Shares, for $95.50 per share, net to the seller in cash, without interest (as such amount may be amended
or adjusted in accordance with the terms of this Agreement, the &ldquo;<U>Offer Price</U>&rdquo;), upon the terms and subject to
the conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(B)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
soon as practicable following the consummation of the Offer, Purchaser will be merged with and into the Company (the &ldquo;<U>Merger</U>&rdquo;),
with the Company continuing as the surviving corporation in the Merger (the &ldquo;<U>Surviving Corporation</U>&rdquo;), on the
terms and subject to the conditions set forth in this Agreement, whereby (i)&nbsp;each issued and outstanding Share not owned by
Parent, Purchaser or the Company as of the Effective Time (other than Excluded Shares and Dissenting Shares) shall be converted
into the right to receive the Offer Price, in cash, without interest, and (ii)&nbsp;the Company shall become a wholly owned Subsidiary
of Parent as a result of the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(C)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
board of directors of the Company (the &ldquo;<U>Board of Directors</U>&rdquo;) has unanimously (i)&nbsp;determined that this Agreement
and the Transactions, including the Offer and the Merger, are fair to, and in the best interest of, the Company and its stockholders,
(ii)&nbsp;declared it advisable to enter into this Agreement, (iii)&nbsp;approved the execution, delivery and performance by the
Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (iv)&nbsp;resolved that
the Merger shall be effected under Section&nbsp;251(h)&nbsp;of the DGCL, and (v)&nbsp;resolved to recommend that the stockholders
of the Company accept the Offer and tender their Shares to Purchaser pursuant to the Offer (the preceding <U>clauses (i)</U>&nbsp;through
<U>(v)</U>, the &ldquo;<U>Company Board Recommendation</U>&rdquo;), in each case, on the terms and subject to the conditions of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(D)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
board of directors of each of Parent and Purchaser have approved this Agreement and declared it advisable for Parent and Purchaser,
respectively, to enter into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(E)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Parent,
Purchaser and the Company acknowledge and agree that the Merger may be effected pursuant to Section&nbsp;251(h)&nbsp;of the DGCL
and shall, subject to the satisfaction of the conditions set forth in this Agreement, be consummated as soon as practicable following
the consummation of the Offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Parties, intending to be legally bound,
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>THE
OFFER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Offer</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Commencement
of the Offer</B>. Provided that this Agreement shall not have been terminated in accordance with <U>Section&nbsp;8</U>, as promptly
as practicable after the date of this Agreement but in no event more than 10 business days after the date of this Agreement (subject
to the Company having timely provided any information required to be provided by it pursuant to <U>Sections 1.1(e)</U>&nbsp;and
<U>1.2(b)</U>), Purchaser shall (and Parent shall cause Purchaser to) commence (within the meaning of Rule&nbsp;14d-2 under the
Exchange Act) the Offer to purchase all of the outstanding Shares (other than Shares to be cancelled pursuant to <U>Sections 2.5(a)(i)</U>&nbsp;and
<U>2.5(a)(ii)</U>&nbsp;(collectively, the &ldquo;<U>Excluded Shares</U>&rdquo;)), at a price per Share equal to the Offer Price,
net to the seller in cash, without interest and subject to any withholding of Tax in accordance with <U>Section&nbsp;2.6(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Terms
and Conditions of the Offer</B>. The obligations of Purchaser to (and of Parent to cause Purchaser to) accept for payment, and
pay for, any Shares validly tendered (and not validly withdrawn) pursuant to the Offer shall be subject to the satisfaction or
waiver (to the extent permitted under applicable Legal Requirements) of the conditions set forth in <U>Annex I</U> (collectively,
the &ldquo;<U>Offer Conditions</U>&rdquo;), and no other conditions. The Offer shall be made by means of an offer to purchase (the
 &ldquo;<U>Offer to Purchase</U>&rdquo;) that contains the terms set forth in this Agreement, the Minimum Condition, the Termination
Condition and the other Offer Conditions. Purchaser expressly reserves the right to (i)&nbsp;increase the amount of cash constituting
the Offer Price, (ii)&nbsp;waive any Offer Condition (to the extent permitted under applicable Legal Requirements) and (iii)&nbsp;make
any other changes in the terms and conditions of the Offer not inconsistent with the terms of this Agreement; <I>provided</I>,
<I>however</I>, notwithstanding anything to the contrary contained in this Agreement, without the prior written consent of the
Company, Parent and Purchaser shall not (A)&nbsp;decrease the Offer Price, (B)&nbsp;change the form of consideration payable in
the Offer (provided that nothing herein shall limit the ability of Parent and Purchaser to increase the cash consideration payable
in the Offer), (C)&nbsp;decrease the maximum number of Shares sought to be purchased in the Offer, (D)&nbsp;impose conditions or
requirements to the Offer in addition to the Offer Conditions, (E)&nbsp;amend, modify or waive the Minimum Condition, Termination
Condition or the conditions set forth in <U>clause (e)</U>&nbsp;or <U>(g)</U>&nbsp;of <U>Annex I</U>, (F)&nbsp;otherwise amend
or modify any of the other terms of the Offer in a manner that adversely affects, or would reasonably be expected to adversely
affect any holder of Shares in its capacity as such, (G)&nbsp;terminate the Offer or accelerate, extend or otherwise change the
Expiration Date, in each case, except as provided in <U>Sections 1.1(c)</U>&nbsp;or <U>1.1(d)</U>&nbsp;or (H)&nbsp;provide any
 &ldquo;subsequent offering period&rdquo; (or any extension thereof) within the meaning of Rule&nbsp;14d-11 promulgated under the
Exchange Act. The Offer may not be withdrawn prior to the Expiration Date (or any rescheduled Expiration Date) of the Offer, unless
this Agreement is terminated in accordance with <U>Section&nbsp;8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Expiration
and Extension of the Offer</B>. The Offer shall initially be scheduled to expire at one minute after 11:59 p.m.&nbsp;Eastern Time
on the date that is 20 business days (determined as set forth in Rule&nbsp;14d-1(g)(3)&nbsp;and Rule&nbsp;14e-1(a)&nbsp;under the
Exchange Act) following the Offer Commencement Date (unless otherwise agreed to in writing by Parent and the Company) (the &ldquo;<U>Initial
Expiration Date</U>&rdquo;, and such date or such subsequent date to which the Initial Expiration Date of the Offer is extended
in accordance with the terms of this Agreement, the &ldquo;<U>Expiration Date</U>&rdquo;). Notwithstanding anything to the contrary
contained in this Agreement, but subject to the Parties&rsquo; respective termination rights under <U>Section&nbsp;8</U>: (i)&nbsp;if,
as of the then-scheduled Expiration Date, any Offer Condition is not satisfied (unless such condition is waivable by Purchaser
or Parent and has been waived) Purchaser shall, and Parent shall cause Purchaser to, extend the Offer for additional periods of
up to 10 business days per extension, to permit such Offer Condition to be satisfied; and (ii)&nbsp;Purchaser shall, and Parent
shall cause Purchaser to, extend the Offer from time to time for any period required by any Legal Requirement, any interpretation
or position of the SEC, the staff thereof or NASDAQ applicable to the Offer; <I>provided</I>, <I>however</I>, that in no event
shall Purchaser (1)&nbsp;be required to extend the Offer beyond the earlier to occur of (x)&nbsp;the valid termination of this
Agreement in accordance with <U>Section&nbsp;8</U> and (y)&nbsp;the End Date (such earlier occurrence, the &ldquo;<U>Extension
Deadline</U>&rdquo;) or (2)&nbsp;be permitted to extend the Offer beyond the Extension Deadline without the prior written consent
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Termination
of Offer</B>. Nothing in this <U>Section&nbsp;1.1</U> shall be deemed to impair, limit or otherwise restrict in any manner the
right of the Company, Parent or Purchaser to terminate this Agreement pursuant to <U>Section&nbsp;8</U>. In the event that this
Agreement is validly terminated pursuant to <U>Section&nbsp;8</U>, Purchaser shall (and Parent shall cause Purchaser to) immediately,
irrevocably and unconditionally terminate the Offer and shall not acquire any Shares pursuant to the Offer. If the Offer is terminated
or withdrawn by Purchaser in accordance with the terms of this Agreement, Purchaser shall immediately return, and shall cause any
depository acting on behalf of Purchaser to return, in accordance with applicable Legal Requirements, all tendered Shares to the
registered holders thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Offer
Documents</B>. As promptly as practicable on the Offer Commencement Date, Parent and Purchaser shall (i)&nbsp;file with the SEC
a tender offer statement on Schedule TO with respect to the Offer (together with any exhibits, amendments or supplements thereto,
the &ldquo;<U>Offer Documents</U>&rdquo;) that will contain or incorporate by reference the Offer to Purchase, form of the related
letter of transmittal and summary advertisement, (ii)&nbsp;make all deliveries, mailings and telephonic notices required by Rule&nbsp;14d-3
under the Exchange Act and (iii)&nbsp;cause the Offer to Purchase and related documents to be disseminated to holders of Shares
as and to the extent required by applicable Legal Requirements. Parent and Purchaser agree that they shall cause the Offer Documents
filed by either Parent or Purchaser with the SEC to (x)&nbsp;comply in all material respects with the Exchange Act and other applicable
Legal Requirements and (y)&nbsp;not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading; <I>provided</I>, <I>however</I>, that no covenant is made by Parent or Purchaser with respect to information
supplied by or on behalf of the Company for inclusion or incorporation by reference in the Offer Documents. Each of Parent, Purchaser
and the Company agrees to respond promptly to any comments (including oral comments) of the SEC or its staff and to promptly correct
any information provided by it for use in the Offer Documents if and to the extent that such information shall have become false
or misleading in any material respect, and Parent and Purchaser further agree to take all steps necessary to promptly cause the
Offer Documents as so corrected to be filed with the SEC and to be disseminated to holders of Shares, in each case as and to the
extent required by applicable Legal Requirements. The Company hereby consents to the inclusion of the Company Board Recommendation
in the Offer Documents. The Company shall promptly furnish or otherwise make available to Parent and Purchaser or Parent&rsquo;s
legal counsel all information concerning the Company and the Company&rsquo;s stockholders that may be required or reasonably requested
in connection with any action contemplated by this <U>Section&nbsp;1.1(e)</U>. The Company and its counsel shall be given reasonable
opportunity to review and comment on the Offer Documents (including any response to any comments (including oral comments) of the
SEC or its staff with respect thereto) prior to the filing thereof with the SEC, and Parent and Purchaser shall give reasonable
consideration to any such comments made by the Company or its counsel. Parent and Purchaser agree to provide the Company and its
counsel with any comments (including oral comments) Parent, Purchaser or their counsel may receive from the SEC or its staff with
respect to the Offer Documents promptly after receipt of those comments (including oral comments).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Funds</B>.
Without limiting the generality of <U>Section&nbsp;9.11</U>, Parent shall cause to be provided to Purchaser, on a timely basis,
all of the funds necessary to purchase all Shares that Purchaser becomes obligated to purchase pursuant to the Offer, and shall
cause Purchaser to perform, on a timely basis, all of Purchaser&rsquo;s obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Adjustments</B>.
If, between the date of this Agreement and the Offer Acceptance Time, the outstanding Shares are changed into a different number
or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation
of shares, reclassification, recapitalization or other similar transaction, then the Offer Price shall be appropriately adjusted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Acceptance</B>.
Subject only to the satisfaction or, to the extent waivable by Purchaser or Parent, waiver by Purchaser or Parent of each of the
Offer Conditions, Purchaser shall (and Parent shall cause Purchaser to) (i)&nbsp;immediately after the Expiration Date irrevocably
accept for payment all Shares tendered (and not validly withdrawn) pursuant to the Offer (the time of such acceptance, the &ldquo;<U>Offer
Acceptance Time</U>&rdquo;) and (ii)&nbsp;as promptly as practicable after the Offer Acceptance Time (and in any event within three
business days) pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Company
Actions</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Schedule
14D-9</B>. Subject to <U>Section&nbsp;6.1(b)</U>, as promptly as practicable on the Offer Commencement Date, following the filing
of the Offer Documents, the Company shall (i)&nbsp;file with the SEC a Tender Offer Solicitation/Recommendation Statement on Schedule
14D-9 (together with any exhibits, amendments or supplements thereto, the &ldquo;<U>Schedule 14D-9</U>&rdquo;) that shall reflect
the Company Board Recommendation and include the fairness opinion of the Company&rsquo;s financial advisor referenced in <U>Section&nbsp;3.23</U>
and the notice and other information required by Section&nbsp;262(d)(2)&nbsp;of the DGCL and (ii)&nbsp;cause the Schedule 14D-9
and related documents to be disseminated to holders of Shares as and to the extent required by applicable Legal Requirements, including
by setting the Stockholder List Date as the record date for purposes of receiving the notice required by Section&nbsp;262(d)(2)&nbsp;of
the DGCL. The Company agrees that it shall cause the Schedule 14D-9 to (x)&nbsp;comply in all material respects with the Exchange
Act and other applicable Legal Requirements and (y)&nbsp;not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading; <I>provided</I>, <I>however</I>, that no covenant is made by the Company with respect
to information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by reference in the Schedule 14D-9.
Each of Parent, Purchaser and the Company agrees to respond promptly to any comments (including oral comments) of the SEC or its
staff and to promptly correct any information provided by it for use in the Schedule 14D-9 if and to the extent that such information
shall have become false or misleading in any material respect, and the Company further agrees to take all steps necessary to promptly
cause the Schedule 14D-9 as so corrected to be filed with the SEC and to be disseminated to holders of Shares, in each case as
and to the extent required by applicable Legal Requirements. Parent and Purchaser shall promptly furnish or otherwise make available
to the Company or the Company&rsquo;s legal counsel all information concerning Parent or Purchaser that may be required or reasonably
requested in connection with any action contemplated by this <U>Section&nbsp;1.2(a)</U>. Parent and its counsel shall be given
reasonable opportunity to review and comment on the Schedule 14D-9 (including any response to any comments (including oral comments)
of the SEC or its staff with respect thereto) prior to the filing thereof with the SEC, and the Company shall give reasonable consideration
to any such comments made by Parent or its counsel. The Company agrees to provide Parent and its counsel with any comments (including
oral comments) the Company or its counsel may receive from the SEC or its staff with respect to the Schedule 14D-9 promptly after
receipt of those comments (including oral comments).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Stockholder
Lists</B>. The Company shall promptly after the date hereof furnish Parent with a list of its stockholders, mailing labels and
any available listing or computer file containing the names and addresses of all record holders of Shares and lists of securities
positions of Shares held in stock depositories, in each case as of the most recent practicable date, and shall provide to Parent
such additional information (including updated lists of stockholders, mailing labels and lists of securities positions) and such
other assistance as Parent may reasonably request in connection with the Offer and the Merger (the date of the list used to determine
the Persons to whom the Offer Documents and the Schedule 14D-9 are first disseminated, which date shall not be more than 10 business
days prior to the date the Offer Documents and the Schedule 14D-9 are first disseminated, the &ldquo;<U>Stockholder List Date</U>&rdquo;).
Subject to applicable Legal Requirements, and except for such steps as are necessary to disseminate the Offer Documents and any
other documents necessary to consummate the Transactions, Parent and Purchaser and their agents shall hold in confidence in accordance
with the Confidentiality Agreement the information contained in any such labels, listings and files.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Share
Registry</B>. The Company shall register (and shall instruct its transfer agent to register) the transfer of the Shares accepted
for payment by Purchaser effective immediately after the Offer Acceptance Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>MERGER
TRANSACTION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Merger
of Purchaser into the Company</FONT></B>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance
with Section&nbsp;251(h)&nbsp;of the DGCL, at the Effective Time, the Company and Parent shall consummate the Merger, whereby
Purchaser shall be merged with and into the Company, the separate existence of Purchaser shall cease, and the Company will continue
as the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Effect
of the Merger</FONT></B>. The Merger shall have the effects set forth in this Agreement and in the applicable provisions of the
DGCL. Without limiting the generality of the foregoing, at the Effective Time, all of the property, rights, privileges, immunities,
powers and franchises of the Company and Purchaser shall vest in the Surviving Corporation, and all of the debts, liabilities
and duties of the Company and Purchaser shall become the debts, liabilities and duties of the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Closing;
Effective Time</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Unless
this Agreement shall have been terminated pursuant to <U>Section&nbsp;8</U>, and unless otherwise mutually agreed in writing between
the Company, Parent and Purchaser, the consummation of the Merger (the &ldquo;<U>Closing</U>&rdquo;) shall take place at the offices
of Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, One Manhattan West, New York, New York 10001, as soon as practicable following
(but in any event on the same date as) the Offer Acceptance Time except if the conditions set forth in <U>Section&nbsp;7.1</U>
shall not be satisfied or, to the extent permitted by applicable Legal Requirements, waived as of such date, in which case the
Closing shall take place on the first business day on which all conditions set forth in <U>Section&nbsp;7.1</U> are satisfied or,
to the extent permitted by applicable Legal Requirements, waived, unless another date or place is agreed to in writing by the Company
and Parent prior to the Offer Acceptance Time. The date on which the Closing occurs is referred to in this Agreement as the &ldquo;<U>Closing
Date</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to the provisions of this Agreement, as soon as practicable on the Closing Date, the Company and Purchaser shall file or cause
to be filed a certificate of merger with the Secretary of State of the State of Delaware with respect to the Merger, in such form
as required by, and executed and acknowledged in accordance with, the relevant provisions of the DGCL, and the Parties shall take
all such further actions as may be required by applicable Legal Requirements to make the Merger effective. The Merger shall become
effective upon the date and time of the filing of that certificate of merger with the Secretary of State of the State of Delaware
or such later date and time as is agreed upon in writing by the Parties and specified in the certificate of merger (such date and
time, the &ldquo;<U>Effective Time</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.4</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Certificate
of Incorporation and Bylaws; Directors and Officers.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the Effective Time, the certificate of incorporation of the Company shall, by virtue of the Merger and without any further action,
be amended and restated to read in its entirety as set forth on <U>Annex II</U> and, as so amended and restated, shall be the certificate
of incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or by applicable Legal Requirements,
subject to <U>Section&nbsp;6.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the Effective Time, the bylaws of the Surviving Corporation shall be amended and restated to conform to the bylaws of Purchaser
as in effect immediately prior to the Effective Time, until thereafter changed or amended as provided therein or by applicable
Legal Requirements, subject to <U>Section&nbsp;6.5(a)</U>, except that references to the name of Purchaser shall be replaced by
references to the name of the Surviving Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the Effective Time, the directors and officers of the Surviving Corporation shall be the respective individuals who served as
the directors and officers of Purchaser as of immediately prior to the Effective Time, until their respective successors are duly
elected and qualified, or their earlier death, resignation or removal. Each director of the Company immediately prior to the Effective
Time shall execute and deliver a letter effectuating his or her resignation as a member of the Board of Directors to be effective
as of the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Conversion
of Shares</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Purchaser, the Company or any
stockholder of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Shares held immediately prior to the Effective Time by the Company (or held in the Company&rsquo;s treasury) shall be cancelled
and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Shares held immediately prior to the Effective Time by Parent, Purchaser or any other direct or indirect wholly owned Subsidiary
of Parent shall be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">except
as provided in <U>clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;above and subject to <U>Section&nbsp;2.5(b)</U>, each Share outstanding
immediately prior to the Effective Time, including any Shares subject to vesting or employment based forfeiture conditions (&ldquo;<U>Restricted
Shares</U>&rdquo;) (other than any Dissenting Shares, which shall have only those rights set forth in <U>Section&nbsp;2.7</U>)
shall be converted into the right to receive the Offer Price (the &ldquo;<U>Merger Consideration</U>&rdquo;), in each case without
any interest thereon, without regard to any vesting or employment based forfeiture conditions which were applicable to the corresponding
Restricted Shares and subject to any withholding of Taxes in accordance with <U>Section&nbsp;2.6(e)</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">each
share of the common stock, $0.01 par value per share, of Purchaser then outstanding shall be converted into one share of common
stock of the Surviving Corporation. From and after the Effective Time, subject to this <U>Section&nbsp;2.5(a)</U>, all Shares shall
no longer be outstanding and shall automatically be cancelled and shall cease to exist, and each applicable holder of such Shares
shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration therefor upon the surrender
of such shares of Company Common Stock in accordance with <U>Section&nbsp;2.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
between the date of this Agreement and the Effective Time, the outstanding Shares are changed into a different number or class
of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of
shares, reclassification, recapitalization or other similar transaction, then the Merger Consideration shall be appropriately adjusted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Surrender
of Certificates; Stock Transfer Books</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Prior
to the Offer Acceptance Time, Parent shall designate a bank or trust company reasonably acceptable to the Company to act as agent
(the &ldquo;<U>Depository Agent</U>&rdquo;) for the holders of Shares to receive the aggregate Offer Price to which holders of
such Shares shall become entitled pursuant to <U>Section&nbsp;1.1(b)</U>&nbsp;and to act as agent (the &ldquo;<U>Paying Agent</U>&rdquo;)
for the holders of Shares to receive the aggregate Merger Consideration to which holders of such Shares shall become entitled pursuant
to <U>Section&nbsp;2.5</U>. Promptly after (and in any event no later than the third business day after) the Offer Acceptance Time,
Parent shall deposit, or shall cause to be deposited, with the Depository Agent cash sufficient to make the payment of the aggregate
Offer Price payable pursuant to <U>Section&nbsp;1.1(h)</U>. On or prior to the Closing Date, Parent shall deposit, or shall cause
to be deposited, with the Paying Agent cash sufficient to pay the aggregate Merger Consideration payable pursuant to <U>Section&nbsp;2.5</U>
(together with the amount deposited pursuant the immediately preceding sentence, the &ldquo;<U>Payment Fund</U>&rdquo;). The Payment
Fund shall not be used for any purpose other than to pay the aggregate Offer Price in the Offer and the aggregate Merger Consideration
in the Merger. The Payment Fund shall be invested by the Paying Agent as directed by the Surviving Corporation; <I>provided</I>
that such investments shall be (w)&nbsp;in obligations of or guaranteed by the United States of America, (x)&nbsp;in commercial
paper obligations rated A-1 or P-1 or better by Moody&rsquo;s Investors Service,&nbsp;Inc. or Standard&nbsp;&amp; Poor&rsquo;s
Corporation, respectively, (y)&nbsp;in certificates of deposit, bank repurchase agreements or banker&rsquo;s acceptances of commercial
banks with capital exceeding one billion dollars, or (z)&nbsp;in money market funds having a rating in the highest investment category
granted by a recognized credit rating agency at the time of acquisition or a combination of the foregoing and, in any such case,
no such instrument shall have a maturity exceeding three months. To the extent Parent becomes aware that (i)&nbsp;there are any
losses with respect to any such investments or (ii)&nbsp;the Payment Fund has diminished for any reason below the level required
for the Paying Agent to make prompt cash payment pursuant to <U>Section&nbsp;1.1(h)</U>&nbsp;and <U>Section&nbsp;2.5</U>, Parent
shall, or shall cause the Surviving Corporation to, promptly replace or restore the cash in the Payment Fund so as to ensure that
the Payment Fund is, at all times during the duration of the Payment Fund, maintained at a level sufficient for the Paying Agent
to make such payments pursuant to <U>Section&nbsp;1.1(h)</U>&nbsp;and <U>Section&nbsp;2.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Promptly
after the Effective Time (but in no event later than three business days thereafter), the Surviving Corporation shall cause to
be delivered to each Person who was, at the Effective Time, a holder of record of (i)&nbsp;Shares represented by a certificate
evidencing such Shares (the &ldquo;<U>Certificates</U>&rdquo;) or (ii)&nbsp;Book-Entry Shares, who, in each case was entitled to
receive the Merger Consideration pursuant to <U>Section&nbsp;2.5</U>, (A)&nbsp;a form of letter of transmittal, which shall be
in reasonable and customary form and shall specify that delivery shall be effected, and risk of loss and title to the Certificates
shall pass, only upon proper delivery of the Certificates (or affidavits of loss in lieu thereof in accordance with <U>Section&nbsp;2.6(f)</U>,
if applicable) to the Paying Agent, or a customary agent&rsquo;s message in respect to Book-Entry Shares, and (B)&nbsp;instructions
for use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for the Merger Consideration issuable and
payable in respect of such Shares pursuant to <U>Section&nbsp;2.5</U>. Upon surrender to the Paying Agent of Certificates (or affidavits
of loss in lieu thereof in accordance with <U>Section&nbsp;2.6(f)</U>, if applicable) or Book-Entry Shares, together with such
letter of transmittal in the case of Certificates, duly completed and validly executed in accordance with the instructions thereto,
and such other documents as may be required pursuant to the instructions, the holder of such Certificates or Book-Entry Shares
shall be entitled to receive in exchange therefor the Merger Consideration for each Share formerly evidenced by such Certificates
or Book-Entry Shares, and such Certificates and Book-Entry Shares shall then be cancelled. No interest shall accrue or be paid
on the Merger Consideration payable upon the surrender of any Certificates or Book-Entry Shares for the benefit of the holder thereof.
If the payment of any Merger Consideration is to be made to a Person other than the Person in whose name the surrendered Certificates
formerly evidencing the Shares is registered on the stock transfer books of the Company, it shall be a condition of payment that
the Certificate so surrendered shall be endorsed properly or otherwise be in proper form for transfer and that the Person requesting
such payment shall have paid all transfer and other similar Taxes required by reason of the payment of the Merger Consideration
to a Person other than the registered holder of the Certificate surrendered, or shall have established to the satisfaction of Parent
that such transfer or other similar Taxes either have been paid or are not applicable. None of Parent, Purchaser and the Surviving
Corporation shall have any liability for the transfer and other similar Taxes described in this <U>Section&nbsp;2.6(b)</U>&nbsp;under
any circumstance. Payment of the applicable Merger Consideration with respect to Book-Entry Shares shall only be made to the Person
in whose name such Book-Entry Shares are registered. Until surrendered as contemplated by this <U>Section&nbsp;2.6</U>, each Certificate
and Book-Entry Share shall be deemed at any time after the Effective Time to represent only the right to receive the applicable
Merger Consideration as contemplated by <U>Section&nbsp;2.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
any time following 12 months after the Effective Time, Parent shall be entitled to require the Paying Agent to deliver to it any
funds (with respect to the aggregate Merger Consideration to which holders of Shares shall become entitled pursuant to <U>Section&nbsp;2.5</U>)
which had been made available to the Paying Agent and not disbursed to holders of Certificates or Book-Entry Shares (including
all interest and other income received by the Paying Agent in respect of all funds made available to it), and, thereafter, such
holders shall be entitled to look to the Surviving Corporation (subject to abandoned property, escheat and other similar Legal
Requirements) only as general creditors thereof with respect to the Merger Consideration that may be payable upon due surrender
of the Certificates or Book-Entry Shares held by them, without any interest thereon. Notwithstanding the foregoing, neither the
Surviving Corporation nor the Paying Agent shall be liable to any holder of Certificates or Book-Entry Shares for the Merger Consideration
delivered in respect of such share to a public official pursuant to any abandoned property, escheat or other similar Legal Requirements.
Any amounts remaining unclaimed by such holders at such time at which such amounts would otherwise escheat to or become property
of any Governmental Body shall become, to the extent permitted by applicable Legal Requirements, the property of the Surviving
Corporation or its designee, free and clear of all claims or interest of any Person previously entitled thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the Shares shall
be closed and thereafter there shall be no further registration of transfers of Shares on the records of the Company. From and
after the Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time shall cease to have any
rights with respect to such Shares except as otherwise provided herein or by applicable Legal Requirements. If, after the Effective
Time, Certificates or Book-Entry Shares are presented to the Surviving Corporation for any reason, they shall be cancelled and
exchanged as provided in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
of the Company, the Surviving Corporation, Parent and Purchaser, and their Affiliates, the Paying Agent or the Depository Agent,
as the case may be, shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts otherwise
payable pursuant to this Agreement, such amounts as are required to be deducted and withheld under any Legal Requirement with respect
to Taxes. Any amounts so deducted and withheld and paid over to the applicable Governmental Body in accordance with applicable
Legal Requirements shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such
deduction or withholding was made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the holder of the Shares
formerly represented by that Certificate, or by a representative of that holder, claiming that Certificate to be lost, stolen or
destroyed and, if required by the Surviving Corporation, the posting by that holder of a bond, in such reasonable amount as Parent
may direct, as indemnity against any claim that may be made against it with respect to such Certificate (which shall not exceed
the Merger Consideration payable with respect to such Certificate), the Paying Agent will pay (less any amounts entitled to be
deducted or withheld pursuant to <U>Section&nbsp;2.6(e)</U>), in exchange for such lost, stolen or destroyed Certificate, the applicable
Merger Consideration to be paid in respect of the Shares formerly represented by such Certificate, as contemplated by this <U>Section&nbsp;2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Dissenters&rsquo;
Rights</FONT></B>. Notwithstanding anything in this Agreement to the contrary, Shares outstanding immediately prior to the Effective
Time, and held by holders who are entitled to appraisal rights under Section&nbsp;262 of the DGCL and have properly exercised
and perfected their respective demands for appraisal of such Shares in the time and manner provided in Section&nbsp;262 of the
DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under
the DGCL (the &ldquo;<U>Dissenting Shares</U>&rdquo;), shall not be converted into the right to receive Merger Consideration,
but shall, by virtue of the Merger, be automatically cancelled and no longer outstanding, shall cease to exist and shall be entitled
to only such consideration as shall be determined pursuant to Section&nbsp;262 of the DGCL; <I>provided </I>that if any such holder
shall have failed to perfect or shall have effectively withdrawn or lost such holder&rsquo;s right to appraisal and payment under
the DGCL, such holder&rsquo;s Shares shall be deemed to have been converted as of the Effective Time into the right to receive
the Merger Consideration (less any amounts entitled to be deducted or withheld pursuant to <U>Section&nbsp;2.6(e)</U>), and such
Shares shall not be deemed to be Dissenting Shares. The Company shall give prompt notice to Parent and Purchaser of any demands
received by the Company for appraisal of any Dissenting Shares, withdrawals of such demands and any other instruments served pursuant
to Section&nbsp;262 of the DGCL, in each case prior to the Effective Time. Parent and Purchaser shall have the right to direct
and participate in all negotiations and proceedings with respect to such demands, and the Company shall not, without the prior
written consent of Parent and Purchaser, settle or offer to settle, or make any payment with respect to, any such demands, approve
any withdrawal of any such demands or agree or commit to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.8</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Treatment
of Company Options.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share
exercise price that is less than the Merger Consideration, shall be cancelled and converted into the right to receive a cash payment
equal to (i)&nbsp;the excess of (A)&nbsp;the Merger Consideration over (B)&nbsp;the exercise price payable per Share under such
Company Option, multiplied by (ii)&nbsp;the total number of Shares subject to such Company Option immediately prior to the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
soon as reasonably practicable after the Effective Time (but in no event later than the second payroll date following the Effective
Time), Parent shall cause the Surviving Corporation to, and the Surviving Corporation shall, pay the consideration payable pursuant
to <U>Section&nbsp;2.8(a)</U>, net of any applicable withholding Taxes, to the holders of Company Options through, to the extent
applicable, the Surviving Corporation&rsquo;s payroll.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Prior
to the Offer Acceptance Time, the Company shall take all actions that are necessary (under the Company Equity Plans and award agreements
pursuant to which Company Options are outstanding or otherwise) to effect the transactions described in this <U>Section&nbsp;2.8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Further
Action</FONT></B>. The Parties agree to take all necessary action to cause the Merger to become effective in accordance with this
<U>Section&nbsp;2</U> as soon as practicable following the consummation of the Offer without a meeting of the Company&rsquo;s
stockholders, as provided in Section&nbsp;251(h)&nbsp;of the DGCL. If, at any time after the Effective Time, any further action
is reasonably determined by Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving
Corporation with full right, title and possession of and to all rights and property of Purchaser and the Company, the officers
and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Purchaser, in the name of the
Company and otherwise) to take such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby represents and warrants
to Parent and Purchaser as follows (it being understood that each representation and warranty contained in this <U>Section&nbsp;3</U>
is subject to (a)&nbsp;exceptions and disclosures set forth in the section or subsection of the Company Disclosure Schedule corresponding
to the particular Section&nbsp;or subsection in this <U>Section&nbsp;3</U>; (b)&nbsp;any exception or disclosure set forth in any
other section or subsection of the Company Disclosure Schedule to the extent it is reasonably apparent on the face of such disclosure
that such exception or disclosure is applicable to qualify such representation and warranty; and (c)&nbsp;disclosure in the Company
SEC Documents, and publicly available prior to the date of this Agreement (other than any general cautionary or forward-looking
statements contained in the &ldquo;Risk Factors&rdquo; or &ldquo;Forward-Looking Statements&rdquo; sections of such Company SEC
Documents); <I>provided</I> that this <U>clause (c)</U>&nbsp;shall not be applicable to <U>Section&nbsp;3.3</U> and <U>Section&nbsp;3.4</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Due
Organization; Subsidiaries, Etc.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company
has no Subsidiaries. The Company has all necessary power and authority: (i)&nbsp;to conduct its business in the manner in which
its business is currently being conducted and (ii)&nbsp;to own and use its assets in the manner in which its assets are currently
owned and used, in each case, except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect. The Company is qualified or licensed to do business as a foreign corporation or other entity, and is
in good standing (with respect to jurisdictions that recognize such concept), in each jurisdiction where the nature of its business
requires such qualification or licensing, except as has not had, and would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company does not own, directly or indirectly, any capital stock or other equity interests in, or subscriptions, options, calls,
warrants or rights (whether or not currently exercisable) to acquire, or other securities convertible into or exchangeable or exercisable
for, any capital stock or other equity interests of any Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Certificate
of Incorporation and Bylaws</FONT>.</B> The Company has delivered or made available to Parent copies of the certificate of incorporation
and bylaws of the Company, including all amendments thereto, as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Capitalization,
Etc.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
authorized capital stock of the Company consists of: (i)&nbsp;200,000,000 Shares, of which 48,145,009 Shares had been issued and
were outstanding as of the close of business on February&nbsp;28, 2020 (the &ldquo;<U>Capitalization Date</U>&rdquo;), of which
no Restricted Shares were outstanding and (ii)&nbsp;10,000,000 shares of Company Preferred Stock, of which no shares are outstanding.
From the Capitalization Date to the execution of this Agreement, the Company has not issued any Shares except pursuant to the exercise
of the purchase rights under the Company ESPP or the exercise of Company Options outstanding as of the Capitalization Date in accordance
with their terms and, since the Capitalization Date, the Company has not issued any Company Options or other equity or equity-based
awards, in each case, other than pursuant to any offer of employment or Contract dated on or prior to the date of the Capitalization
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;None
of the outstanding equity interests of the Company are entitled or subject to any preemptive right, right of repurchase or forfeiture,
right of participation, right of maintenance or any similar right; (ii)&nbsp;there are no outstanding bonds, debentures, notes
or other indebtedness of the Company having a right to vote on any matters on which the holders of the outstanding equity interests
of the Company have a right to vote, as applicable; and (iii)&nbsp;there is no Contract to which the Company is bound relating
to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from
granting any option or similar right with respect to), any equity interests of the Company. The Shares constitute the only outstanding
class of securities of the Company registered under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the close of business on the Capitalization Date: (i)&nbsp;4,265,130 Shares were subject to issuance pursuant to Company Options
granted and outstanding under the Company Equity Plans, (ii)&nbsp;5,323,581 Shares were reserved for future issuance under Company
Equity Plans and (iii)&nbsp;1,038,984 Shares were reserved for future issuance under the Company ESPP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as set forth in this <U>Section&nbsp;3.3</U> and except for the Company Options outstanding as of the date of this Agreement (and
Shares issuable upon the exercise thereof), there are no: (i)&nbsp;outstanding shares of capital stock or other securities of the
Company; (ii)&nbsp;outstanding subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire
any shares of the capital stock, restricted stock unit, stock-based performance unit or any other right that is linked to, or the
value of which is in any way based on or derived from the value of any shares of capital stock or other securities of the Company,
in each case other than derivative securities not issued by the Company; (iii)&nbsp;outstanding securities, instruments, bonds,
debentures, notes or obligations that are or may become convertible into or exchangeable for any shares of the capital stock or
other securities of the Company; (iv)&nbsp;stockholder rights plans (or similar plans commonly referred to as a &ldquo;poison pill&rdquo;)
or Contracts under which the Company is or may become obligated to sell or otherwise issue any shares of its capital stock or any
other securities; or (v)&nbsp;voting trusts or other Contract to which the Company is a party with respect to the voting of capital
stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;3.3(e)</U>&nbsp;of
the Company Disclosure Schedule sets forth a listing of all Persons who hold outstanding Company Options as of the close of business
on the Capitalization Date, indicating, with respect to each Company Option, the number of Shares subject thereto, the date of
grant, the vesting schedule and the per Share exercise price, and expiration date. Other than Shares reserved for future issuance
under the Company ESPP, the outstanding purchase rights under the Company ESPP or as set forth in this <U>Section&nbsp;3.3(e)</U>,
as of the date of the Capitalization Date, there is no issued, reserved for issuance, outstanding or authorized stock option, stock
appreciation, phantom stock, profit participation or similar equity or equity-based awards with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Authority;
Binding Nature of Agreement</FONT></B>. The Company has the corporate power and authority to execute and deliver and to perform
its obligations under this Agreement and to consummate the Transactions. The Board of Directors has (a)&nbsp;determined that this
Agreement and the Transactions, including the Offer and the Merger, are fair to, and in the best interest of, the Company and
its stockholders, (b)&nbsp;declared it advisable to enter into this Agreement, (c)&nbsp;approved the execution, delivery and performance
by the Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (d)&nbsp;resolved
that the Merger shall be effected under Section&nbsp;251(h)&nbsp;of the DGCL and (e)&nbsp;resolved to recommend that the stockholders
of the Company accept the Offer and tender their Shares to Purchaser pursuant to the Offer, which resolutions, subject to <U>Section&nbsp;6.1</U>,
have not been subsequently withdrawn or modified in a manner adverse to Parent as of the date of this Agreement. This Agreement
has been duly executed and delivered by the Company, and assuming due authorization, execution and delivery by Parent and Purchaser,
this Agreement constitutes the legal, valid and binding obligation of the Company and is enforceable against the Company in accordance
with its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and other similar laws of general applicability relating to or affecting creditors&rsquo; rights, and by general equitable principles.
If the Merger is consummated in accordance with Section&nbsp;251(h)&nbsp;of the DGCL as contemplated hereby, no vote of the Company&rsquo;s
stockholders or any holder of Shares is necessary to authorize or adopt this Agreement or to consummate the Transactions, assuming
the accuracy of the representations set forth in Section&nbsp;4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">SEC
Filings; Financial Statements</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2018, the Company has filed or furnished on a timely basis all reports, schedules, forms, statements and other
documents (including exhibits and all other information incorporated therein) required to be filed or furnished by the Company
with the SEC (as supplemented, modified or amended since the time of filing, the &ldquo;<U>Company SEC Documents</U>&rdquo;). As
of their respective dates, or, if amended prior to the date of this Agreement, as of the date of (and giving effect to) the last
such amendment (and, in the case of registration statements and proxy statements, on the date of effectiveness and the dates of
the relevant meetings, respectively), the Company SEC Documents complied in all material respects with the requirements of the
Securities Act, the Exchange Act or the Sarbanes-Oxley Act of 2001, as amended (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;), as
the case may be, and the rules&nbsp;and regulations of the SEC promulgated thereunder applicable to those Company SEC Documents,
and, except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded
(prior to the date of this Agreement) by a later filed Company SEC Document, none of the Company SEC Documents when filed or furnished
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
financial statements (including any related notes and schedules) contained or incorporated by reference in the Company SEC Documents:
(i)&nbsp;complied as to form in all material respects with the published rules&nbsp;and regulations of the SEC applicable thereto;
(ii)&nbsp;were prepared in accordance with United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;)
applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements
or, in the case of unaudited interim financial statements, as may be permitted by the SEC on Form&nbsp;10-Q, 8-K or any successor
form under the Exchange Act); and (iii)&nbsp;fairly presented, in all material respects, the financial position of the Company
as of the respective dates thereof and the results of operations and cash flows of the Company for the periods covered thereby
(subject, in the case of the unaudited financial statements, to the absence of notes and to normal and recurring year-end adjustments
that are not, individually or in the aggregate, material).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company maintains a system of &ldquo;internal control over financial reporting&rdquo; (as defined in Rule&nbsp;13a-15 under the
Exchange Act), which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (i)&nbsp;pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the
assets of the Company; (ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations
of management and the Board of Directors; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the assets of the Company that could have a material effect on its financial
statements. The Company&rsquo;s management has completed an assessment of the effectiveness of the Company&rsquo;s system of internal
control over financial reporting in compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act for the fiscal
year ended December&nbsp;31, 2019, and, except as set forth in the Company SEC Documents filed prior to the date of this Agreement,
that assessment concluded that those controls were effective. To the knowledge of the Company, since January&nbsp;1, 2020, neither
the Company nor the Company&rsquo;s independent registered accountant has identified or been made aware of: (1)&nbsp;any significant
deficiency or material weakness in the design or operation of the internal control over financial reporting utilized by the Company,
which is reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
or (2)&nbsp;any fraud, whether or not material, that involves the management or other employees of the Company who have a significant
role in the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company maintains disclosure controls and procedures as defined in and required by Rule&nbsp;13a-15 or 15d-15 under the Exchange
Act that are reasonably designed to ensure that all information required to be disclosed in the Company&rsquo;s reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
rules&nbsp;and forms of the SEC and that all such information is accumulated and communicated to the Company&rsquo;s management
as appropriate to allow timely decisions regarding required disclosure and to enable the principal executive officer of the Company
and the principal financial officer of the Company to make the certifications required under the Exchange Act with respect to such
reports. The Company is in compliance in all material respects with all current listing and corporate governance requirements of
NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is not a party to, nor does it have any obligation or other commitment to become a party to, &ldquo;off-balance sheet
arrangements&rdquo; (as defined in Item 303(a)&nbsp;of Regulation S-K under the Exchange Act) where the result, purpose or intended
effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company
in the Company SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect
to the Company SEC Documents. To the knowledge of the Company, none of the Company SEC Documents is the subject of ongoing SEC
review and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened in writing,
in each case regarding any accounting practices of the Company, except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
document required to be filed by the Company with the SEC in connection with the Offer, including the Schedule 14D-9 (the &ldquo;<U>Company
Disclosure Documents</U>&rdquo;), and any amendments or supplements thereto, when filed, distributed or otherwise disseminated
to the Company&rsquo;s stockholders, as applicable, will comply as to form in all material respects with the applicable requirements
of the Exchange Act. The Company Disclosure Documents, at the time of the filing of such Company Disclosure Documents or any supplement
or amendment thereto with the SEC and at the time such Company Disclosure Documents or any supplements or amendments thereto are
first distributed or otherwise disseminated to the Company&rsquo;s stockholders, will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
information with respect to the Company that the Company furnishes to Parent or Purchaser specifically for use in the Offer Documents,
at the time of the filing of and at the time of any distribution or dissemination of the Offer Documents, will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements made therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, the Company makes no representation with respect to statements made or incorporated by reference therein based on
information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by reference in the Company Disclosure
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Absence
of Changes; No Material Adverse Effect</FONT></B>. Except as expressly contemplated by this Agreement, from September&nbsp;30,
2019, through the date of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;the
Company has operated in all material respects in the ordinary course of business consistent with past practice, and (ii)&nbsp;the
Company has not taken any action or failed to take any action that would have constituted a breach of <U>Sections 5.2(b)(i)</U>,
<U>5.2(b)(ii)</U>, <U>5.2(b)(vi)</U>, <U>5.2(b)(vii)</U>, <U>5.2(b)(viii)</U>, <U>5.2(b)(x)</U>, <U>5.2(b)(xiii)</U>, <U>5.2(b)(xv)</U>,
<U>5.2(b)(xvi)</U>, <U>5.2(b)(xvii)</U>, <U>5.2(b)(xviii)</U>&nbsp;or <U>5.2(b)(xix)</U>&nbsp; had such action been taken after
the execution of this Agreement without the prior consent of Parent; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">there
has not occurred any change, circumstance, condition, development, effect, event, occurrence or state of facts that, individually
or in the aggregate, has had or would reasonably be expected to have, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.7</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Title
to Assets. </FONT></B>The Company has good and valid title to all assets (excluding Intellectual Property Rights) owned by it
as of the date of this Agreement, and all of such assets are owned by the Company free and clear of any Encumbrances (other
than Permitted Encumbrances), in each case, except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Real
Property</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company does not own any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company holds valid and existing leasehold interests in the real property that is leased or subleased by the Company from another
Person (the &ldquo;<U>Leased Real Property</U>&rdquo;), free and clear of all Encumbrances other than Permitted Encumbrances, in
each case, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. Since January&nbsp;1, 2018, the Company has not received any notice regarding (i)&nbsp;any material violation or breach
or default under any lease related to the Leased Real Property that has not since been cured, (ii)&nbsp;any material pending or
threatened in writing condemnation of any portion of the Leased Real Property or (iii)&nbsp;building, fire or zoning code violations
with respect to the Leased Real Property, in each case in this <U>clause (iii)</U>&nbsp;that is material to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Intellectual
Property</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Sections
3.9(a)(i)</U>&nbsp;and <U>3.9(a)(ii)</U>&nbsp;of the Company Disclosure Schedule sets forth a list of all Registered IP (including
issued Patents and Patent applications, Trademark registrations and applications, and Copyright registrations and applications),
which constitutes (i)&nbsp;Owned Registered IP or (ii)&nbsp;Licensed Registered IP (respectively). All such Registered IP is, to
the knowledge of the Company, subsisting, and, other than any pending applications therefor, valid and enforceable and is not subject
to any outstanding order, judgment or decree adversely affecting the Company&rsquo;s use thereof or rights thereto. The Company
is the sole and exclusive beneficial (and in the case of Registered IP, record owner) of all Company IP solely owned or purported
to be solely owned by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
interference, opposition, reissue, reexamination proceeding, cancellation proceeding, investigation or other Legal Proceeding (other
than routine examination proceedings with respect to pending applications) is pending against the Company or threatened in writing
against the Company in which the claim construction, validity, enforceability, priority, inventorship or ownership of any Owned
Registered IP or Licensed Registered IP that is exclusively licensed to the Company is being or has been contested or challenged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company owns and possesses all right, title and interest in and to or has the valid right to use all Company IP, free and clear
of all Encumbrances other than Permitted Encumbrances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has used commercially reasonable efforts to maintain the confidentiality of material Trade Secrets owned, purported to
be owned, or used by the Company, including requiring all Persons to whom such Trade Secrets have been disclosed by the Company
to execute written non-disclosure agreements, other than disclosures made in the ordinary course of business consistent with past
practice, such as in connection with an industry publication or presentation, or as embodied in a new Patent application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;3.9(e)(i)</U>&nbsp;of
the Company Disclosure Schedule sets forth each In-bound License and <U>Section&nbsp;3.9(e)(ii)</U>&nbsp;of the Company Disclosure
Schedule sets forth each Out-bound License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;To
the knowledge of the Company, the operation of the Company&rsquo;s business as currently conducted since January&nbsp;1, 2018 through
the date of this Agreement and as contemplated to be conducted does not and will not infringe, misappropriate or otherwise violate,
and has not infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by any other Person and (ii)&nbsp;since
January&nbsp;1, 2018 through the date of this Agreement, there has been no Legal Proceeding pending or threatened in any written
notice or other written communication directed to the Company (or to the knowledge of the Company, to any other Person) including
any such allegations (including in the form of an invitation to enter into a license) against the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2018 through the date of this Agreement, to the knowledge of the Company, (i)&nbsp;no Person is infringing, misappropriating
or otherwise violating, or has infringed, misappropriated or otherwise violated, any Company IP and (ii)&nbsp;there has been no
Legal Proceeding pending or threatened in writing including any such allegations against any Person by the Company (or to the knowledge
of the Company, by any other Person).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">None
of the Company IP owned or purported to be owned by or exclusively licensed to, the Company is subject to any outstanding injunction,
order, decree, charge, consent, judgment, covenant not to sue, settlement, ruling or other disposition of dispute, in each case,
that adversely restricts the use, transfer, registration or licensing of any such Company IP by the Company, or otherwise adversely
affects the validity, scope, use, registrability, or enforceability of any such Company IP, <I>provided</I> that the foregoing
representations and warranties are made solely to the knowledge of the Company with respect to Company IP exclusively licensed
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
current and former employee, officer and direct independent contractor (excluding, for clarity, contract service organizations)
of the Company who is or was involved in the creation or development of any material Company IP has signed a valid, enforceable
agreement containing a present assignment of such Intellectual Property Rights to the Company and confidentiality provisions protecting
such Intellectual Property Rights, and, to the Company&rsquo;s knowledge, there is no material breach under any such agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
material Company IP was conceived or developed with any funding, facilities, personnel, or other material support or resources
from any Governmental Body, any foundation, nonprofit, charity, non-governmental organization, or any public or private university,
college, or other educational institution or research center, <I>provided</I> that the foregoing representations and warranties
are made solely to the knowledge of the Company with respect to Company IP licensed to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (i)&nbsp;the
Company IT Assets operate in accordance with their specifications and related documentation and perform in a manner that permits
the Company to conduct its business as currently conducted, and (ii)&nbsp;the Company has taken commercially reasonable actions,
consistent with current industry standards, to protect the confidentiality, integrity and security of the Company IT Assets (and
all data and other information and transactions stored or contained therein or processed or transmitted thereby) against any unauthorized
use, access, interruption, modification or corruption, including the implementation of commercially reasonable data backup, disaster
avoidance and recovery procedures and business continuity procedures. Since January&nbsp;1, 2018, there has been no unauthorized
use, access or security breaches, or interruption, modification, loss or corruption of any of Company IT Assets (or any data or
other information or transactions stored or contained therein or processed or transmitted thereby).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is in compliance with applicable Legal Requirements, as well as its own policies, relating to privacy, data protection,
and the collection and use of personally identifiable information collected, used, or held for use by the Company, except as has
not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and, as of
the date of this Agreement, no Legal Proceedings or claims are pending or threatened in writing against the Company alleging a
violation of any Person&rsquo;s privacy with respect to personally identifiable information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
consummation of the Transactions will not result in the loss or impairment of or payment of any additional amounts with respect
to, nor require the consent of any other Person in respect of, the Company&rsquo;s right to own or use any of the material Company
IP owned by the Company or, to the knowledge of Company, use any of the material Company IP used by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.10</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Contracts</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;3.10(a)</U>&nbsp;of
the Company Disclosure Schedule identifies each Contract to which the Company is a party, or by which it is bound, that constitutes
a Material Contract as of the date of this Agreement and identifies, with respect to each Material Contract, the clause of <U>Section&nbsp;3.10</U></FONT><U><FONT STYLE="font-size: 1pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">(a)</FONT></U><FONT STYLE="font-size: 10pt">&nbsp;to
which it applies. For purposes of this Agreement, each of the following to which the Company is a party or by which it is bound
as of the date of this Agreement (other than (1)&nbsp;nondisclosure agreements entered into (x)&nbsp;in the ordinary course of
business consistent with past practice or (y)&nbsp;in connection with discussions, negotiations and transactions related to this
Agreement or other potential strategic transactions or (2)&nbsp;any Employee Plan) constitutes a &ldquo;<U>Material Contract</U>&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract that is a settlement, conciliation or similar agreement with or approved by any Governmental Body and pursuant to which
(A)&nbsp;the Company will be required after the date of this Agreement to pay any monetary obligations or (B)&nbsp;that contains
material obligations or limitations on the Company&rsquo;s conduct;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract (A)&nbsp;materially limiting the freedom or right of the Company to engage in any line of business or to compete with
any other Person in any location or line of business, (B)&nbsp;containing any &ldquo;most favored nations&rdquo; terms and conditions
(including with respect to pricing) granted by the Company, or (C)&nbsp;containing exclusivity obligations or otherwise materially
limiting the freedom or right of the Company to sell, distribute or manufacture any products or services for any other Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract that requires by its terms or is reasonably expected to require the payment or delivery of cash or other consideration
to the Company in an amount having a value in excess of $2,000,000 in the fiscal year ending December&nbsp;31, 2019, or by the
Company in an amount having a value in excess of $2,000,000 in the fiscal year ending December&nbsp;31, 2019, and in each case
(A)&nbsp;that cannot be cancelled by the Company without penalty or further payment without more than sixty (60) days&rsquo; notice
and (B)&nbsp;excluding commercially available off-the-shelf software licenses and Software-as-a-Service offerings, generally available
patent license agreements, material transfer agreements, clinical trial agreements and non-exclusive outbound license agreements
(in each case, entered into in the ordinary course of business);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract relating to Indebtedness in excess of $500,000 (whether incurred, assumed, guaranteed or secured by any asset) of the
Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract with any Person constituting a material joint venture, collaboration, partnership or similar profit sharing arrangement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract that by its express terms requires the Company, or any successor to, or acquirer of, the Company, to make any payment
to another Person as a result of a change of control of the Company (a &ldquo;<U>Change of Control Payment</U>&rdquo;) or gives
another Person a right to receive or elect to receive a Change of Control Payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract that prohibits the declaration or payment of dividends or distributions in respect of the capital stock of the Company,
the pledging of the capital stock or other equity interest of the Company or the issuance of any guaranty by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
(A)&nbsp;In-bound License and (B)&nbsp;Out-bound License;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract pursuant to which the Company has continuing obligations or interests involving (A)&nbsp;&ldquo;milestone&rdquo; or other
similar contingent payments, including upon the achievement of regulatory or commercial milestones which would result in a payment
in excess of $2,000,000, or (B)&nbsp;payment of royalties or other amounts calculated based upon any revenues or income of the
Company, in each case that cannot be terminated by the Company without penalty without more than sixty (60) days&rsquo; notice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">each
Contract for the acquisition or divestiture of a business or of material assets that contains continuing representations, covenants,
indemnities or other obligations (including &ldquo;earn out&rdquo; or other contingent payment obligations), but excluding any
material transfer agreements, clinical trial agreements and non-exclusive licenses, in each case, in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract that relates to any swap, forward, futures, or other similar derivative transaction with a notional value in excess of
$500,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract between the Company and any Governmental Body;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xiii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract for material Leased Real Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xiv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
other Contract that is currently in effect and has been filed (or is required to be filed) by the Company as an exhibit pursuant
to Item 601(b)(10)&nbsp;of Regulation S-K under the Securities Act or that would be required to be disclosed under Item 404 of
Regulation S-K under the Securities Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
Contract (A)&nbsp;with any Affiliate, director, executive officer (as such term is defined in the Exchange Act), Person holding
5% or more of the Shares, or, to the knowledge of the Company, any Affiliate (other than the Company) or immediate family member
of any of the foregoing or (B)&nbsp;in which any of the foregoing Persons has a direct or indirect material financial interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has either delivered or made available to Parent an accurate and complete copy of each Material Contract or has publicly
filed each Material Contract in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC. Neither the
Company nor, to the knowledge of the Company as of the date of this Agreement, any other party is in material breach of, or material
default under, any Material Contract and neither the Company nor to the knowledge of the Company, any other party to a Material
Contract has taken or failed to take any action that with or without notice, lapse of time or both would constitute a material
breach of or material default under any Material Contract. Each Material Contract is, with respect to the Company and, to the knowledge
of the Company, each other party thereto, a valid and binding agreement in full force and effect, enforceable in accordance with
its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and other similar laws of general applicability relating to or affecting creditors&rsquo; rights, and by general equitable principles.
Since January&nbsp;1, 2018 through the date of this Agreement, the Company has not received or delivered any notice regarding any
material violation or breach or default under any Material Contract that has not since been cured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.11</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Liabilities. </FONT></B>The
Company does not have any liabilities of any nature (whether accrued, absolute, contingent or otherwise), which would be
required to be reflected or reserved against on a consolidated balance sheet of the Company prepared in accordance with GAAP
or the notes thereto, except for: (a)&nbsp;liabilities reflected or reserved against in the financial statements or notes
thereto included in the Company SEC Documents filed prior to the date of this Agreement; (b)&nbsp;liabilities or obligations
incurred pursuant to the terms of this Agreement; (c)&nbsp;liabilities for performance of obligations under Contracts binding
upon the Company (other than resulting from any breach or acceleration thereof); (d)&nbsp;liabilities incurred in the
ordinary course of business consistent with past practice since December&nbsp;31, 2019; and (e)&nbsp;liabilities that have
not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.12</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Compliance
with Legal Requirements. </FONT></B>The Company is, and since January&nbsp;1, 2018 has been, in compliance with all
applicable Legal Requirements, except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. Since January&nbsp;1, 2018 through the date of this Agreement, the Company has not been
given written notice of, or been charged with, any violation of, any applicable Legal Requirement, except as has not had, and
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.13</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Regulatory
Matters.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2018, the Company has filed, maintained or furnished with the applicable regulatory authorities (including the
FDA, European Medicines Agency (&ldquo;<U>EMA</U>&rdquo;) or any other Governmental Body performing functions similar to those
performed by the FDA, EMA or otherwise having jurisdiction over the safety, efficacy, approval, development, testing, labeling,
manufacture, or storage of pharmaceutical products (such other Governmental Bodies, collectively, the &ldquo;<U>Specified Governmental
Bodies</U>&rdquo;)) all required material filings, declarations, listings, registrations, reports, submissions, applications, amendments,
modifications, notices and other documents, including but not limited to adverse event reports. All such material filings, declarations,
listings, registrations, reports, submissions, applications, amendments, modifications, notices and other documents filed or submitted
after January&nbsp;1, 2018: (i)&nbsp;have been made available to Parent and (ii)&nbsp;were in compliance with applicable Legal
Requirements, including all applicable Health Care Laws in all material respects when filed, and no material deficiencies have
been asserted by any applicable Governmental Body with respect to any such filings, declarations, listing, registrations, reports,
submissions, applications, amendments, modifications, notices and other documents. Any updates, changes, corrections or modifications
to such materials required under applicable Legal Requirements, including all applicable Health Care Laws, have been submitted
in compliance with such Legal Requirements in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">All
preclinical and clinical investigations sponsored or conducted by or on behalf of the Company or, to the knowledge of the Company,
by any of the Company&rsquo;s research, development, collaboration or similar partners with respect to any Product Candidates of
the Company while acting in such capacity (each such party a &ldquo;<U>Collaboration Partner</U>&rdquo;), have been and are being
conducted in material compliance with all applicable Legal Requirements, rules, regulations and binding guidances, including Good
Clinical Practices requirements, other Health Care Laws, applicable research protocols and federal and state laws, rules, regulations
and binding guidances relating to patient privacy requirements or restricting the use and disclosure of individually identifiable
health information. Since January&nbsp;1, 2018, except as has not had, or would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect, no clinical trial sponsored or conducted by or on behalf of the Company or by any
Collaboration Partner has been terminated, delayed or suspended prior to completion for safety or other non-business reasons, and
neither the FDA, the EMA nor any other Specified Governmental Body, clinical investigator or contract research organization that
has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial
conducted or sponsored by or on behalf of the Company or by any Collaboration Partner has commenced, or, to the knowledge of the
Company, threatened in writing to initiate, any action to place a clinical hold order on, or otherwise terminate, materially delay
or suspend, any proposed or ongoing clinical trial conducted or proposed to be conducted by or on behalf of the Company or by any
Collaboration Partner, or alleged any violation of any Health Care Law in connection with any such clinical trial. The Company
or an agent on its behalf periodically reviews clinical trial sites participating in any Company-sponsored trial for compliance
with all applicable Health Care Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2018, neither the Company nor, to the knowledge of the Company any Company Associate, employee, agent, clinical
investigator or Collaboration Partner has (i)&nbsp;made an untrue statement of a material fact or fraudulent statement to the FDA,
EMA or any other Specified Governmental Body, (ii)&nbsp;failed to disclose a material fact required to be disclosed to the FDA,
EMA, Centers for Medicare and Medicaid Services or any other Specified Governmental Body or (iii)&nbsp;committed any other act,
made any statement or failed to make any statement, that (in any such case) establishes a reasonable basis for the FDA to invoke
its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy or for the EMA or any other Specified
Governmental Body to invoke any similar policy. Neither the Company nor, to the knowledge of the Company, any Collaboration Partner,
is the subject of any pending or, to the knowledge of the Company, threatened in writing investigation or other action by the FDA
pursuant to its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy or by the EMA or any other
Governmental Body in any similar investigation or other action. Since January&nbsp;1, 2018, neither the Company nor any Company
Associate or clinical investigator of any Product Candidates of the Company or, to the knowledge of the Company, any Collaboration
Partner of the Company has been suspended, debarred or convicted of any crime or engaged in any conduct that would reasonably be
expected to result in (A)&nbsp;debarment under 21 U.S.C. Section&nbsp;335a or any similar Legal Requirement or (B)&nbsp;exclusion
under 42 U.S.C. Section&nbsp;1320a-7 or any similar Legal Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Product Candidates are being, and since January&nbsp;1, 2018, have been, developed, tested, labeled, manufactured, and stored,
as applicable, in all material respects with all Health Care Laws. Since January&nbsp;1, 2018, except as has not had, and would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect (i)&nbsp;the Company and, to the
knowledge of the Company, any Collaboration Partner, are and have not been subject to any enforcement, regulatory or administrative
proceedings against or affecting the Company or any Product Candidate relating to or arising under any Health Care Law or other
applicable Legal Requirement, and no such enforcement, regulatory or administrative proceeding has been threatened in writing,
(ii)&nbsp;neither the Company nor, to the knowledge of the Company, any Collaboration Partner, has received written notice of any
pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other Legal Proceeding,
and to the knowledge of the Company, there is not pending any allegation that any operation or activity of the Company or any Collaboration
Partner relating to the Company&rsquo;s business or any Product Candidate is in violation of any Health Care Law or other applicable
Legal Requirement and (iii)&nbsp;as of the date of this Agreement, the Company has not received any FDA Forms 483 or other Specified
Governmental Body notices of violations, inspectional observations, &ldquo;warning letters,&rdquo; &ldquo;untitled letters&rdquo;
or other similar written administrative, regulatory or enforcement notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2018, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect (i)&nbsp;no investigational new drug application or similar document filed by or on behalf of the Company
with the FDA, EMA or any other Specified Governmental Body has, to the knowledge of the Company, been terminated or suspended,
and (ii)&nbsp;neither the Company nor, to the knowledge of the Company, any Collaboration Partner, has received any written notice
from a Governmental Body that any Product Candidate cannot be developed, tested, labeled, manufactured or stored, substantially
in the manner presently performed or contemplated by the Company or any Collaboration Partner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the
Company and, to the knowledge of the Company, its Collaboration Partners have prepared, submitted and implemented timely responses
and, as applicable, any corrective action plans required to be prepared and submitted in response to all (i)&nbsp;internal or third-party
audits, inspections, investigations or examinations of the Product Candidates or the Company&rsquo;s business; (ii)&nbsp;adverse
event reports relating to the Product Candidates; (iii)&nbsp;material patient complaints relating to the Product Candidates; (iv)&nbsp;medical
incident reports relating to the Product Candidates; and (v)&nbsp;material corrective and preventive actions relating to the Product
Candidates or the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has not submitted any claim for payment to any government healthcare program in connection with any referrals related to
any Product Candidate, or engaged in any other conduct, that violated in any material respect any applicable self-referral Legal
Requirement, including the U.S. Federal Ethics in Patient Referrals Act, 42 U.S.C. &sect; 1395nn (known as the Stark Law), any
anti-kickback Legal Requirement, including the U.S. Federal Anti-Kickback Statute, 42 U.S.C. &sect; 1320a-7b, any false claims
Legal Requirement, including the U.S. Federal False Claims Act, 31 U.S.C. &sect; 3729 <I>et seq.</I>, or any other applicable similar
state or non-U.S. Legal Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has operated its business in compliance in all material respects with all applicable Legal Requirements, clinical trial
protocols, and contractual or other requirements relating to medical records and medical information privacy that regulate or limit
the maintenance, use, disclosure or transmission of medical records, clinical trial data, patient information or other personal
information made available to or collected by the Company in connection with the operation of the Company&rsquo;s business, including
the Standards for Privacy of Individually Identifiable Health Information at 45 C.F.R. Parts 160 and 164 (subparts A and E), the
Security Standards at 45 C.F.R. Parts 160 and 164 (subparts A and C), the Standards for Electronic Transactions and Code Sets at
45 C.F.R. Parts 160 and 162 promulgated under the U.S. Health Insurance Portability and Accountability Act of 1996, as amended
by the U.S. Health Information Technology for Economic and Clinical Health Act of 2009, including the regulations promulgated thereunder
(collectively &ldquo;<U>HIPAA</U>&rdquo;), the U.S. Health Information Technology for Economic and Clinical Health Act (Pub. L.
No.&nbsp;111-5) (&ldquo;<U>HITECH</U>&rdquo;) and HITECH implementing regulations, Directive 95/46/EC and all comparable Legal
Requirements relating to any of the foregoing (the &ldquo;<U>Health Care Data Requirements</U>&rdquo;). The Company has implemented
in all material respects any confidentiality, security and other measures required by the Health Care Data Requirements. The Company
is and has at all times been in compliance in all material respects with the applicable privacy and security requirements of HIPAA
and HITECH in conducting the Company&rsquo;s business. As of the date hereof, the Company has not suffered any accidental, unauthorized,
or unlawful destruction, loss, alteration, or disclosure of, or access to, personal data or suffered a security breach in relation
to any other data which it holds. As of the date hereof, no material breach has occurred with respect to any unsecured Protected
Health Information, as that term is defined in 45 C.F.R. &sect;160.103, maintained by or for the Company that is subject to the
notification requirements of 45 C.F.R. Part&nbsp;164, Subpart D, and, as of the date hereof, no information security or privacy
breach event has occurred that would require notification under any comparable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.14</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Certain
Business Practices. </FONT></B>Neither the Company nor, to the knowledge of the Company, any of its Representatives (in each
case, acting in the capacity of a Representative, and for the benefit, of the Company) has (i)&nbsp;used any funds (whether
of the Company or otherwise) for contributions, gifts, entertainment or other expenses relating to political activity in
violation of applicable Legal Requirements, (ii)&nbsp;made any payment to foreign or domestic government officials or
employees or to foreign or domestic political parties or campaigns in violation of applicable Legal Requirements or
(iii)&nbsp;violated any provision of any Anti-Corruption Laws or any rules&nbsp;or regulations promulgated thereunder,
anti-money laundering laws or any rules&nbsp;or regulations promulgated thereunder or any other applicable Legal Requirement
of similar effect, in each case of (i), (ii)&nbsp;and (iii), except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect. During the three-year period prior to the date of this
Agreement, the Company has not received any written communication from a Governmental Body that alleges any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.15</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Governmental
Authorizations. </FONT></B>The Governmental Authorizations held by the Company are valid and in full force and effect, except
as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
The Company is in compliance with the terms and requirements of such Governmental Authorizations, except as has not had, and
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.16</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Tax
Matters.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except for matters that, individually or in
the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
of the Tax Returns required to be filed by the Company with any Governmental Body (the &ldquo;<U>Company Returns</U>&rdquo;) have
been filed, and such Tax Returns (taking into account any amendments thereto) are complete and accurate. All Taxes required to
have been paid by the Company (whether or not shown on the Company Returns) have been paid to the relevant Governmental Body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has complied with all applicable Legal Requirements relating to the payment, collection, withholding and remittance of
Taxes (including information reporting requirements) with respect to payments made to any employee, creditor, stockholder, customer
or other third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;There
is no audit, examination or Legal Proceeding that is ongoing, pending or has been threatened in writing with regard to any Company
Return and (ii)&nbsp;no written claim has been received by the Company from any Governmental Body in any jurisdiction where the
Company does not file Tax Returns or pay Taxes that the Company is or may be required to file a Tax Return or be subject to Tax
in that jurisdiction. No tolling, extension or waiver of the statute of limitation period applicable to any of the Company Returns
has been granted and is currently in effect (other than pursuant to customary extensions of the due date for filing a Tax Return).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
audit, examination or Legal Proceeding involving the IRS or any other Governmental Body is ongoing, pending or has been threatened
in writing against or with respect to the Company in respect of any Tax, and no deficiency of Taxes has been asserted in writing
as a result of any audit, examination or Legal Proceeding by any Governmental Body that has not been paid, accrued for or been
contested in good faith and in accordance with applicable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company (i)&nbsp;has never been a member of an affiliated group (within the meaning of Section&nbsp;1504(a)&nbsp;of the Code) filing
a consolidated federal income Tax Return (other than a group the common parent of which is or was the Company), and (ii)&nbsp;has
no material liability for the Taxes of any other Person under Section&nbsp;1.1502-6 of the Treasury Regulations (or any corresponding
or similar provision of any state, local or non-U.S. Tax law), or as a transferee or successor or otherwise (other than pursuant
to agreements not primarily related to Taxes and entered into in the ordinary course of business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">During
the two-year period ending on the date hereof, the Company has not been either a &ldquo;distributing corporation&rdquo; or a &ldquo;controlled
corporation&rdquo; in a distribution of stock intended to qualify for tax-free treatment under Section&nbsp;355 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has not participated in any &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulations Section&nbsp;1.6011-4</FONT><FONT STYLE="font-size: 1pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 1pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">(2)&nbsp;in
any tax year for which the statute of limitations has not expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is not a party to, bound by, or has any obligation under any Tax sharing, Tax allocation or Tax indemnity agreement or
similar Contract or arrangement relating to the apportionment, sharing, assignment, indemnification or allocation of any Tax or
Tax asset (other than customary gross-up or indemnification provisions in credit agreements, derivatives, leases, employment agreements
and similar agreements entered into in the ordinary course of business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">There
are no Encumbrances with respect to Taxes upon any of the assets or properties of the Company, other than Permitted Encumbrances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
representation or warranty is made with respect to the amount or availability of any Tax attribute (including a net operating loss
or Tax credit) for any taxable period or portion thereof beginning after the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.17</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Employee
Matters; Benefit Plans.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as required by applicable Legal Requirements, the employment of each of the Company&rsquo;s employees is terminable by the Company
at will.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is not a party to, nor bound by, any collective bargaining agreement or any other labor-related Contract or arrangements
with any labor union or labor organization representing any of its employees; and no employees of the Company are represented by
any labor union or labor organization with respect to their employment with the Company. Since January&nbsp;1, 2018, there has
not been any unfair labor practice charge, material grievance, material arbitration, strike, lockout, or other union organizing
activity or dispute, or any threat thereof, by any employees of the Company with respect to their employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, the Company has been in material compliance with all applicable Legal Requirements related to employment
and employment practices, including, without limitation, all laws respecting terms and conditions of employment, health and safety,
wages and hours, child labor, immigration, employment discrimination, disability rights or benefits, equal opportunity, plant closures
and layoffs, affirmative action, workers&rsquo; compensation, labor relations, employee leave issues and unemployment insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the three-year period prior to the date of this Agreement, to the knowledge of the Company, no allegations of sexual harassment
or misconduct have been made against (i)&nbsp;any officer, or director of the Company or (ii)&nbsp;any employee of the Company
who, directly or indirectly, supervises other employees of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">To
the knowledge of the Company, no employee of the Company is in any respect in violation of any term of any employment agreement,
nondisclosure agreement, common law nondisclosure obligation, fiduciary duty, non-competition agreement, restrictive covenant or
other obligation: (i)&nbsp;to the Company or (ii)&nbsp;to a former of employer of any such employee relating to (A)&nbsp;the right
of any such employee to be employed by the Company or (B)&nbsp;the knowledge or use of trade secrets in proprietary information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">To
the knowledge of the Company, no current employee of the Company, at the level of Vice President or higher, intends to terminate
his or her employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;3.17(g)</U>&nbsp;of
the Company Disclosure Schedule sets forth a list of each material Employee Plan (other than any employment or severance agreement
for non-executive employees of the Company; equity grant notices, agreements and instruments that do not materially deviate from
the forms delivered or made available to Parent prior to the execution of this Agreement in accordance with <U>Section&nbsp;3.17(l)</U>;
and agreements with consultants entered into in the ordinary course of business consistent with past practice). The Company has
either delivered or made available to Parent prior to the execution of this Agreement with respect to each Employee Plan listed
on <U>Section&nbsp;3.17(g)</U>&nbsp;of the Company Disclosure Schedule copies of: (i)&nbsp;all plan documents and all amendments
thereto, and all related trust or other funding documents, (ii)&nbsp;the most recent annual actuarial valuation, if any, and the
most recent annual report (Form&nbsp;Series&nbsp;5500 and all schedules and financial statements attached thereto), (iii)&nbsp;all
material correspondence to or from the IRS, the United States Department of Labor or any other Governmental Body with respect to
an Employee Plan and (iv)&nbsp;the most recent determination letter received from the IRS with respect to the Employee Plan (if
applicable).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Company nor any other Person that would be or, at any relevant time, would have been considered a single employer with the
Company under the Code or ERISA has ever sponsored, maintained, contributed to, or been required to contribute to a plan subject
to Title IV of ERISA or Code Section&nbsp;412, including any &ldquo;single employer&rdquo; defined benefit plan or any &ldquo;multiemployer
plan,&rdquo; each as defined in Section&nbsp;4001 of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
of the Employee Plans that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code has obtained a favorable determination
letter (or opinion letter, if applicable) as to its qualified status under the Code, and, to the knowledge of the Company, there
are no existing circumstances or any events that have occurred that would reasonably be expected to affect materially and adversely
the qualified status of any such Employee Plan. Each of the Employee Plans has been operated in compliance with its terms and all
applicable Legal Requirements, including but not limited to ERISA and the Code, except as has not had, or would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect. To the knowledge of the Company, the Company
is not and could not reasonably be expected to be subject to a liability pursuant to Section&nbsp;502 of ERISA or a Tax imposed
pursuant to Section&nbsp;4975 or 4976 of the Code, except as has not had, or would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect. There are no pending, or, to the knowledge of the Company, threatened in writing
or anticipated material claims by, on behalf of or with respect to any Employee Plan, by any employee or beneficiary covered under
any such plan, or otherwise involving any such plan (other than routine claims for benefits), except as has not had, or would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
to the extent required under Section&nbsp;601 et seq. of ERISA or 4980B of the Code (or any other similar state or local Legal
Requirement), or where the full cost of such benefit is borne entirely by the applicable individual (or his or her eligible dependents
or beneficiaries), neither the Company nor any Employee Plan has any present or future obligation to provide post-employment welfare
benefits to or make any payment to, or with respect to, any present or former employee, officer or director of the Company pursuant
to any retiree medical benefit plan or other retiree welfare plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as provided in <U>Section&nbsp;2.8</U>, the consummation of the Transactions will not (either alone or in combination with other
events or circumstances) (i)&nbsp;entitle any current or former employee, director, officer, independent contractor or other service
provider of the Company to severance pay, unemployment compensation or any other payment, (ii)&nbsp;accelerate the time of payment
or vesting, or increase the amount of, compensation or benefits due to any such employee, director, officer, independent contractor
or (iii)&nbsp;directly or indirectly cause the Company to transfer or set aside any assets to fund any payments or benefits under
any Employee Plan. No amounts payable under an Employee Plan will fail to be deductible due to the operation of Section&nbsp;280G
of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has delivered or made available to Parent copies of the Company Equity Plans and the forms of all agreements and instruments
relating to or issued under the Company Equity Plans. Each outstanding Company Option has an exercise price equal to or above the
fair market value on the date of grant (within the meaning of Section&nbsp;409A of the Code) and is otherwise not subject to Section&nbsp;409A
of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Employee Plan maintained for the benefit of any employee or service provider (or former employee or service provider) who performs
services outside the United States is now and has been operated in material compliance with its terms and all applicable Legal
Requirements, except as has not had, or would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.18</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Environmental
Matters.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is and, since January&nbsp;1, 2018, has been in compliance with all applicable Environmental Laws, which compliance includes
obtaining, maintaining and complying with all Governmental Authorizations required under Environmental Laws for the operation of
its business, except as has not had, or would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2018 through the date of this Agreement, except as has not had, or would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect, the Company has not received any written notice, report or other information of
or entered into any legally binding agreement, order, settlement, judgment, injunction or decree involving uncompleted, outstanding
or unresolved material violations, liabilities or requirements on the part of the Company relating to or arising under Environmental
Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as has not had, or would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, to the
knowledge of the Company, there are and, since January&nbsp;1, 2018, and have been no Hazardous Materials present or Releases on,
at, under or from any property or facility, including the Leased Real Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.19</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Insurance</FONT></B>.
The Company has delivered or made available to Parent a copy of all material insurance policies relating to the business, assets
and operations of the Company. Except as has not had, or would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect, the Company maintains insurance coverage in such amounts and covering such risks as are in accordance
with normal industry practice for companies in the biotechnology industry of similar size and stage of development. To the knowledge
of the Company, all such insurance policies are in full force and effect, no notice of cancellation or material modification has
been received (other than a notice in connection with ordinary renewals), and there is no existing default or event which, with
the giving of notice or lapse of time or both, would constitute a default, by any insured thereunder except for such defaults
as have not had, or would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. There
is no claim pending under any of the Company&rsquo;s insurance policies as to which coverage has been questioned, denied or disputed
by the underwriters of such policies except for such claims as have not had, or would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.20</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Legal
Proceedings; Orders</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the date of this Agreement, there are no material Legal Proceedings pending and served (or, to the knowledge of the Company,
pending and not served or threatened in writing) against the Company or, to the knowledge of the Company, against any present or
former officer, director or employee of the Company in such individual&rsquo;s capacity as such, except as has not had, or would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
of the date of this Agreement, to the knowledge of the Company, there is no material order, writ, injunction or judgment to which
the Company is subject that is reasonably likely to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">To
the knowledge of the Company, as of the date of this Agreement, no material investigation or review by any Governmental Body with
respect to the Company is pending or is being threatened in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.21</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Takeover
Laws</FONT></B>. Assuming the accuracy of the representations and warranties of Parent and Purchaser set forth in <U>Section&nbsp;4.8</U>,
the Board of Directors has taken all actions necessary or appropriate, and will take after the date hereof, all actions that may
be necessary or appropriate, so that the restrictions applicable to business combinations contained in Section&nbsp;203 of the
DGCL and any other Takeover Law are, and will be, to the extent such restrictions can be rendered inapplicable by action of the
Board of Directors under Legal Requirements, inapplicable to the execution, delivery and performance of this Agreement and to
the consummation of the Offer, the Merger and the other Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.22</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Non-Contravention;
Consents</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Assuming
compliance with the applicable provisions of the DGCL, the HSR Act, any applicable filing, notification or approval in any foreign
jurisdiction required by Antitrust Laws (if any), and the rules&nbsp;and regulations of the SEC and NASDAQ, the execution and delivery
of this Agreement by the Company and the consummation of the Transactions will not: (i)&nbsp;cause a violation of any of the provisions
of the certificate of incorporation or bylaws (or other organizational documents) of the Company; (ii)&nbsp;cause a violation by
the Company of any Legal Requirement or order applicable to the Company, or to which the Company is subject; (iii)&nbsp;require
any consent or notice under, conflict with, result in breach of, or constitute a default under (or an event that with notice or
lapse of time or both would become a default), or give rise to any right of purchase, termination, amendment, cancellation, acceleration
or other change of any right or obligation or the loss of any benefit to which the Company is entitled under any provision of any
Material Contract; or (iv)&nbsp;result in an Encumbrance (other than a Permitted Encumbrance) on any of the property or assets
of the Company, in the case of each of <U>clauses (ii)</U>, <U>(iii)</U>&nbsp;and <U>(iv)</U>&nbsp;except as would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required by the Exchange
Act (including the filing with the SEC of the Schedule 14D-9 and such reports under the Exchange Act as may be required in connection
with this Agreement and the Transactions), the DGCL, Takeover Laws, the HSR Act and any applicable filing, notification or approval
in any foreign jurisdiction required by Antitrust Laws (if any) and the applicable rules&nbsp;and regulations of the SEC and any
national securities exchange, the Company is not required to give notice to, make any filing with, or obtain any Consent from any
Governmental Body at any time prior to the Closing in connection with the execution and delivery of this Agreement by the Company,
or the consummation by the Company of the Merger or the other Transactions, except those that the failure to make or obtain would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.23</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Opinion
of Financial Advisor</FONT></B>. The Board of Directors has received the written opinion of Centerview Partners LLC (the &ldquo;<U>Financial
Advisor</U>&rdquo;), financial advisor to the Company, that, as of the date of such opinion, and based upon and subject to the
various assumptions made, procedures followed, matters considered, and qualifications and limitations set forth therein, the $95.50
Merger Consideration per Share to be paid to the holders of the Shares (except as otherwise provided in <U>Sections 2.5(a)(i)</U>,
<U>2.5(a)(ii)</U>&nbsp;and <U>2.7</U> and other than any Shares held by any Affiliate of the Company or Parent) pursuant to this
Agreement is fair, from a financial point of view, to such holders. The Company will make available to Parent solely for informational
purposes and on a non-reliance basis, a signed copy of such opinion as soon as possible on or after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.24</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Brokers
and Other Advisors</FONT></B>. Except for the Financial Advisor, no broker, finder, investment banker, financial advisor or other
Person is entitled to any brokerage, finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission, or the reimbursement
of expenses in connection therewith, in connection with the Transactions based upon arrangements made by or on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>REPRESENTATIONS
AND WARRANTIES OF PARENT AND PURCHASER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Parent and Purchaser represent and warrant
to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Due
Organization</FONT></B>. Each of Parent and Purchaser is a corporation or other Entity duly organized, validly existing and in
good standing under the laws of its jurisdiction of organization and has all necessary power and authority: (a)&nbsp;to conduct
its business in the manner in which its business is currently being conducted; and (b)&nbsp;to own and use its assets in the manner
in which its assets are currently owned and used, except where the failure has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Purchaser</FONT></B>.
Purchaser was formed solely for the purpose of engaging in the Transactions and activities incidental thereto and has not engaged,
and prior to the Effective Time will not engage, in any business activities or conducted any operations other than in connection
with the Transactions and those incident to Purchaser&rsquo;s formation. Either Parent or a wholly owned Subsidiary of Parent
owns beneficially and of record all of the outstanding capital stock of Purchaser, free and clear of all Encumbrances and transfer
restrictions, except for Encumbrances or transfer restrictions of general applicability as may be provided under the Securities
Act or applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Authority;
Binding Nature of Agreement</FONT></B>. Parent and Purchaser have the corporate power and authority to execute and deliver and
perform their obligations under this Agreement and to consummate the Transactions. The board of directors of each of Parent and
Purchaser have approved this Agreement and declared it advisable for Parent and Purchaser, respectively, to enter into this Agreement
and approved the execution, delivery and performance by Parent and Purchaser of this Agreement and the consummation of the Transactions,
including the Offer and the Merger. This Agreement has been duly executed and delivered by Parent and Purchaser, and assuming
due authorization, execution and delivery by the Company, this Agreement constitutes the legal, valid and binding obligation of
Parent and Purchaser and is enforceable against Parent and Purchaser in accordance with its terms, except as such enforcement
may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability
relating to or affecting creditors&rsquo; rights, and by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Non-Contravention;
Consents</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Assuming
compliance with the applicable provisions of the DGCL, the HSR Act and any applicable filing, notification or approval in any foreign
jurisdiction required by Antitrust Laws (if any), the execution and delivery of this Agreement by Parent and Purchaser, and the
consummation of the Transactions, will not: (i)&nbsp;cause a violation of any of the provisions of the certificate of incorporation
or bylaws (or other organizational documents) of Parent or Purchaser; (ii)&nbsp;cause a violation by Parent or Purchaser of any
Legal Requirement or order applicable to Parent or Purchaser, or to which Parent or Purchaser are subject; or (iii)&nbsp;require
any consent or notice under, conflict with, result in breach of, or constitute a default under (or an event that with notice or
lapse of time or both would become a default), or give rise to any right of purchase, termination, amendment, cancellation, acceleration
or other adverse change of any right or obligation or the loss of any benefit to which Parent or Purchaser is entitled under any
provision of any Contract, except in the case of <U>clauses (ii)</U>&nbsp;and <U>(iii)</U>, as would not reasonably be expected
to have, individually or in the aggregate, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required by the Exchange
Act (including the filing with the SEC of the Offer Documents), Takeover Laws, the DGCL, the HSR Act and any applicable filing,
notification or approval in any foreign jurisdiction required by Antitrust Laws (if any) and the applicable rules&nbsp;and regulations
of the SEC and any national securities exchange, neither Parent nor Purchaser, nor any of Parent&rsquo;s other Affiliates, is required
to give notice to, make any filing with or obtain any Consent from any Governmental Body at any time prior to the Closing in connection
with the execution and delivery of this Agreement by Parent or Purchaser, or the consummation by Parent or Purchaser of the Offer,
the Merger or the other Transactions, except those that the failure to make or obtain as would not, individually or in the aggregate,
reasonably be expected to have a Parent Material Adverse Effect. No vote of Parent&rsquo;s or Purchaser&rsquo;s stockholders is
necessary to approve this Agreement or any of the Transactions (except in the case of Purchaser as has been obtained prior to the
execution hereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Disclosure</FONT></B>.
None of the Offer Documents will contain any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. None of the information with respect to Parent or Purchaser supplied or to be supplied by or on behalf of Parent
or Purchaser or any of their Subsidiaries, specifically for inclusion or incorporation by reference in the Schedule 14D-9 will,
(a)&nbsp;at the time such document is filed with the SEC, (b)&nbsp;at any time such document is amended or supplemented or (c)&nbsp;at
the time such document is first published, sent or given to the Company&rsquo;s stockholders, contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. For clarity, the representations and warranties
in this <U>Section&nbsp;4.5</U> will not apply to statements or omissions included or incorporated by reference in the Offer Documents
or the Schedule 14D-9 based upon information supplied to Parent by the Company or any of its Representatives on behalf of the
Company specifically for inclusion therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Absence
of Litigation</FONT></B>. As of the date of this Agreement, there is no Legal Proceeding pending and served or, to the knowledge
of Parent, pending and not served, against Parent or Purchaser, except as would not, and would not reasonably be expected to,
individually or in the aggregate, have a Parent Material Adverse Effect. As of the date of this Agreement, neither Parent nor
Purchaser is subject to any continuing order of, consent decree, settlement agreement or similar written agreement with, or continuing
investigation by, any Governmental Body, or any order, writ, judgment, injunction, decree, determination or award of any Governmental
Body, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Funds</FONT></B>.
Parent has and as of the Offer Acceptance Time will have, through cash, marketable investments and existing credit facilities,
available funds in an amount sufficient to consummate the Transactions by payment in cash of the aggregate Offer Price, the aggregate
Merger Consideration payable following the Effective Time and the aggregate amounts payable pursuant to the terms hereof to holders
of Company Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Ownership
of Shares</FONT></B>. Except for any Shares acquired in the Offer, neither Parent nor any of Parent&rsquo;s Affiliates directly
or indirectly owns, and at all times for the past three years, neither Parent nor any of Parent&rsquo;s Affiliates has owned,
beneficially or otherwise, any Shares or any securities, Contracts or obligations convertible into or exercisable or exchangeable
for Shares. Neither Parent nor Purchaser is, nor for the past three years has been, an &ldquo;interested stockholder&rdquo; of
the Company under Section&nbsp;203(c)&nbsp;of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Acknowledgement
by Parent and Purchaser</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
Parent nor Purchaser is relying, and neither Parent nor Purchaser has relied, on any representations or warranties whatsoever regarding
the subject matter of this Agreement, express or implied, except for the representations and warranties in <U>Section&nbsp;3</U>,
including the Company Disclosure Schedule. Such representations and warranties by the Company constitute the sole and exclusive
representations and warranties of the Company in connection with the Transactions and each of Parent and Purchaser understands,
acknowledges and agrees that all other representations and warranties of any kind or nature whether express, implied or statutory
are specifically disclaimed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
connection with the due diligence investigation of the Company by Parent and Purchaser and their respective Affiliates, stockholders
or Representatives, Parent and Purchaser and their respective Affiliates, stockholders and Representatives have received and may
continue to receive after the date hereof from the Company and its Affiliates, stockholders and Representatives certain estimates,
projections, forecasts and other forward-looking information, as well as certain business plan information, regarding the Company
and its businesses and operations. Parent and Purchaser acknowledge that there are uncertainties inherent in attempting to make
such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, and that Parent
and Purchaser will have no claim against the Company, or any of its Affiliates, stockholders or Representatives, or any other Person
with respect thereto unless any such information is expressly included in a representation or warranty contained in this Agreement.
Accordingly, Parent and Purchaser acknowledge and agree that neither the Company nor any of its Affiliates, stockholders or Representatives,
nor any other Person, has made or is making any express or implied representation or warranty with respect to such estimates, projections,
forecasts, forward-looking statements or business plans unless any such information is expressly included in a representation or
warranty contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.10</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Brokers
and Other Advisors</FONT></B>. Except for Persons, if any, whose fees and expenses shall be paid by Parent or Purchaser, no broker,
finder, investment banker, financial advisor or other Person is entitled to any brokerage, finder&rsquo;s, financial advisor&rsquo;s
or other similar fee or commission, or the reimbursement of expenses in connection therewith, in connection with the Transactions
based upon arrangements made by or on behalf of Parent, Purchaser, or any of their respective Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>CERTAIN
COVENANTS OF THE COMPANY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Access
and Investigation</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">During
the period from the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement pursuant
to <U>Section&nbsp;8</U> (the &ldquo;<U>Pre-Closing Period</U>&rdquo;), upon reasonable advance notice to the Company, the Company
shall, and shall cause its Representatives to, provide Parent and Parent&rsquo;s Representatives with reasonable access during
normal business hours of the Company to the Company&rsquo;s Representatives, designated personnel and assets and to all existing
books, records, documents and information relating to the Company, and promptly provide Parent and Parent&rsquo;s Representatives
with all reasonably requested information regarding the business of the Company and such additional financial, operating and other
data and information regarding the Company, as Parent may reasonably request, in each case for any reasonable business purpose
related to the consummation of the Transactions; <I>provided</I>, <I>however</I>, that any such access shall be conducted at Parent&rsquo;s
expense, at a reasonable time, under the supervision of appropriate personnel of the Company and in such a manner as not to unreasonably
interfere with the normal operation of the business of the Company. Any such access shall be subject to the Company&rsquo;s reasonable
security measures and insurance requirements and shall not include invasive testing. Nothing herein shall require the Company to
disclose any information to Parent if such disclosure would, in its reasonable discretion and after notice to Parent (i)&nbsp;jeopardize
any attorney-client or other legal privilege (so long as the Company has reasonably cooperated with Parent to permit such inspection
of or to disclose such information on a basis that does not waive such privilege with respect thereto), (ii)&nbsp;contravene any
applicable Legal Requirement or Contract (so long as the Company has reasonably cooperated with Parent to permit disclosure to
the extent permitted by Legal Requirements or the contractual counterparty); <I>provided, however</I>, in the case of <U>clause
(ii)</U>, that the Parties shall cooperate in seeking to find a way to allow disclosure of such information to the extent doing
so could reasonably (in the good faith belief of the Company (after consultation with outside counsel)) be managed through the
use of customary &ldquo;clean room&rdquo; arrangements pursuant to which non-employee Representatives of Parent could be provided
access to such information. With respect to the information disclosed pursuant to this <U>Section&nbsp;5.1</U>, Parent shall comply
with, and shall instruct Parent&rsquo;s Representatives to comply with, all of its obligations under the Mutual Confidential Disclosure
Agreement, effective as of January&nbsp;7, 2020, between the Company and Parent (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to applicable Legal Requirements, each of the Company and Parent shall promptly notify the other of (A)&nbsp;any notice or other
communication received by such Party from any Governmental Body in connection with this Agreement, the Offer, the Merger or the
other Transactions, or from any Person alleging that the consent of such Person is or may be required in connection with the Offer,
the Merger or the other Transactions; or (B)&nbsp;any Legal Proceeding commenced or, to any Party&rsquo;s knowledge, threatened
in writing against, such Party or any of its Subsidiaries or otherwise relating to, involving or affecting such Party or any of
its Subsidiaries, in each case in connection with, arising from or otherwise relating to the Offer, the Merger or any other Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;The Company shall give
prompt notice to Parent of any change, circumstance, condition, development, effect, event, occurrence or state of facts that has
had or would reasonably be expected to have a Material Adverse Effect, or would reasonably be expected to make the satisfaction
of any of the Offer Conditions impossible or unlikely, and (B)&nbsp;Parent shall give prompt notice to the Company of any change,
circumstance, condition, development, effect, event, occurrence or state of facts that has had or would reasonably be expected
to have a Parent Material Adverse Effect, or would reasonably be expected to make the satisfaction of any of the Offer Conditions
impossible or unlikely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)&nbsp;For the avoidance of doubt, the
delivery of any notice pursuant to this <U>Section&nbsp;5.1(b)</U>&nbsp;shall not cure any breach of any representation or warranty
requiring disclosure of such matter prior to the date of this Agreement or otherwise limit or affect the remedies available hereunder
to any Party. The failure to deliver any such notice shall not affect any Offer Condition or any of the conditions set forth in
<U>Section&nbsp;7</U> or give rise to any right to terminate under <U>Section&nbsp;8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Operation
of the Company&rsquo;s Business</FONT></B>. During the Pre-Closing Period, except (x)&nbsp;as expressly required by this Agreement
or as required by applicable Legal Requirements or to the extent necessary to comply with any obligation under any Contracts made
available to Parent on or prior to the date of this Agreement, (y)&nbsp;with the written consent of Parent (which consent shall
not be unreasonably withheld, conditioned or delayed), or (z)&nbsp;as set forth in <U>Section&nbsp;5.2</U> of the Company Disclosure
Schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company shall use commercially reasonable efforts to (i)&nbsp;conduct its business in the ordinary course consistent with past
practice and (ii)&nbsp;preserve intact its material assets, properties, Contracts, licenses and business organization and to preserve
satisfactory business relationships with licensors, licensees, lessors, Governmental Bodies and others having material business
dealings with the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company shall not:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(A)&nbsp;establish
a record date for, declare, set aside or pay any dividend or make any other distribution in respect of any shares of its capital
stock (including the Shares), or (B)&nbsp;repurchase, redeem or otherwise reacquire any of the Shares, or any rights, warrants
or options to acquire any of the Shares, other than: (1)&nbsp;repurchases of Shares outstanding as of the date hereof pursuant
to the Company&rsquo;s right (under written commitments in effect as of the date hereof that have been delivered or made available
to Parent) to purchase Shares held by a Company Associate in connection with the termination of such Person&rsquo;s employment
or engagement by the Company; (2)&nbsp;cancellation of Company Options (or Shares issued upon the exercise thereof) outstanding
on the date hereof pursuant to the terms of any such Company Option (in effect as of the date hereof) between the Company and a
Company Associate or member of the Board of Directors upon termination of such Person&rsquo;s employment or engagement by the Company;
or (3)&nbsp;in connection with withholding to satisfy the exercise price and/or Tax obligations with respect to Company Options
in accordance with the present terms of such Company Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">split,
combine, subdivide or reclassify any Shares or other equity interests;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sell,
issue, grant, deliver, pledge, transfer, encumber or authorize the sale, issuance, grant, delivery, pledge, transfer or encumbrance
of (A)&nbsp;any capital stock, equity interest or other security, (B)&nbsp;any option, call, warrant, restricted securities, restricted
stock unit or right to acquire any capital stock, voting securities, equity interest or other security or (C)&nbsp;any instrument
convertible into, exchangeable for or settled in any capital stock, voting securities, equity interest or other security (except
that the Company may issue Shares as required to be issued upon the exercise of Company Options outstanding as of the date of
this Agreement in accordance with their present terms or pursuant to the terms of the Company ESPP in accordance with its present
terms, but subject to <U>Section&nbsp;6.4</U>);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as set forth in <U>Section&nbsp;2.8</U>, establish, adopt, terminate or materially amend any Employee Plan (or any plan, program,
arrangement or agreement that would be an Employee Plan if it were in existence on the date hereof) or any collective bargaining
agreement or other labor agreement, or amend or waive any of its material rights under, or accelerate the payment or vesting of
compensation or benefits under, any provision of any of the Employee Plans or grant any employee or director any increase in compensation,
bonuses or severance, retention or other payments or benefits (except that the Company may: (A)&nbsp;provide increases in salary,
wages or benefits to non-executive employees in the ordinary course of business; (B)&nbsp;amend any Employee Plan to the extent
required by applicable Legal Requirements; (C)&nbsp;enter into at-will employment agreements with new non-executive employees
in the ordinary course of business; and (D)&nbsp;enter into agreements with consultants in the ordinary course of business);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">other
than offers of employment or engagement made by the Company as of the date of this Agreement that has been made available to Parent,
hire any employee or retain any consultant or promote any employee (other than non-executive employees in the ordinary course of
business consistent with past practice with compensation generally consistent with similarly situated employees);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">commence,
alone or with any third party, any clinical trial in respect of any Product Candidate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">terminate,
allow to lapse or expire, suspend, modify or otherwise take any step to limit the effectiveness or validity of, or fail to maintain
as valid and in full force and effect, any applicable material Governmental Authorization;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">qualify
any new site for manufacturing of any Product Candidate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">amend
or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;<FONT STYLE="font-size: 10pt">form
any Subsidiary, acquire any equity interest in any other Entity or enter into any joint venture, development, partnership or similar
arrangement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">make
or authorize any capital expenditure (except that the Company may make capital expenditures in the ordinary course of business
consistent with past practice that do not exceed $500,000 individually or $2,000,000 in the aggregate);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">acquire,
lease, license, sublicense, pledge, sell or otherwise dispose of, divest or spin-off, abandon, waive, covenant not to assert, relinquish
or permit to lapse (other than any Patent expiring at the end of its statutory term and not capable of being extended), transfer
or assign any material right or other material asset or property (except (A)&nbsp;licenses or sublicenses of Patents in the ordinary
course of business consistent with past practice (including entering into clinical trial agreements solely with respect to clinical
trials that are ongoing as of the date of this Agreement and material transfer agreements in the ordinary course of business consistent
with past practice) in amounts not exceeding $2,000,000 individually or in the aggregate, (B)&nbsp;pursuant to dispositions of
obsolete, surplus or worn out assets that are no longer useful in the conduct of the business of the Company in amounts not exceeding
$2,000,000 individually or in the aggregate or (C)&nbsp;capital expenditures permitted by <U>clause (xi)</U>&nbsp;of this <U>Section&nbsp;5.2(b)</U>);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xiii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">lend
money or make capital contributions or advances to or make investments in, any Person, or incur or guarantee any Indebtedness in
excess of $500,000 (except for advances to employees and consultants for travel and other business related expenses in the ordinary
course of business consistent with past practice and in compliance with the Company&rsquo;s policies related thereto);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xiv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(A)&nbsp;other
than in the ordinary course of business, amend or modify in any material respect, or waive or release any material rights under
or voluntarily terminate, any Material Contract, or (B)&nbsp;enter into any contract that would constitute a Material Contract
if it were in effect on the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">except
as required by applicable Legal Requirements, (A)&nbsp;make any material change to any accounting method, principle or practice
or accounting period used for Tax purposes; (B)&nbsp;make, change or revoke any material Tax election; (C)&nbsp;file a material
amended Tax Return; (D)&nbsp;enter into a &ldquo;closing agreement&rdquo; within the meaning of Section&nbsp;7121 of the Code (or
any corresponding or similar provision of any state, local or non-U.S. Tax law) with any Governmental Body regarding any material
Tax liability or assessment; (E)&nbsp;request any letter ruling from the IRS (or any comparable ruling from any other taxing authority);
(F)&nbsp;settle or compromise any material Legal Proceeding relating to Taxes or surrender a right to a material Tax refund; (G)&nbsp;waive
or extend the statute of limitations with respect to any material Tax or material Tax Return (other than pursuant to customary
extensions of the due date for filing a Tax Return); or (H)&nbsp;enter into any Tax allocation, indemnity or sharing agreement
(other than customary gross-up or indemnification provisions in credit agreements, derivatives, leases, employment agreements and
similar agreements entered into in the ordinary course of business);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xvi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(A)&nbsp;settle,
release, waive or compromise any Legal Proceeding or other claim (or threatened Legal Proceeding or other claim), other than any
settlement, release, waiver or compromise that (1)&nbsp;results solely in monetary obligations involving only the payment of monies
by the Company of not more than $2,000,000 in the aggregate (excluding monetary obligations that are funded by an indemnity obligation
to, or an insurance policy of, the Company) or (2)&nbsp;results in no monetary or other material non-monetary obligation of the
Company; <I>provided, however</I> that the settlement, release, waiver or compromise of any Legal Proceeding or claim brought by
the stockholders of the Company against the Company and/or its directors relating to the Transactions or a breach of this Agreement
or any other agreements contemplated hereby shall be subject to <U>Section&nbsp;2.7</U> or <U>Section&nbsp;6.6</U>, as applicable,
and <I>provided further</I> the foregoing shall not permit the Company to settle, release, waive or compromise any Legal Proceeding
or claim (x)&nbsp;that provides for the grant to any third party of a license or other grant of rights to any material Intellectual
Property Rights or (y)&nbsp;that would impose any material restrictions or changes on the business or operations of, or the admission
of wrongdoing by, the Company or (B)&nbsp;commence any material Legal Proceeding, other than in the ordinary course of business
consistent with past practice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xvii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">enter
into any collective bargaining agreement or other agreement with any labor organization (except to the extent required by applicable
Legal Requirements);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xviii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">adopt
or implement any stockholder rights plan (or similar plans or arrangements);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xix)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">adopt
a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation, restructuring, recapitalization or
other reorganization of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;authorize
any of, or agree or commit to take, any of the actions described in the foregoing <U>clauses (i)</U>&nbsp;through <U>(xix)</U>&nbsp;of
this <U>Section&nbsp;5.2(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding the foregoing, nothing contained herein shall
give to Parent or Purchaser, directly or indirectly, rights to control or direct the operations of the Company prior to the Offer
Acceptance Time. Prior to the Effective Time, each of Parent and the Company shall exercise, consistent with the terms and conditions
hereof, complete control and supervision of its and its, if applicable, Subsidiaries&rsquo; respective operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.3</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">No
Solicitation.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as permitted by this <U>Section&nbsp;5.3</U>, during the Pre-Closing Period the Company shall not, and shall cause its officers
and directors not to, and shall use reasonable best efforts to cause its other Representatives not to, directly or indirectly,
(i)&nbsp;continue any solicitation, knowing encouragement, discussions or negotiations with any Persons that may be ongoing with
respect to an Acquisition Proposal; (ii)&nbsp;(A)&nbsp;solicit, initiate or knowingly facilitate or encourage (including by way
of furnishing non-public information) any inquiries regarding, or the making of any proposal or offer that constitutes, or would
reasonably be expected to lead to, an Acquisition Proposal (other than discussions solely to clarify the terms and conditions of
such proposal or offer), (B)&nbsp;engage in, continue or otherwise participate in any discussions or negotiations regarding, or
furnish to any other Person any non-public information in connection with, or for the purpose of soliciting or knowingly encouraging
or facilitating, an Acquisition Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal
(other than to state that the terms of this provision prohibit such discussion), (C)&nbsp;approve, adopt, endorse or recommend
or enter into any letter of intent, acquisition agreement, agreement in principle or similar agreement with respect to an Acquisition
Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal (other than an Acceptable
Confidentiality Agreement) or (D)&nbsp;take any action to exempt any Person (other than Parent and its Subsidiaries) from the restrictions
on &ldquo;business combinations&rdquo; or any similar provision contained in applicable Takeover Laws or the Company&rsquo;s organizational
and other governing documents; (iii)&nbsp;waive or release any Person from, forebear in the enforcement of, or amend any standstill
agreement or any standstill provisions of any other Contract; or (iv)&nbsp;resolve or agree to do any of the foregoing. As promptly
as reasonably practicable (and in any event within two business days) following the date hereof, the Company shall discontinue
electronic or physical data room access granted, and request the prompt return or destruction (to the extent provided for by the
applicable confidentiality agreement) of all information or documents previously furnished to any Person (other than Parent, its
Affiliates and their respective Representatives) that has made, has indicated an intention to make an Acquisition Proposal and
all material incorporating such information created by any such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
at any time on or after the date of this Agreement and prior to the Offer Acceptance Time the Company or any of its Representatives
receives a <I>bona fide</I> written Acquisition Proposal from any Person or group of Persons, which Acquisition Proposal was made
on or after the date of this Agreement and did not result from a material breach of this <U>Section&nbsp;5.3</U>, and the Board
of Directors determines in good faith, after consultation with its financial advisor and outside legal counsel, that such Acquisition
Proposal constitutes or would reasonably be expected to result in a Superior Offer and that the failure to take such action described
in <U>clauses (x)</U>&nbsp;and <U>(y)</U>&nbsp;below would be inconsistent with its fiduciary duties under applicable Legal Requirements,
then, notwithstanding anything in <U>Section&nbsp;5.3(a)</U>&nbsp;to the contrary, the Company and its Representatives may (x)&nbsp;furnish,
pursuant to an Acceptable Confidentiality Agreement, information (including non-public information) with respect to the Company
to the Person or group of Persons who has made such Acquisition Proposal, <I>provided </I>that the Company shall as promptly as
practicable (and in any event within 36 hours) provide to Parent any information concerning the Company that is provided to any
Person to the extent access to such information was not previously provided to Parent or its Representatives; and (y)&nbsp;engage
in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal;
<I>provided</I>, in the case of <U>clauses (x)</U>&nbsp;and <U>(y)</U>, that at or prior to the first time that the Company furnishes
any information to or participates in any discussions or negotiations with any Person on or after the date of this Agreement, the
Company shall provide written notice to Parent of such determination in good faith of the Board of Directors as provided for above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">During
the Pre-Closing Period, the Company shall (i)&nbsp;promptly (and in any event within 36 hours) notify Parent orally and in writing
if any inquiries, proposals or offers with respect to, or that would reasonably be expected to lead to, an Acquisition Proposal
are received by the Company or any of its Representatives and provide to Parent a copy of any written Acquisition Proposal (including
any proposed term sheet, letter of intent, acquisition agreement or other agreement or other supporting materials with respect
thereto) and a summary of any material unwritten terms and conditions thereof (and indicate the identity of such Person), and (ii)&nbsp;keep
Parent reasonably informed of any material developments, discussions or negotiations regarding any Acquisition Proposal on a prompt
basis (and in any event within 36 hours of such material development, discussion or negotiation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Nothing
in this <U>Section&nbsp;5.3</U> or elsewhere in this Agreement shall prohibit the Company from disclosing to the stockholders of
the Company any &ldquo;stop, look and listen&rdquo; communication pursuant to Rule&nbsp;14d-9(f)&nbsp;promulgated under the Exchange
Act or from taking and disclosing such other position or disclosure as is required under Rule&nbsp;14e-2(a), Rule&nbsp;14d-9 or
Item 1012(a)&nbsp;of Regulation M-A promulgated under the Exchange Act or from taking any action necessary to comply with applicable
Legal Requirements; <I>provided, however</I>, that, the Board of Directors shall not effect a Company Adverse Change Recommendation
except in accordance with <U>Section&nbsp;6.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company agrees that in the event any Representative of the Company acting on behalf of the Company takes any action that, if taken
by the Company, would constitute a breach of this <U>Section&nbsp;5.3</U>, the Company shall be deemed to be in breach of this
<U>Section&nbsp;5.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>ADDITIONAL
COVENANTS OF THE PARTIES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.1</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Company
Board Recommendation.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;6.1(b)</U>, the Company hereby consents to the inclusion of a description of the Company Board Recommendation
in the Offer Documents. During the Pre-Closing Period, subject to <U>Section&nbsp;6.1(b)</U>, neither the Board of Directors nor
any committee thereof shall (i)(A)&nbsp;withdraw or withhold (or modify or qualify in a manner adverse to Parent or Purchaser),
or publicly propose to withdraw or withhold (or modify or qualify in a manner adverse to Parent or Purchaser), the Company Board
Recommendation, (B)&nbsp;adopt, approve, recommend or declare advisable, or publicly propose to adopt, approve, recommend or declare
advisable, any Acquisition Proposal, (C)&nbsp;after public announcement of an Acquisition Proposal (other than a tender offer or
exchange offer), fail to publicly affirm the Company Board Recommendation within three business days after a written request by
Parent to do so (or, if earlier, by the close of business on the business day immediately preceding the scheduled date of the Offer
Acceptance Time), <I>provided</I>, that Parent may only make such request once with respect to any Acquisition Proposal (<I>provided</I>,
that each time a Determination Notice is given Parent shall, subject to the following provision, be entitled to make a new such
request); and <I>provided</I>, <I>further</I>, that the Company shall not be required to provide any such affirmation during the
two or three business day periods, as applicable, following the giving of a Determination Notice, (D)&nbsp;following the commencement
of a tender offer or exchange offer relating to the Shares by a Person unaffiliated with Parent, fail to publicly affirm the Company
Board Recommendation and recommend that the Company&rsquo;s stockholders reject such tender offer or exchange offer within 10 business
days after the commencement of such tender offer or exchange offer pursuant to Rule&nbsp;14d-9(f)&nbsp;promulgated under the Exchange
Act (or, if earlier, by the close of business on the business day immediately preceding the scheduled date of the Offer Acceptance
Time) or (E)&nbsp;fail to include the Company Board Recommendation in the Schedule 14D-9 when filed with the SEC or disseminated
to the Company&rsquo;s stockholders (any action described in this <U>clause (i)</U>&nbsp;being referred to as a &ldquo;<U>Company
Adverse Change Recommendation</U>&rdquo;) or (ii)&nbsp;approve, recommend or declare advisable, or propose to approve, recommend
or declare advisable, or cause or allow the Company to execute or enter into any Contract, letter of intent, memorandum of understanding,
agreement in principle or term sheet with respect to, or that is intended to or would reasonably be expected to lead to, any Acquisition
Proposal, or requiring, or reasonably expected to cause, the Company to abandon, terminate, delay or fail to consummate, or that
would otherwise materially impede, interfere with or be inconsistent with, the Transactions (other than an Acceptable Confidentiality
Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary contained in this Agreement, at any time prior to the Offer Acceptance Time, and subject to compliance
with the other provisions of this <U>Section&nbsp;6.1</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;<FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">if
the Company has received a <I>bona fide</I> written Acquisition Proposal from any Person that has not been withdrawn and after
consultation with outside legal counsel and its financial advisor, the Board of Directors shall have determined, in good faith,
that such Acquisition Proposal constitutes a Superior Offer, (x)&nbsp;the Board of Directors may make a Company Adverse Change
Recommendation, or (y)&nbsp;provided that the Company is not in breach of <U>Section&nbsp;5.3 </U>in any material respect and
in a manner that led to such Acquisition Proposal and subject to the other provisions of <U>Section&nbsp;8.1</U></FONT><U><FONT STYLE="font-size: 1pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">(e)</FONT></U><FONT STYLE="font-size: 10pt">,
the Company may terminate this Agreement pursuant to <U>Section&nbsp;8.1(e)</U>&nbsp;to enter into a Specified Agreement with
respect to such Superior Offer, in each case, if and only if: (A)&nbsp;the Board of Directors determines in good faith, after
consultation with the Company&rsquo;s outside legal counsel and its financial advisor, that the failure to do so would be inconsistent
with the fiduciary duties of the Board of Directors under applicable Legal Requirements; (B)&nbsp;the Company shall have given
Parent prior written notice of its intention to consider making a Company Adverse Change Recommendation or terminating this Agreement
pursuant to <U>Section&nbsp;8.1(e)</U>&nbsp;at least three business days prior to making any such Company Adverse Change Recommendation
or termination (a &ldquo;<U>Determination Notice</U>&rdquo;) (which notice shall not constitute a Company Adverse Change Recommendation
or termination) and, if requested in writing by Parent during such three business day period, shall have negotiated, and caused
its Representatives to negotiate, in good faith with respect to any revisions to the terms of this Agreement or another proposal
to the extent proposed by Parent so that such Acquisition Proposal would cease to constitute a Superior Offer; and (C)&nbsp;(1)&nbsp;the
Company shall have provided to Parent information with respect to such Acquisition Proposal in accordance with <U>Section&nbsp;5.3(c)</U>,
as well as a copy of any acquisition agreement with respect to such Acquisition Proposal and a copy of any financing commitments
relating thereto (or, if not provided in writing to the Company, a written summary of the material terms thereof), (2)&nbsp;the
Company shall have given Parent the three business day period after the Determination Notice to propose revisions to the terms
of this Agreement or make another proposal so that such Acquisition Proposal would cease to constitute a Superior Offer, and (3)&nbsp;after
giving effect to the proposals made by Parent during such period, if any, after consultation with outside legal counsel and its
financial advisor, the Board of Directors shall have determined, in good faith, that such Acquisition Proposal constitutes a Superior
Offer and that the failure to make the Company Adverse Change Recommendation or terminate this Agreement pursuant to <U>Section&nbsp;8.1(e)</U>&nbsp;would
be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements. Issuance of any &ldquo;stop,
look and listen&rdquo; communication by or on behalf of the Company pursuant to Rule&nbsp;14d-9(f)&nbsp;promulgated under the
Exchange Act, taking and disclosing a position or otherwise making any disclosure as is required under Rule&nbsp;14e-2(a), Rule&nbsp;14d-9
or Item 1012(a)&nbsp;of Regulation M-A promulgated under the Exchange Act or otherwise complying with applicable Legal Requirements
shall not, in and of itself, be considered a Company Adverse Change Recommendation and shall not require the giving of a Determination
Notice or compliance with the procedures set forth in this <U>Section&nbsp;6.1</U>. The provisions of this <U>Section&nbsp;6.1(b)(i)</U>&nbsp;shall
also apply to any change to any of the financial terms (including the form, amount and timing of payment of consideration) or
other material amendment to any Acquisition Proposal and require a new Determination Notice (<I>provided</I> that for the purposes
of such subsequent Determination Notice, all references to &ldquo;three business days&rdquo; shall be deemed to be &ldquo;two
business days&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;<FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">other
than in connection with a Superior Offer (which shall be subject to <U>Section&nbsp;6.1(b)(i)</U>), the Board of Directors may
make a Company Adverse Change Recommendation in response to an Intervening Event if: (A)&nbsp;the Board of Directors determines
in good faith, after consultation with the Company&rsquo;s outside legal counsel and its financial advisor, that the failure to
do so would be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements; (B)&nbsp;the
Company shall have given Parent a Determination Notice at least three business days prior to making any such Company Adverse Change
Recommendation and, if desired by Parent, during such three business day period shall have negotiated, and caused its Representatives
to negotiate, in good faith with respect to any revisions to the terms of this Agreement or another proposal to the extent proposed
by Parent so that a Company Adverse Change Recommendation would no longer be necessary; and (C)&nbsp;(1)&nbsp;the Company shall
have specified in reasonable detail the facts and circumstances that render a Company Adverse Change Recommendation necessary,
(2)&nbsp;the Company shall have given Parent the three business day period after the Determination Notice to propose revisions
to the terms of this Agreement or make another proposal so that a Company Adverse Change Recommendation would no longer be necessary,
and (3)&nbsp;after giving effect to the proposals made by Parent during such period, if any, after consultation with outside legal
counsel, the Board of Directors shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation
would be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements. The provisions of
this <U>Section&nbsp;6.1(b)(ii)</U>&nbsp;shall also apply to any material change to the facts and circumstances specified by the
Company pursuant to <U>clause (C)(1)</U>&nbsp;above and require a new Determination Notice (<I>provided</I> that for the purposes
of such subsequent Determination Notice, all references to &ldquo;three business days&rdquo; shall be deemed to be &ldquo;two business
days&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.2</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Filings,
Consents and Approvals.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties agree to use their reasonable best efforts to take promptly any and all steps necessary to avoid or eliminate each and
every impediment under the Antitrust Laws, that may be asserted by any Governmental Body, so as to enable the Closing to occur
as promptly as practicable, but in no case later than the End Date, including providing as promptly as reasonably practicable and
advisable all non-legally privileged information reasonably required by any Governmental Body pursuant to its evaluation of the
Transactions under the HSR Act. Subject to the terms of this <U>Section&nbsp;6.2</U>, the Parties shall use their reasonable best
efforts to obtain from any Governmental Body all consents, approvals authorizations or orders required to be obtained under the
Antitrust Laws or to avoid the entry or enactment of any injunction or other order or decree relating to any Antitrust Law that
would delay, restrain, prevent, enjoin or otherwise prohibit consummation of the Transactions. Notwithstanding anything to the
contrary in this Agreement, Parent and its Affiliates shall not be required to, and without the prior written consent of Parent
the Company shall not, sell, license, divest or dispose of or hold separate (through the establishment of a trust or otherwise)
or agree to any other structural, behavioral or conduct remedy, before or after the Offer Acceptance Time or the Effective Time,
any entities, businesses, divisions, operations, products or product lines, assets,&nbsp;Intellectual Property Rights or businesses
of Parent, the Company (or any of their respective Subsidiaries or other Affiliates) or agree to any restriction on the conduct
of such businesses which (A)&nbsp;would materially and adversely affect the business of Parent and its Subsidiaries, taken as a
whole, or (B)&nbsp;would require the sale, license, divestiture, disposal, or holding separate of, or any other structural, behavioral
or conduct remedy involving the Product Candidates. Nothing in this <U>Section&nbsp;6.2</U> shall require the Parent or the Company
to take or agree to take any action unless the effectiveness of such action is conditioned upon Closing. Notwithstanding the foregoing
and any other provision of this Agreement to the contrary, in no event shall Parent, Purchaser, the Company or any of their respective
Subsidiaries be obligated to litigate or participate in the litigation of any action, whether judicial or administrative, brought
by any Governmental Body challenging or seeking to restrain, prohibit or place conditions on the consummation of the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to the terms and conditions of this Agreement, each of the Parties shall (and shall cause their respective Affiliates, if applicable,
to): (i)&nbsp;as promptly as reasonably practicable (but no later than 10 business days after the date of this Agreement), make
an appropriate filing of all Notification and Report forms as required by the HSR Act, with respect to the Transactions and (ii)&nbsp;cooperate
with each other in determining whether, and promptly preparing and making, any other filings, notifications or other consents are
required to be made with, or obtained from, any other Governmental Bodies in connection with the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Without
limiting the generality of anything contained in this <U>Section&nbsp;6.2</U>, during the Pre-Closing Period, each Party shall
(i)&nbsp;give the other Parties prompt notice of the making or commencement of any request, inquiry, investigation, action or Legal
Proceeding brought by a Governmental Body or brought by a third party before any Governmental Body, in each case, with respect
to the Transactions under the Antitrust Laws, (ii)&nbsp;keep the other Parties reasonably informed as to the status of any such
request, inquiry, investigation, action or Legal Proceeding, (iii)&nbsp;promptly inform the other Parties of, and wherever practicable
give the other party reasonable advance notice of, and the opportunity to participate in, any communication to or from the FTC,
DOJ or any other Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (iv)&nbsp;promptly
furnish to the other Party, subject to an appropriate confidentiality agreement to limit disclosure to counsel and outside consultants,
with copies of documents provided to or received from any Governmental Body in connection with any such request, inquiry, investigation,
action or Legal Proceeding (except that documents, including &ldquo;4(c)&nbsp;and 4(d)&nbsp;documents&rdquo; as that term is used
under the HSR Act, that contain valuation information can be redacted), (v)&nbsp;subject to an appropriate confidentiality agreement
to limit disclosure to counsel and outside consultants, and to the extent reasonably practicable, consult and cooperate with the
other Parties and consider in good faith the views of the other Parties in connection with any written analysis, appearance, presentation,
memorandum, brief, argument, opinion or proposal made or submitted in connection with any such request, inquiry, investigation,
action or Legal Proceeding, and (vi)&nbsp;except as may be prohibited by any Governmental Body or by any Legal Requirement, in
connection with any such request, inquiry, investigation, action or Legal Proceeding in respect of the Transactions, give the other
Party reasonable prior notice and permit authorized Representatives of the other Party to be present at each meeting or conference,
including by telephone, relating to such request, inquiry, investigation, action or Legal Proceeding and to have access to and
be consulted in advance in connection with any argument, opinion or proposal made or submitted to any Governmental Body in connection
with such request, inquiry, investigation, action or Legal Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">During
the Pre-Closing Period, the Company shall to the extent permissible under applicable Legal Requirements and reasonably practicable
and where doing so would not reasonably be expected to impair or adversely affect the Company, any of its plans with respect to
the Product Candidates or its ability to interact with any Governmental Body consistent with companies at similar stages of development
in the pharmaceutical industry (in each case as determined in good faith by the Company) (i)&nbsp;offer Parent the opportunity
to consult with the Company prior to any proposed material meeting or other material communication with the FDA, EMA, the Centers
for Medicare&nbsp;&amp; Medicaid Services (&ldquo;<U>CMS</U>&rdquo;) or any other Specified Governmental Body relating to any Product
Candidate or material Governmental Authorization (it being understood that in no event shall the Company be required to delay or
modify any of its actions as a result of this <U>Section&nbsp;6.2(d)</U>), (ii)&nbsp;promptly inform Parent of, and provide Parent
with a reasonable opportunity to review, in advance, any material filing proposed to be made by or on behalf of the Company, and
any material correspondence or other material communication proposed to be submitted or otherwise transmitted to the FDA, EMA,
CMS or any other Specified Governmental Body by or on behalf of the Company, in each case relating to any Product Candidate or
material Governmental Authorization (it being understood that in no event shall the Company be required to delay any such filings,
correspondence or communication), (iii)&nbsp;keep Parent reasonably informed of any material communication (written or oral) with
or from the FDA, EMA, CMS or any other Specified Governmental Body or relating to any Product Candidate or Governmental Authorization
and (iv)&nbsp;promptly inform Parent and provide Parent with a reasonable opportunity (but no more than two business days, to the
extent practicable) to comment, in each case, prior to making any material change to any study protocol, adding any new trial,
making any material change to a manufacturing plan or process, making any material change to a development timeline or initiating,
or making any material change to, commercialization and reimbursement activities or materials (including promotional and marketing
activities and materials) relating to any Product Candidate. The Company shall promptly notify Parent of any significant data relating
to any Product Candidate, including information related to any significant adverse events with respect to any Product Candidate,
in each case which it discovers after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
Party shall enter into any agreement, transaction, or any agreement to effect any transaction (including any merger or acquisition)
that would reasonably be expected to make it materially more difficult, or to materially increase the time required, to (i)&nbsp;obtain
the expiration or termination of the waiting period under the HSR Act, (ii)&nbsp;avoid the entry of, the commencement of litigation
seeking the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other order that would materially
delay or prevent the consummation of the transactions contemplated hereby, or (iii)&nbsp;obtain all authorizations, consents, orders
and approvals of Governmental Bodies necessary for the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.3</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Employee
Benefits.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
a period commencing at the Effective Time and ending on the one year anniversary of the Effective Time, Parent shall provide, or
cause to be provided, to those employees of the Company who are employed by the Company as of immediately prior to the Effective
Time and who continue to be actively employed by the Surviving Corporation (or any Affiliate thereof) during such period (the &ldquo;<U>Continuing
Employees</U>&rdquo;) with (i)&nbsp;the base salary or wage rate and annual cash bonus opportunities (excluding equity-based compensation
opportunities) that are, in each case, no less than those provided by the Company immediately prior to the Offer Acceptance Time;
(ii)&nbsp;retirement and welfare benefits that are no less favorable in the aggregate than those provided by the Company immediately
prior to the Offer Acceptance Time; and (iii)&nbsp;severance benefits no less favorable than those provided to by the Company immediately
prior to the Offer Acceptance Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Parent
agrees that all Continuing Employees shall be eligible to continue to participate in the Surviving Corporation&rsquo;s health and
welfare benefit plans (to the same extent such Continuing Employees were eligible to participate under the health and welfare benefit
plans of the Company immediately prior to the Effective Time); <I>provided, however</I>, that (i)&nbsp;nothing in this <U>Section&nbsp;6.3</U>
or elsewhere in this Agreement shall limit the right of Parent or the Surviving Corporation to amend or terminate any such health
or welfare benefit plan at any time, subject to the requirements set forth in <U>Section&nbsp;6.3(a)</U>, and (ii)&nbsp;if Parent
or the Surviving Corporation terminates any such health or welfare benefit plan (upon expiration of any appropriate transition
period), then the Continuing Employees shall be eligible to participate in the Surviving Corporation&rsquo;s (or an Affiliate&rsquo;s)
health and welfare benefit plans to the extent that coverage under such plans is replacing comparable coverage under an Employee
Plan in which such Continuing Employee participated immediately before the Effective Time. To the extent that service is relevant
under any benefit plan of Parent or an Affiliate and/or the Surviving Corporation, then Parent shall ensure that such benefit plan
shall, for all purposes, credit Continuing Employees for service prior to the Effective Time with the Company and its Affiliates
or their respective predecessors; <I>provided</I>, that, if such benefit plan replaces a benefit plan of the Company that recognized
service for the same purpose, such service will be recognized to the same extent that such service was recognized prior to the
Effective Time under the corresponding benefit plan of the Company. Nothing in this <U>Section&nbsp;6.3</U> or elsewhere in this
Agreement shall be construed to create a right in any Person to employment with Parent, the Surviving Corporation or any other
Affiliate of the Surviving Corporation and the employment of each Continuing Employee shall be &ldquo;at will&rdquo; employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">To
the extent permitted under applicable Legal Requirements, with respect to any employee benefit plans maintained for the benefit
of the Continuing Employees following the Effective Time, Parent shall, and shall cause the Surviving Corporation, any of its Affiliates,
and any successor thereto, to (i)&nbsp;cause there to be waived any eligibility requirements or pre-existing condition limitations
or waiting period requirements to the same extent waived or satisfied under comparable plans of the Company or its Subsidiaries,
and (ii)&nbsp;give effect, in determining any deductible, co-insurance and maximum out-of-pocket limitations, amounts paid by such
employees during the calendar year in which the Effective Time occurs under similar plans maintained by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
provisions of this <U>Section&nbsp;6.3</U> are solely for the benefit of the Parties, and no provision of this <U>Section&nbsp;6.3</U>
is intended to, or shall, constitute the establishment or adoption of or an amendment to any employee benefit plan for purposes
of ERISA or otherwise, and no current or former employee or any other individual associated therewith shall be regarded for any
purpose as a third party beneficiary of this Agreement or have the right to enforce the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.4</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">ESPP. </FONT></B>As
soon as reasonably practicable after the date of this Agreement, the Company shall take all necessary actions under the
Company ESPP to provide that (a)&nbsp;the &ldquo;Offering&rdquo; (as defined in the Company ESPP) in effect as of the date of
this Agreement shall be the final Offering (such period, the &ldquo;<U>Final Offering</U>&rdquo;) and no further Offering
shall commence pursuant to the Company ESPP after the date of this Agreement, and (b)&nbsp;each individual participating in
the Final Offering on the date of this Agreement shall not be permitted to (i)&nbsp;increase his or her payroll contribution
rate pursuant to the Company ESPP from the rate in effect when the Final Offering commenced or (ii)&nbsp;make separate
non-payroll contributions to the Company ESPP on or following the date of this Agreement, except as may be required by
applicable Legal Requirement. Prior to the Offer Acceptance Time, the Company shall take all action that may be necessary to,
effective upon the Offer Acceptance Time, (A)&nbsp;cause the Final Offering, to the extent that it would otherwise be ongoing
at the Offer Acceptance Time, to be terminated no later than five business days prior to the date on which the Offer
Acceptance Time occurs; (B)&nbsp;make any pro rata adjustments that may be necessary to reflect the Final Offering, but
otherwise treat the Final Offering as a fully effective and completed Offering for all purposes pursuant to the Company ESPP;
and (C)&nbsp;cause the exercise (as of no later than five business days prior to the date on which the Offer Acceptance Time
occurs) of each outstanding purchase right pursuant to the Company ESPP. On such exercise date, the Company shall apply the
funds credited as of such date pursuant to the Company ESPP within each participant&rsquo;s payroll withholding account to
the purchase of Shares in accordance with the terms of the Company ESPP, and each Share shall be an outstanding Share and
entitled to the Merger Consideration. The Company shall adopt such resolutions as are necessary to terminate the Company ESPP
effective as of immediately prior to, and conditional upon the occurrence of, the Offer Acceptance Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.5</B></FONT><B><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Indemnification
of Officers and Directors.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
a period of six years from the Effective Time, Parent agrees that all rights to indemnification, advancement of expenses and exculpation
from liabilities for acts or omissions occurring at or prior to the Effective Time (whether asserted or claimed prior to, at or
after the Effective Time) now existing in favor of the current or former directors or officers of the Company under the certificate
of incorporation and bylaws of the Company and any indemnification or other similar agreements of the Company set forth on <U>Section&nbsp;6.5(a)</U>&nbsp;of
the Company Disclosure Schedule, in each case as in effect on the date of this Agreement, shall continue in full force and effect
in accordance with their terms and shall not be amended, repealed or otherwise modified in any manner that would adversely affect
the rights thereunder of any Indemnified Person (as defined below), and Parent shall cause the Company to perform its obligations
thereunder. Without limiting the foregoing, during the period commencing at the Effective Time and ending on the sixth anniversary
of the Effective Time, Parent shall cause the Surviving Corporation and its Subsidiaries to, and the Surviving Corporation agrees
that it will, indemnify and hold harmless each individual who is as of the date of this Agreement, or who becomes prior to the
Effective Time, a director or officer of the Company or who is as of the date of this Agreement, or who thereafter commences prior
to the Effective Time, serving at the request of the Company as a director or officer of another Person (the &ldquo;<U>Indemnified
Persons</U>&rdquo;), against all claims, losses, liabilities, damages, judgments, inquiries, fines and reasonable fees, costs and
expenses, including attorneys&rsquo; fees and disbursements, incurred in connection with any claim, action, suit or proceeding,
whether civil, criminal, administrative or investigative (including with respect to matters existing or occurring at or prior to
the Effective Time, including this Agreement and the transactions and actions contemplated hereby), arising out of or pertaining
to the fact that the Indemnified Person is or was a director or officer of the Company or is or was serving at the request of the
Company as a director or officer of another Person, whether asserted or claimed prior to, at or after the Effective Time, to the
fullest extent permitted under applicable Legal Requirements. In the event of any such claim, action, suit or proceeding, (x)&nbsp;each
Indemnified Person will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit or proceeding
from Parent, the Surviving Corporation or its Subsidiaries, as applicable, in accordance with the organizational documents and
any indemnification or other similar agreements of the Surviving Corporation or its Subsidiaries, as applicable, as in effect on
the date of this Agreement; <I>provided</I> that any Indemnified Person to whom expenses are advanced provides an undertaking,
if and only to the extent required by the DGCL or the Surviving Corporation&rsquo;s or any of its Subsidiaries&rsquo; certificate
of incorporation or bylaws (or comparable organizational documents) or any such indemnification or other similar agreements, as
applicable; to repay such advances if it is ultimately determined by final adjudication that such Indemnified Person is not entitled
to indemnification and (y)&nbsp;Parent, the Surviving Corporation and its Subsidiaries, as applicable, shall reasonably cooperate
in the defense of any such matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
a period of six years from and after the Effective Time, Parent and the Surviving Corporation shall either cause to be maintained
in effect the current policies of directors&rsquo; and officers&rsquo; liability insurance maintained by the Company or provide
substitute policies for the Company and its current and former directors and officers who are currently covered by the directors&rsquo;
and officers&rsquo; insurance coverage currently maintained by the Company, in either case, of not less than the existing coverage
and having other terms not less favorable to the insured persons than the directors&rsquo; and officers&rsquo; liability insurance
coverage currently maintained by the Company with respect to claims arising from facts or events that occurred at or before the
Effective Time (with insurance carriers having at least an &ldquo;A&rdquo; rating by A.M.&nbsp;Best with respect to directors&rsquo;
and officers&rsquo; liability insurance), except that in no event shall Parent or the Surviving Corporation be required to pay
with respect to such insurance policies an annual premium greater than 300% of the aggregate annual premium most recently paid
by the Company prior to the date of this Agreement (the &ldquo;<U>Maximum Amount</U>&rdquo;), and if the Surviving Corporation
is unable to obtain the insurance required by this <U>Section&nbsp;6.5(b)</U>&nbsp;it shall obtain as much comparable insurance
as possible for the years within such six year period for a premium equal to the Maximum Amount. In lieu of such insurance, prior
to the Closing Date the Company may purchase a &ldquo;tail&rdquo; directors&rsquo; and officers&rsquo; liability insurance policy
for the Company and its current and former directors and officers who are currently covered by the directors&rsquo; and officers&rsquo;
liability insurance coverage currently maintained by the Company, such tail to provide coverage in an amount not less than the
existing coverage and to have other terms not less favorable to the insured persons than the directors&rsquo; and officers&rsquo;
liability insurance coverage currently maintained by the Company with respect to claims arising from facts or events that occurred
at or before the Effective Time; <I>provided</I> that in no event shall the cost of any such tail policy exceed the Maximum Amount.
Parent and the Surviving Corporation shall maintain such policies in full force and effect, and continue to honor the obligations
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event that the Company or any of its successors or assigns (i)&nbsp;consolidates with or merges into any other Person and is
not the continuing or surviving corporation or Entity of such consolidation or merger or (ii)&nbsp;transfers or conveys all or
substantially all of its properties and assets to any Person, then, and in each such case, the Company, as applicable, shall cause
proper provision to be made so that the successors and assigns of the Company assume the obligations set forth in this <U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
provisions of this <U>Section&nbsp;6.5</U> (i)&nbsp;shall survive the acceptance of Shares for payment pursuant to the Offer and
the consummation of the Merger and (ii)&nbsp;are intended to be for the benefit of, and will be enforceable by, each indemnified
or insured party (including the Indemnified Persons), his or her heirs, successors, assigns and representatives, and (iii)&nbsp;are
in addition to, and not in substitution for, any other rights to indemnification, advancement of expenses, exculpation or contribution
that any such Person may have by contract or otherwise. Unless required by applicable Legal Requirement, this <U>Section&nbsp;6.5</U>
may not be amended, altered or repealed after the Offer Acceptance Time in such a manner as to adversely affect the rights of any
Indemnified Person or any of their successors, assigns or heirs without the prior written consent of the affected Indemnified Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Stockholder
Litigation</FONT></B>. In the event that any litigation related to this Agreement, the Offer, the Merger or the other Transactions
is brought by any stockholder or other holder of Company securities (whether directly or on behalf of the Company or otherwise)
against the Company and/or its directors or officers, the Company shall promptly notify Parent and shall keep Parent reasonably
and promptly informed with respect to the status thereof. The Company shall give Parent the (a)&nbsp;opportunity to participate
in the defense of any such litigation, (b)&nbsp;right to review and comment on all material filings or responses to be made by
the Company in connection with such litigation (and shall give due consideration to Parent&rsquo;s comments and other advice with
respect to such litigation) and (c)&nbsp;right to consult on any settlement with respect to such litigation, and no such settlement
shall be agreed to without Parent&rsquo;s prior written consent, such consent not to be unreasonably withheld; <I>provided</I>,
<I>however</I>, that in no event shall Parent be required to consent (such consent not to be unreasonably withheld, conditioned
or delayed) to any such settlement that does not provide for the unconditional release of Parent, its Affiliates and Representatives
and all Persons entitled to indemnification by Parent or the Company, in each case from any liability in connection with such
litigation; <I>provided further</I>, that the Company shall otherwise control the defense and/or settlement and the disclosure
of information in connection therewith shall be subject to the provisions of <U>Section&nbsp;5.1</U>, including regarding attorney-client
privilege or other applicable legal privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Additional
Agreements</FONT></B>. Subject to the terms and conditions of this Agreement, including <U>Section&nbsp;6.2(a)</U>, Parent and
the Company shall use reasonable best efforts to take, or cause to be taken, all actions necessary to consummate the Offer and
the Merger and make effective the other Transactions. Without limiting the generality of the foregoing, subject to the terms and
conditions of this Agreement, each Party to this Agreement shall use commercially reasonable efforts to (a)&nbsp;make all filings
(if any) and give all notices (if any) required to be made and given by such Party pursuant to any Material Contract in connection
with the Offer and the Merger and the other Transactions to the extent requested in writing by Parent, (b)&nbsp;seek each Consent
(if any) required to be obtained pursuant to any Material Contract by such Party in connection with the Transactions to the extent
requested in writing by Parent; <I>provided</I>, <I>however</I>, each of the Parties acknowledges and agrees that obtaining any
such consent or approval shall not, in and of itself, be a condition to the Offer or the Merger and (c)&nbsp;seek to lift any
restraint, injunction or other legal bar to the Offer or the Merger brought by any third Person against such Party. Notwithstanding
anything in this <U>Section&nbsp;6.7</U> to the contrary, neither Parent, the Company nor any of their respective Subsidiaries
shall be required to pay any consent or other similar fee, payment or consideration, make any other concession or provide any
additional security (including a guaranty), to obtain any third party consents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Disclosure</FONT></B>.
The initial press release relating to this Agreement shall be a joint press release issued by the Company and Parent, and thereafter
Parent and the Company shall consult with each other before issuing any further press release(s)&nbsp;or otherwise making any
public statement or making any announcement to Company Associates (to the extent not previously issued or made in accordance with
this Agreement) with respect to the Offer, the Merger, this Agreement or any of the other Transactions and shall not issue any
such press release, public statement or announcement to Company Associates without the other Party&rsquo;s written consent. Notwithstanding
the foregoing: (a)&nbsp;each Party may, without such consultation or consent, make any public statement in response to questions
from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make
disclosures in Company SEC Documents, so long as such statements substantially reiterate (and are not inconsistent with) previous
press releases, public disclosures or public statements made jointly by the Parties (or individually, if approved by the other
Party); (b)&nbsp;a Party may, without the prior consent of the other Party but subject to giving advance notice to the other Party
and consulting with the other Party with respect to the content thereof, issue any such press release or make any such public
announcement or statement that, after consultation with outside legal counsel, is determined to be required by Legal Requirement;
(c)&nbsp;the Company need not consult with Parent in connection with such portion of any press release, public statement or filing
to be issued or made pursuant to <U>Section&nbsp;5.3(d)</U>; and (d)&nbsp;neither Party need consult with the other in connection
with such portion of any press release, public statement or filing to be issued with respect to any Acquisition Proposal or Company
Adverse Change Recommendation (but without limiting the Company&rsquo;s obligations under <U>Section&nbsp;5.3</U> or <U>Section&nbsp;6.1</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Takeover
Laws</FONT></B>. If any Takeover Law may become, or may purport to be, applicable to the Transactions, each of Parent and the
Company and the members of their respective Boards of Directors shall use their respective reasonable best efforts to grant such
approvals and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable on the
terms and conditions contemplated hereby and otherwise act to lawfully eliminate the effect of any Takeover Law on any of the
Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.10</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Section&nbsp;16
Matters</FONT></B>. The Company, and the Board of Directors (or a duly formed committee thereof consisting of non-employee directors
(as such term is defined for the purposes of Rule&nbsp;16b-3 promulgated under the Exchange Act)), shall, to the extent necessary,
take appropriate action, prior to or as of the Offer Acceptance Time, to approve, for purposes of Section&nbsp;16(b)&nbsp;of the
Exchange Act, the disposition and cancellation or deemed disposition and cancellation of Shares and Company Options in the Merger
by applicable individuals and to cause such dispositions and/or cancellations to be exempt under Rule&nbsp;16b-3 promulgated under
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.11</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Rule&nbsp;14d-10
Matters</FONT></B>. Prior to the Offer Acceptance Time and to the extent permitted by applicable Legal Requirements, the compensation
committee of the Board of Directors, at a meeting duly called and held, will approve, as an &ldquo;employment compensation, severance
or other employee benefit arrangement&rdquo; within the meaning of Rule&nbsp;14d-10(d)(2)&nbsp;under the Exchange Act, each agreement,
arrangement or understanding between Purchaser, the Company or their respective Affiliates and any of the officers, directors
or employees of the Company that are effective as of the date of this Agreement or are entered into after the date of this Agreement
and prior to the Offer Acceptance Time pursuant to which compensation is paid to such officer, director or employee and will take
all other action reasonably necessary to satisfy the requirements of the non-exclusive safe harbor set forth in Rule&nbsp;14d<FONT STYLE="font-size: 1pt">&nbsp;</FONT>-<FONT STYLE="font-size: 1pt">&nbsp;</FONT>10<FONT STYLE="font-size: 1pt">&nbsp;</FONT>(d)<FONT STYLE="font-size: 1pt">&nbsp;</FONT>(2)&nbsp;under
the Exchange Act. Promptly upon Parent or any of its Affiliates entering into any such arrangement with any of the officers, directors
or employees of the Company, Parent will provide to the Company any and all information concerning such arrangements as may be
needed by the Company to comply with this <U>Section&nbsp;6.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.12</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Stock
Exchange Delisting; Deregistration</FONT></B>. Prior to the Closing Date, the Company shall cooperate with Parent and use its
reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary,
proper or advisable on its part under applicable laws and rules&nbsp;and policies of NASDAQ to enable the delisting by the Surviving
Corporation of the Shares from NASDAQ and the deregistration of the Shares under the Exchange Act as promptly as practicable after
the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.13</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">401(k)&nbsp;Plan</FONT></B>.
To the extent requested in writing by Parent at least 10 days prior to the Offer Acceptance Time, the Company shall take all actions
that may be necessary under the Company&rsquo;s 401(k)&nbsp;plan to terminate the Company&rsquo;s 401(k)&nbsp;plan at least one
day prior to the Effective Time. If the Company terminates the Company&rsquo;s 401(k)&nbsp;plan in accordance with the preceding
sentence, (1)&nbsp;prior to the Effective Time and thereafter (as applicable), the Company and Parent shall take any and all actions
as may be required, including amendments to the Company&rsquo;s 401(k)&nbsp;plan and/or the tax-qualified defined contribution
retirement plan designated by Parent (the &ldquo;<U>Parent 401(k)&nbsp;Plan</U>&rdquo;) to permit each Continuing Employee to
make rollover contributions of &ldquo;eligible rollover distributions&rdquo; (within the meaning of Section&nbsp;401(a)(31) of
the Code, including of loans) in the form of cash, or notes (in the case of loans) or a combination thereof, in an amount equal
to the full account balance distributed or distributable to such Continuing Employee from the Company 401(k)&nbsp;plan to the
Parent 401(k)&nbsp;Plan and (2)&nbsp;each Continuing Employee shall become a participant in the Parent 401(k)&nbsp;Plan on the
Closing Date (giving effect to the service crediting provisions of <U>Section&nbsp;6.3(b)</U>); it being agreed that there shall
be no gap in participation in a tax-qualified defined contribution plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>CONDITIONS
PRECEDENT TO THE MERGER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligations of the Parties to effect
the Merger are subject to the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver as of the Closing
of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Restraints</FONT></B>. There shall not have been issued by any Governmental Body of competent jurisdiction in any jurisdiction
in which Parent or the Company has material business operations, and remain in effect, any temporary restraining order, preliminary
or permanent injunction or other order preventing the consummation of the Merger, nor shall any Legal Requirement have been promulgated,
enacted, issued or deemed applicable to the Merger by any Governmental Body in any jurisdiction in which Parent or the Company
has material business operations, which prohibits or makes illegal the consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0 0pt 0in"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Consummation
of Offer</FONT></B>. Purchaser (or Parent on Purchaser&rsquo;s behalf) shall have accepted for payment all of the Shares validly
tendered pursuant to the Offer and not validly withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>TERMINATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Termination</FONT></B>.
This Agreement may be terminated prior to the Offer Acceptance Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
mutual written consent of Parent and the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
either Parent or the Company, if the Closing shall not have occurred on or prior to midnight Eastern Time, on June&nbsp;1, 2020
(the &ldquo;<U>End Date</U>&rdquo;); <I>provided</I>, <I>however</I>, that in the case of this <U>Section&nbsp;8.1(b)</U>, (i)&nbsp;if
on the End Date all of the conditions set forth in <U>Annex I</U>, other than <U>clause (e)</U>&nbsp;or <U>(g)</U>&nbsp;(solely
in respect of the HSR Act) set forth in <U>Annex&nbsp;I</U> shall have been satisfied or waived by Parent or Purchaser, to the
extent waivable by Parent or Purchaser (other than conditions that by their nature are to be satisfied at the Offer Acceptance
Time, each of which is then capable of being satisfied), then the End Date shall automatically be extended by a period of ninety
(90) days (and all references to the End Date herein and in <U>Annex I</U> shall be as so extended) and (ii)&nbsp;the right to
terminate this Agreement pursuant to this <U>Section&nbsp;8.1(b)</U>&nbsp;shall not be available to any Party whose willful and
material breach of covenants in this Agreement has caused or resulted in the Offer not being consummated by such date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
either Parent or the Company if a Governmental Body of competent jurisdiction shall have issued an order, injunction, decree or
ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting
the acceptance for payment of Shares pursuant to the Offer or the Merger or making the consummation of the Offer or the Merger
illegal, which order, decree, ruling or other action shall be final and nonappealable; <I>provided</I>, <I>however</I>, that the
right to terminate this Agreement pursuant to this <U>Section&nbsp;8.1(c)</U>&nbsp;shall not be available to any Party whose material
breach of this Agreement has caused or resulted in such final and nonappealable order, injunction, decree, ruling or other action;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
Parent, if the Board of Directors shall have effected a Company Adverse Change Recommendation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
the Company, if the Board of Directors has made a Company Adverse Change Recommendation in order to accept a Superior Offer (in
compliance with the terms of this Agreement, including <U>Section&nbsp;6.1(b)</U>) and concurrently enter into a binding written
definitive acquisition agreement providing for the consummation of a transaction for a Superior Offer (a &ldquo;<U>Specified Agreement</U>&rdquo;);
<I>provided</I> that (i)&nbsp;neither the Company nor any of its officers or directors shall have violated <U>Section&nbsp;5.3</U>
in any material respect, (ii)&nbsp;the Company and the Board of Directors shall have complied with <U>Section&nbsp;6.1(b)</U>&nbsp;and
(iii)&nbsp;the Company shall have paid the Termination Fee immediately before or simultaneously with and as a condition to such
termination;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
Parent, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant or obligation
in this Agreement on the part of the Company shall have occurred such that a condition set forth in <U>clause (b)</U>&nbsp;or <U>(c)</U>&nbsp;of
<U>Annex I</U> would not be satisfied and cannot be cured by the Company by the End Date, or if capable of being cured in such
time period, shall not have been cured within forty-five (45) days of the date Parent gives the Company written notice of such
breach or failure to perform; <I>provided</I>, <I>however</I>, that Parent shall not have the right to terminate this Agreement
pursuant to this <U>Section&nbsp;8.1(f)</U>&nbsp;if either Parent or Purchaser is then in material breach of any representation,
warranty, covenant or obligation hereunder; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
the Company, if (i)&nbsp;a breach of any representation or warranty contained in this Agreement or failure to perform any covenant
or obligation in this Agreement on the part of Parent or Purchaser shall have occurred, in each case, if such breach or failure
would reasonably be expected to prevent Parent or Purchaser from consummating the Offer and the Merger and such breach or failure
cannot be cured by Parent or Purchaser, as applicable, by the End Date, or, if capable of being cured in such time period, shall
not have been cured within forty-five (45) days of the date the Company gives Parent written notice of such breach or failure to
perform; <I>provided</I>, <I>however</I>, that the Company shall not have the right to terminate this Agreement pursuant to this
<U>Section&nbsp;8.1(g)</U>&nbsp;if the Company is then in material breach of any representation, warranty, covenant or obligation
hereunder or (ii)&nbsp;Purchaser fails to commence the Offer on or prior to the 10th business day following the date of this Agreement
or if Purchaser fails to consummate the Offer in accordance with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Effect
of Termination</FONT></B>. In the event of the termination of this Agreement as provided in <U>Section&nbsp;8.1</U>, written notice
thereof shall be given to the other Party or Parties, specifying the provision hereof pursuant to which such termination is made,
and this Agreement shall be of no further force or effect and there shall be no liability on the part of Parent, Purchaser or
the Company or any of their respective former, current or future officers, directors, partners, stockholders, managers, members
or Affiliates following any such termination; <I>provided</I>, <I>however</I>, that (a)&nbsp;the final sentence of <U>Section&nbsp;1.2(b)</U>,
the final sentence of <U>Section&nbsp;5.1(a)</U>, this <U>Section&nbsp;8.2</U>, <U>Section&nbsp;8.3</U> and <U>Section&nbsp;9
</U>(other than <U>Section&nbsp;9.5(b)</U>) shall survive the termination of this Agreement and shall remain in full force and
effect, (b)&nbsp;the Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force
and effect in accordance with its terms and (c)&nbsp;except as set forth in <U>Section&nbsp;8.3</U>, the termination of this Agreement
shall not relieve any Party from any liability for fraud or willful and material breach of this Agreement prior to termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Expenses;
Termination Fees.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as set forth in this <U>Section&nbsp;8.3</U>, all fees and expenses incurred in connection with this Agreement and the Transactions
shall be paid by the Party incurring such expenses, whether or not the Offer and Merger are consummated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement is terminated by the Company pursuant to <U>Section&nbsp;8.1(e)</U>, the Company shall pay to Parent or its designee
the Termination Fee by wire transfer of same day funds prior to or simultaneously with (and as a condition to the effectiveness
of) such termination;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement is terminated by Parent pursuant to <U>Section&nbsp;8.1(d)</U>, the Company shall pay to Parent or its designee the Termination
Fee by wire transfer of same day funds within one business day after such termination; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(x)&nbsp;this
Agreement is terminated by Parent or the Company pursuant to <U>Section&nbsp;8.1(b)</U>&nbsp;(but in the case of a termination
by the Company, only if at such time Parent would not be prohibited from terminating this Agreement pursuant to the proviso to
<U>Section&nbsp;8.1(b)</U>) or by Parent pursuant to <U>Section&nbsp;8.1(f)</U>&nbsp;resulting from a willful and material breach
of any covenant in this Agreement, (y)&nbsp;any Person shall have publicly disclosed a <I>bona fide</I> Acquisition Proposal, or
such Acquisition Proposal has otherwise been communicated to the Board of Directors or the Company&rsquo;s stockholders and shall
have become publicly known, after the date hereof and prior to such termination and such Acquisition Proposal has not been unconditionally
withdrawn prior to such termination and (z)&nbsp;within twelve (12) months of such termination the Board of Directors shall have
approved or recommended any Acquisition Proposal (regardless of when made), and the Company shall have entered into a definitive
agreement with respect to such Acquisition Proposal, which shall have been consummated (<I>provided</I> that for purposes of this
<U>clause (z)</U>&nbsp;the references to &ldquo;20%&rdquo; in the definition of &ldquo;Acquisition Proposal&rdquo; shall be deemed
to be references to &ldquo;50%&rdquo;), the Company shall pay to Parent or its designee the Termination Fee by wire transfer of
same day funds prior to the consummation of such Acquisition Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">It
is understood that in no event shall the Company be required to pay the Termination Fee on more than one occasion. As used herein,
 &ldquo;<U>Termination Fee</U>&rdquo; shall mean a cash amount equal to $160,000,000. In any circumstance in which the Termination
Fee becomes due and payable and is paid by the Company in accordance with this <U>Section&nbsp;8.3</U>, the Termination Fee shall
be deemed to be liquidated damages for, and the sole and exclusive monetary remedy available to Parent and Purchaser in connection
with, any and all losses or damages suffered or incurred by Parent, Purchaser, any of their respective Affiliates or any other
Person in connection with this Agreement (collectively, &ldquo;<U>Parent Related Parties</U>&rdquo;) (and the termination hereof),
the Transactions (and the abandonment thereof) or any matter forming the basis for such termination, and none of Parent, Purchaser
or any of their respective Affiliates shall be entitled to bring or maintain any claim, action or proceeding against the Company
or any of its Affiliates arising out of or in connection with this Agreement, any of the Transactions or any matters forming the
basis for such termination. For the avoidance of doubt, Parent and Purchaser may seek specific performance to cause the Company
to consummate the Transactions in accordance with <U>Section&nbsp;9.5</U> or the payment of the Termination Fee pursuant to this
<U>Section&nbsp;8.3(c)</U>, but in no event shall Parent or Purchaser be entitled to both (i)&nbsp;specific performance to cause
the Company to consummate the Transactions in accordance with <U>Section&nbsp;9.5</U> and (ii)&nbsp;the payment of the Termination
Fee pursuant to this <U>Section&nbsp;8.3(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Parent&rsquo;s
right to receive payment from the Company of the Termination Fee and any other payments pursuant to <U>Section&nbsp;8.3</U> shall
be the sole and exclusive remedy of the Parent Related Parties against the Company and any of their respective former, current
or future officers, directors, partners, stockholders, optionholders, managers, members or Affiliates (collectively, &ldquo;<U>Company
Related Parties</U>&rdquo;) for any loss suffered as a result of the failure of the Offer or the Merger to be consummated or for
a breach or failure to perform hereunder or otherwise, and upon payment of such amount(s), none of the Company Related Parties
shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties acknowledge (i)&nbsp;that the agreements contained in this <U>Section&nbsp;8.3</U> are an integral part of the transactions
contemplated by this Agreement, (ii)&nbsp;that the Termination Fee is not a penalty, but a reasonable amount that will compensate
Parent and Purchaser in the circumstances in which such payment is payable for the efforts and resources expended and opportunities
foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the Transactions
and (iii)&nbsp;that, without these agreements, the Parties would not enter into this Agreement; accordingly, if the Company fails
to timely pay any amount due pursuant to <U>Section&nbsp;8.3(b)</U>, and, in order to obtain the payment, Parent commences a Legal
Proceeding which results in a judgment against the Company, the Company shall pay Parent its reasonable and documented costs and
expenses (including reasonable and documented attorneys&rsquo; fees) in connection with such suit, together with interest on such
amount at the prime rate as published in the Wall Street Journal in effect on the date such payment was required to be made through
the date such payment was actually received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section&nbsp;9</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>MISCELLANEOUS
PROVISIONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amendment</FONT></B>.
Prior to the Offer Acceptance Time, this Agreement may be amended with the approval of the respective Boards of Directors of the
Company, Parent and Purchaser at any time; <I>provided </I>that, following the consummation of the Offer, this Agreement may not
be amended in any manner that causes the Merger Consideration to differ from the Offer Price. This Agreement may not be amended
except by an instrument in writing signed on behalf of each of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Waiver</FONT></B>.
No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the
part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such
power, right, privilege or remedy. No single or partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or remedy. No Party shall be deemed to have waived
any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such
claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf
of such Party and any such waiver or failure to insist on strict compliance with an obligation, covenant, agreement or condition
shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. At any time prior to the Offer
Acceptance Time, Parent and Purchaser, on the one hand, and the Company, on the other hand, may (a)&nbsp;extend the time for the
performance of any of the obligations or other acts of the other, (b)&nbsp;waive any breach of the representations and warranties
of the other contained herein or in any document delivered pursuant hereto or (c)&nbsp;waive compliance by the other with any
of the agreements or covenants contained herein. Any such extension or waiver shall be valid only if is expressly set forth in
a written instrument duly executed and delivered on behalf of the Party or Parties to be bound thereby, but such extension or
waiver or failure to insist on strict compliance with an obligation, covenant, agreement or condition shall not operate as a waiver
of, or estoppel with respect to, any subsequent or other failure. The rights and remedies provided herein shall be cumulative
and not exclusive of any rights or remedies provided by any Legal Requirement except to the extent set forth in <U>Section&nbsp;8.3(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Survival of Representations and Warranties</FONT></B>. None of the representations and warranties contained in this Agreement,
the Company Disclosure Schedule or in any certificate or schedule or other document delivered by any Person pursuant to this Agreement
shall survive the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Entire
Agreement; Counterparts</FONT></B>. This Agreement (including its Exhibits, Annexes and the Company Disclosure Schedule) and the
Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written
and oral, among or between any of the Parties and their respective Affiliates, with respect to the subject matter hereof and thereof.
The Confidentiality Agreement shall survive the execution and delivery of this Agreement except that the restrictions on contact
and restrictions on disclosure (to the extent to be included in SEC filings in connection with the Transactions) in the Confidentiality
Agreement shall terminate immediately following the execution and delivery of this Agreement solely for purposes of permitting
the actions contemplated hereby to be consummated. This Agreement may be executed in one or more counterparts, including by facsimile
or by email with .pdf attachments, all of which shall be considered one and the same agreement, and shall become effective when
one or more counterparts have been signed by each of the Parties and delivered to the other Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Applicable
Legal Requirements; Jurisdiction; Specific Performance; Remedies.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that
might otherwise govern under applicable principles of conflicts of laws thereof. In any action or proceeding arising out of or
relating to this Agreement or any of the Transactions: (i)&nbsp;each of the Parties irrevocably and unconditionally consents and
submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and any state appellate court therefrom
or, if (but only if) such court lacks subject matter jurisdiction, the United States District Court sitting in New Castle County
in the State of Delaware and any appellate court therefrom (collectively, the &ldquo;<U>Delaware Courts</U>&rdquo;); and (ii)&nbsp;each
of the Parties irrevocably consents to service of process by first class certified mail, return receipt requested, postage prepaid,
to the address at which such Party is to receive notice in accordance with <U>Section&nbsp;9.9</U>. Each of the Parties irrevocably
and unconditionally (1)&nbsp;agrees not to commence any such action or proceeding except in the Delaware Courts, (2)&nbsp;agrees
that any claim in respect of any such action or proceeding may be heard and determined in the Delaware Courts, (3)&nbsp;waives,
to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction
or laying of venue of any such action or proceeding in the Delaware Courts and (4)&nbsp;waives, to the fullest extent permitted
by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. The Parties
agree that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by applicable Legal Requirements; <I>provided</I>, <I>however</I>, that nothing
in the foregoing shall restrict any Party&rsquo;s rights to seek any post-judgment relief regarding, or any appeal from, such final
trial court judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur
in the event that the Parties do not perform their obligations under the provisions of this Agreement in accordance with its specified
terms or otherwise breach such provisions. Subject to the following sentence, the Parties acknowledge and agree that (i)&nbsp;the
Parties shall be entitled to an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches
of this Agreement and to enforce specifically the terms and provisions hereof in the courts described in <U>Section&nbsp;9.5(a)</U>&nbsp;without
proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement, and
(ii)&nbsp;the right of specific performance is an integral part of the Transactions and without that right, neither the Company
nor Parent would have entered into this Agreement. The right to specific enforcement hereunder shall include the right of the Company,
on behalf of itself and any third party beneficiaries to this Agreement, to cause Parent and Purchaser to cause the Offer, the
Merger and the other Transactions to be consummated on the terms and subject to the conditions set forth in this Agreement. Each
of the Parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on
the basis that the other Parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy
for any reason at law or equity. The Parties acknowledge and agree that any Party seeking an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this <U>Section&nbsp;9.5(b)</U>&nbsp;shall
not be required to provide any bond or other security in connection with any such order or injunction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">EACH
OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES (WHETHER BASED
ON CONTRACT, TORT OR OTHERWISE),&nbsp;INCLUDING ANY COUNTERCLAIM, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF.
EACH PARTY (I)&nbsp;MAKES THIS WAIVER VOLUNTARILY AND (II)&nbsp;ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN THIS <U>SECTION&nbsp;9.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Assignability</FONT></B>.
This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective
successors and permitted assigns; <I>provided</I>, <I>however</I>, that neither this Agreement nor any of the rights hereunder
may be assigned by a Party without the prior written consent of the other Parties, and any attempted assignment of this Agreement
or any of such rights without such consent shall be void and of no effect; <I>provided further</I>, <I>however</I>, that Parent
may designate, by written notice to the Company, another wholly-owned direct or indirect Delaware corporate Subsidiary of Parent
to act as Purchaser, in which event all references to Purchaser in this Agreement shall be deemed references to such other Subsidiary;
<I>provided</I> such assignment shall not impede or delay the consummation of the Transactions or relieve Parent of its obligations
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Third Party Beneficiaries. </FONT></B><FONT STYLE="font-size: 10pt">N</FONT>othing in this Agreement, express or implied, is intended
to or shall confer upon any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by
reason of this Agreement; except for: (a)&nbsp;if the Offer Acceptance Time occurs, (i)&nbsp;the right of the Company&rsquo;s
stockholders to receive the Offer Price or Merger Consideration, as applicable, pursuant to <U>Section&nbsp;1</U> or <U>Section&nbsp;2
</U>following the Offer Acceptance Time or the Effective Time, as applicable, in accordance with the terms of this Agreement,
and (ii)&nbsp;the right of the holders of Company Options to receive the applicable treatment pursuant to <U>Section&nbsp;2.8
</U>following the Effective Time in accordance with the terms of this Agreement; and (b)&nbsp;the provisions set forth in <U>Section&nbsp;6.5
</U>of this Agreement with respect to the Persons referred to therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Transfer
Taxes. </FONT></B>Except as otherwise provided in <U>Section&nbsp;2.6(b)</U>, all transfer, documentary, sales, use, stamp, registration
and other similar Taxes and fees imposed on the Company with respect to the transfer of Shares pursuant to the Offer or the Merger
shall be borne by the Company and expressly shall not be a liability of holders of Shares, expressly excluding any such Taxes
imposed on the holders of Shares. The Company shall cooperate with Purchaser and Parent in preparing, executing and filing any
Tax Returns with respect to such Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notices.
</FONT></B><FONT STYLE="font-size: 10pt">A</FONT>ny notice or other communication required or permitted to be delivered to any
Party under this Agreement shall be in writing and shall be deemed properly delivered, given and received (a)&nbsp;upon receipt
when delivered by hand, (b)&nbsp;two business days after being sent by registered mail or by courier or express delivery service,
or (c)&nbsp;upon confirmation of successful transmission if sent by email followed up within one business day by dispatch pursuant
to one of the other methods described herein; <I>provided </I>that in each case the notice or other communication is sent to the
physical address or email address set forth beneath the name of such Party below (or to such other physical address or email address
as such Party shall have specified in a written notice given to the other Parties):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to Parent or Purchaser (or following the Effective
Time, the Surviving Corporation):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Gilead Sciences, Inc.<BR>
333 Lakeside Drive<BR>
Foster City, California 94404<BR>
Attention: General Counsel<BR>
Email: generalcounsel@gilead.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Skadden, Arps, Slate, Meagher &amp; Flom LLP<BR>
One Manhattan West<BR>
New York, NY 10001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">500 Boylston Street<BR>
Boston, MA 02116</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attention: &nbsp;&nbsp;&nbsp;Stephen Arcano</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Graham Robinson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stephen.arcano@skadden.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; graham.robinson@skadden.com &nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Company (prior to the Effective Time):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Forty Seven, Inc.<BR>
1490 O&rsquo;Brien Drive, Suite A<BR>
Menlo Park, California<BR>
Attention: Ann D. Rhoads, Chief Financial Officer<BR>
Email: arhoads@fortyseveninc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">101 California Street, 5<SUP>th</SUP> Floor<BR>
San Francisco, CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Jamie Leigh; Ben Beerle<BR>
Email: jleigh@cooley.com; bbeerle@cooley.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.10</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Severability.
</FONT></B><FONT STYLE="font-size: 10pt">A</FONT>ny term or provision of this Agreement that is invalid or unenforceable in any
situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement
or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a
final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable,
the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific
words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest
to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable
as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to
replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the
extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.11</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Obligation
of Parent</FONT></B>. Parent shall ensure that Purchaser duly performs, satisfies and discharges on a timely basis each of the
covenants, obligations and liabilities applicable to Purchaser under this Agreement, and Parent shall be jointly and severally
liable with Purchaser for the due and timely performance and satisfaction of each of said covenants, obligations and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.12</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Construction.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the
neuter gender shall include masculine and feminine genders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties agree that any rule&nbsp;of construction to the effect that ambiguities are to be resolved against the drafting Party shall
not be applied in the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, shall not be deemed
to be terms of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as otherwise indicated, all references in this Agreement to &ldquo;Sections,&rdquo; &ldquo;Exhibits&rdquo; or &ldquo;Annexes&rdquo;
are intended to refer to Sections of this Agreement and Exhibits or Annexes to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this
Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
term &ldquo;dollars&rdquo; and character &ldquo;$&rdquo; shall mean United States dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature page&nbsp;follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 7 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Parties have
caused this Agreement to be executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">FORTY
    SEVEN,&nbsp;INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">/s/
    Mark A. McCamish, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mark A. McCamish, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">President and Chief Executive
    Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">GILEAD
    SCIENCES,&nbsp;INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">/s/
    Daniel P. O&rsquo;Day</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Daniel P. O&rsquo;Day</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">TORO
    MERGER SUB,&nbsp;INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">/s/
    Andrew D. Dickinson</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Andrew D. Dickinson</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President and Treasurer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><I>[Signature
Page&nbsp;to Agreement and Plan of Merger]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of the Agreement (including
this <B><U>Exhibit&nbsp;A</U></B>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Acceptable Confidentiality Agreement</B>.
 &ldquo;<U>Acceptable Confidentiality Agreement</U>&rdquo; shall mean any customary confidentiality agreement that is (a)&nbsp;in
effect as of the execution and delivery of this Agreement or (b)&nbsp;executed, delivered and effective after the execution and
delivery of this Agreement that (i)&nbsp;contains provisions that are not less favorable in the aggregate to the Company than those
contained in the Confidentiality Agreement (it being understood that such agreement need not contain any &ldquo;standstill&rdquo;
or similar provisions or otherwise prohibit the making of any Acquisition Proposal) and (ii)&nbsp;does not prohibit the Company
from providing any information to Parent in accordance with <U>Section&nbsp;5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Acquisition Proposal</B>. &ldquo;<U>Acquisition
Proposal</U>&rdquo; shall mean any proposal or offer from any Person (other than Parent and its Affiliates) or &ldquo;group&rdquo;,
within the meaning of Section&nbsp;13(d)&nbsp;of the Exchange Act, including any amendment or modification to any existing proposal
or offer, relating to, in a single transaction or series of related transactions, any (i)&nbsp;acquisition or license of assets
of the Company equal to 20% or more of the Company&rsquo;s consolidated assets, (ii)&nbsp;acquisition or exclusive license of the
Product Candidates, (iii)&nbsp;issuance or acquisition of 20% or more of the outstanding Company Common Stock, (iv)&nbsp;recapitalization,
tender offer or exchange offer that if consummated would result in any Person or group beneficially owning 20% or more of the outstanding
Company Common Stock or (v)&nbsp;merger, consolidation, amalgamation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction involving the Company that if consummated would result in any Person or group beneficially owning
20% or more of the outstanding Company Common Stock, in each case other than the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Affiliate</B>. &ldquo;<U>Affiliate</U>&rdquo;
shall mean, as to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common
control with, such Person. For this purpose, &ldquo;control&rdquo; (including, with its correlative meanings, &ldquo;controlled
by&rdquo; and &ldquo;under common control with&rdquo;) shall mean the possession, directly or indirectly, of the power to direct
or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other
ownership interests, by Contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Agreement</B>. &ldquo;<U>Agreement</U>&rdquo;
is defined in the preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Anti-Corruption Laws</B>. &ldquo;<U>Anti-Corruption
Laws</U>&rdquo; shall mean the Foreign Corrupt Practices Act of 1977, as amended, the Anti-Kickback Act of 1986, as amended, the
UK Bribery Act of 2012, and the Anti-Bribery Laws of the People&rsquo;s Republic of China or any applicable Legal Requirements
of similar effect, and the related regulations and published interpretations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Antitrust Laws</B>. &ldquo;<U>Antitrust
Laws</U>&rdquo; shall mean the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission
Act, as amended, all applicable foreign anti-trust laws and all other applicable Legal Requirements issued by a Governmental Body
that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint
of trade or lessening of competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Board of Directors</B>. &ldquo;<U>Board
of Directors</U>&rdquo; is defined in <U>Recital (C)</U>&nbsp;to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Book-Entry Shares</B>. &ldquo;<U>Book-Entry
Shares</U>&rdquo; shall mean non-certificated Shares represented by book-entry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>business day</B>. &ldquo;<U>business
day</U>&rdquo; has the meaning set forth in Rule&nbsp;14d-1(g)(3)&nbsp;of the Exchange Act; <I>provided, however</I>, that any
day on which banks in the City of New York are authorized or required by Legal Requirements to be closed shall not be a &ldquo;business
day&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Capitalization Date.</B> &ldquo;<U>Capitalization
Date</U>&rdquo; is defined in <U>Section&nbsp;3.3(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Certificates</B>. &ldquo;<U>Certificates</U>&rdquo;
is defined in <U>Section&nbsp;2.6(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Change of Control Payment</B>. &ldquo;<U>Change
of Control Payment</U>&rdquo; is defined in <U>Section&nbsp;3.10(a)(vi)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Closing</B>. &ldquo;<U>Closing</U>&rdquo;
is defined in <U>Section&nbsp;2.3(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Closing Date</B>. &ldquo;<U>Closing Date</U>&rdquo;
is defined in <U>Section&nbsp;2.3(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>CMS</B>. &ldquo;<U>CMS</U>&rdquo; is
defined in <U>Section&nbsp;6.2(d)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Code</B>. &ldquo;<U>Code</U>&rdquo; shall
mean the Internal Revenue Code of 1986, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Collaboration Partner</B>. &ldquo;<U>Collaboration
Partner</U>&rdquo; is defined in <U>Section&nbsp;3.13(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company</B>. &ldquo;<U>Company</U>&rdquo;
is defined in the preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Adverse Change Recommendation</B>.
 &ldquo;<U>Company Adverse Change Recommendation</U>&rdquo; is defined in <U>Section&nbsp;6.1(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Associate</B>. &ldquo;<U>Company
Associate</U>&rdquo; shall mean each current and former officer or other employee, or individual who is or was at any time an independent
contractor, consultant or director, of or to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Board Recommendation</B>. &ldquo;<U>Company
Board Recommendation</U>&rdquo; is defined in <U>Recital (C)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Common Stock</B>. &ldquo;<U>Company
Common Stock</U>&rdquo; shall mean the common stock, $0.0001 par value per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Disclosure Documents</B>. &ldquo;<U>Company
Disclosure Documents</U>&rdquo; is defined in <U>Section&nbsp;3.5(g)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Disclosure Schedule</B>. &ldquo;<U>Company
Disclosure Schedule</U>&rdquo; shall mean the disclosure schedule that has been prepared by the Company in accordance with the
requirements of the Agreement and that has been delivered by the Company to Parent on the date of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Equity Plans</B>. &ldquo;<U>Company
Equity Plans</U>&rdquo; shall mean the Forty Seven,&nbsp;Inc. 2015 Equity Incentive Plan, as amended, and the Forty Seven,&nbsp;Inc.
2018 Equity Incentive Plan, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company ESPP</B>. &ldquo;<U>Company ESPP</U>&rdquo;
shall mean the Forty Seven,&nbsp;Inc. 2018 Employee Stock Purchase Plan, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company IP</B>. &ldquo;<U>Company IP</U>&rdquo;
shall mean any and all (i)&nbsp;Intellectual Property Rights owned or purported to be owned by the Company, and (ii)&nbsp;other
Intellectual Property Rights used or held for use in, or necessary for the conduct of, the Company&rsquo;s business as currently
conducted and as contemplated to be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company IT Assets</B>. &ldquo;<U>Company
IT Assets</U>&rdquo; shall mean computers, computer software, firmware, middleware, servers, workstations, routers, hubs, switches,
data communications lines and all other information technology equipment, and all associated documentation owned by the Company
or licensed or leased by the Company (excluding any public networks).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Options</B>. &ldquo;<U>Company
Options</U>&rdquo; shall mean all options to purchase Shares (whether granted by the Company pursuant to the Company Equity Plans,
assumed by the Company in connection with any merger, acquisition or similar transaction or otherwise issued or granted).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Preferred Stock</B>. &ldquo;<U>Company
Preferred Stock</U>&rdquo; shall mean the preferred stock, $0.0001 par value per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Related Parties</B>. &ldquo;<U>Company
Related Parties</U>&rdquo; is defined in <U>Section&nbsp;8.3(d)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company Returns</B>. &ldquo;<U>Company
Returns</U>&rdquo; is defined in <U>Section&nbsp;3.16(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Company SEC Documents</B>. &ldquo;<U>Company
SEC Documents</U>&rdquo; is defined in <U>Section&nbsp;3.5(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Confidentiality Agreement</B>. &ldquo;<U>Confidentiality
Agreement</U>&rdquo; is defined in <U>Section&nbsp;5.1(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Consent</B>. &ldquo;<U>Consent</U>&rdquo;
shall mean any approval, consent, ratification, permission, waiver or authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Continuing Employees</B>. &ldquo;<U>Continuing
Employees</U>&rdquo; is defined in <U>Section&nbsp;6.3</U> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Contract</B>. &ldquo;<U>Contract</U>&rdquo;
shall mean any written binding agreement, contract, subcontract, lease, settlement agreement, understanding, instrument, loan,
credit agreement, bond, debenture, note, option, warrant, license, sublicense, commitment or undertaking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Copyrights</B>. &ldquo;<U>Copyrights</U>&rdquo;
is defined in the definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Delaware Courts</B>. &ldquo;<U>Delaware
Courts</U>&rdquo; is defined in <U>Section&nbsp;9.5(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Depository Agent</B>. &ldquo;<U>Depository
Agent</U>&rdquo; is defined in <U>Section&nbsp;2.6(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Determination Notice</B>. &ldquo;<U>Determination
Notice</U>&rdquo; is defined in <U>Section&nbsp;6.1(b)(i)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>DGCL</B>. &ldquo;<U>DGCL</U>&rdquo; shall
mean the Delaware General Corporation Law, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Dissenting Shares</B>. &ldquo;<U>Dissenting
Shares</U>&rdquo; is defined in <U>Section&nbsp;2.7</U> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>DOJ</B>. &ldquo;<U>DOJ</U>&rdquo; shall
mean the U.S. Department of Justice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Effective Time</B>. &ldquo;<U>Effective
Time</U>&rdquo; is defined in <U>Section&nbsp;2.3(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>EMA</B>. &ldquo;<U>EMA</U>&rdquo; is
defined in <U>Section&nbsp;3.13(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Employee Plan</B>. &ldquo;<U>Employee
Plan</U>&rdquo; shall mean each deferred compensation and each bonus or other incentive compensation, stock purchase, stock option
and other equity compensation plan, program, agreement or arrangement; each severance or termination pay, medical, surgical, hospitalization,
life insurance and other &ldquo;welfare&rdquo; plan, fund or program (within the meaning of section 3(1)&nbsp;of ERISA (whether
or not subject to ERISA)); each profit sharing, stock bonus or other &ldquo;pension&rdquo; plan, fund or program (within the meaning
of section 3(2)&nbsp;of ERISA (whether or not subject to ERISA)); each employment, termination, severance, change in control, retention
or similar agreement; and each other employee benefit plan, fund, program, agreement or arrangement, in each case, that is sponsored,
maintained or contributed to or required to be contributed to by the Company or by any trade or business, whether or not incorporated
(an &ldquo;<U>ERISA Affiliate</U>&rdquo;), that together with the Company would be deemed a &ldquo;single employer&rdquo; within
the meaning of section 4001(b)&nbsp;of ERISA, or to which the Company or an ERISA Affiliate is party, whether written or oral,
for the benefit of any employee or former employee of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Encumbrance</B>. &ldquo;<U>Encumbrance</U>&rdquo;
shall mean any lien, pledge, charge, hypothecation, mortgage, security interest, encumbrance, claim, option, right of first refusal,
preemptive right, community property interest or similar restriction of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>End Date</B>. &ldquo;<U>End Date</U>&rdquo;
is defined in <U>Section&nbsp;8.1(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Entity</B>. &ldquo;<U>Entity</U>&rdquo;
shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint
stock company), firm, society or other enterprise, association, organization or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Environmental Law</B>. &ldquo;<U>Environmental
Law</U>&rdquo; shall mean any federal, state, local or foreign Legal Requirement relating to pollution or protection of worker
health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any
law or regulation relating to emissions, discharges, Releases or threatened Releases of Hazardous Materials, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>ERISA</B>. &ldquo;<U>ERISA</U>&rdquo;
shall mean the Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>ERISA Affiliate</B>. &ldquo;<U>ERISA
Affiliate</U>&rdquo; is defined in the definition of Employee Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Exchange Act</B>. &ldquo;<U>Exchange
Act</U>&rdquo; shall mean the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Excluded Shares</B>. &ldquo;<U>Excluded
Shares</U>&rdquo; is defined in <U>Section&nbsp;1.1(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Expiration Date</B>. &ldquo;<U>Expiration
Date</U>&rdquo; is defined in <U>Section&nbsp;1.1(c)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Extension Deadline</B>. &ldquo;<U>Extension
Deadline</U>&rdquo; is defined in <U>Section&nbsp;1.1(c)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FDA</B>. &ldquo;<U>FDA</U>&rdquo; shall
mean the United States Food and Drug Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FDCA</B>. &ldquo;<U>FDCA</U>&rdquo; shall
mean the Federal Food, Drug and Cosmetic Act, as amended, and all related rules, regulations and guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Final Offering</B>. &ldquo;<U>Final Offering</U>&rdquo;
is defined in <U>Section&nbsp;6.4</U> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Financial Advisor</B>. &ldquo;<U>Financial
Advisor</U>&rdquo; is defined in <U>Section&nbsp;3.23</U> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FTC</B>. &ldquo;<U>FTC</U>&rdquo; shall
mean the U.S. Federal Trade Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>GAAP</B>. &ldquo;<U>GAAP</U>&rdquo; is
defined in <U>Section&nbsp;3.5(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Good Clinical Practices</B>. &ldquo;<U>Good
Clinical Practices</U>&rdquo; shall mean FDA&rsquo;s standards for the design, conduct, performance, monitoring, auditing, recording,
analysis, and reporting of clinical trials, including those standards contained in 21 C.F.R. Parts 50, 54, 56 and 312, and all
comparable standards of the EMA and any other applicable Governmental Body or other entity with authority over the safety, efficacy,
approval, development, testing, labeling, manufacture, storage, marketing, promotion, sale, commercialization, shipment, import,
export or distribution of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Good Laboratory Practices</B>. &ldquo;<U>Good
Laboratory Practices</U>&rdquo; shall mean the FDA&rsquo;s standards for conducting non-clinical laboratory studies, including
those standards contained in 21 C.F.R. Part&nbsp;58, and all comparable standards of the EMA and any other applicable Governmental
Body or other entity with authority over the safety, efficacy, approval, development, testing, labeling, manufacture, storage,
marketing, promotion, sale, commercialization, shipment, import, export or distribution of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Good Manufacturing Practices</B>. &ldquo;<U>Good
Manufacturing Practices</U>&rdquo; shall mean the requirements set forth in the quality systems regulations for drugs contained
in 21 C.F.R. Parts 210 and 211, and all comparable standards of the EMA and any other applicable Governmental Body or other entity
with authority over the safety, efficacy, approval, development, testing, labeling, manufacture, storage, marketing, promotion,
sale, commercialization, shipment, import, export or distribution of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Governmental Authorization</B>. &ldquo;<U>Governmental
Authorization</U>&rdquo; shall mean any: permit, license, certificate, approval, consent, grant, franchise, permission, clearance,
registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any
Governmental Body or pursuant to any Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Governmental Body</B>. &ldquo;<U>Governmental
Body</U>&rdquo; shall mean any: (i)&nbsp;nation, state, commonwealth, province, territory, county, municipality, district or other
jurisdiction of any nature; (ii)&nbsp;federal, state, local, municipal, foreign, international, multinational, supranational or
other government; or (iii)&nbsp;governmental or quasi-governmental authority of any nature including any governmental division,
department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit or body and any
court, arbitrator or other tribunal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Hazardous Materials</B>. &ldquo;<U>Hazardous
Materials</U>&rdquo; shall mean any waste, material, or substance that is listed, regulated or defined under any Environmental
Law and includes any pollutant, chemical substance, hazardous substance, hazardous waste, special waste, solid waste, asbestos,
mold, radioactive material, polychlorinated biphenyls, petroleum or petroleum-derived substance or waste.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Health Care Data Requirements</B>. &ldquo;<U>Health
Care Data Requirements</U>&rdquo; is defined in <U>Section&nbsp;3.13(h)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Health Care Laws</B>. &ldquo;<U>Health
Care Laws</U>&rdquo; shall mean all health care Legal Requirements applicable to the safety, efficacy, approval, development, testing,
labeling, manufacture, storage, marketing, promotion, sale, commercialization, import, export or distribution of pharmaceutical
products or otherwise applicable to the operation of the Company&rsquo;s business as currently conducted and as contemplated by
the Company to be conducted, including (i)&nbsp;the FDCA and the regulations promulgated thereunder, including, as applicable,
those requirements relating to the FDA&rsquo;s current Good Manufacturing Practices, Good Laboratory Practices, Good Clinical Practices,
investigational use, pre-market approval and applications to market new pharmaceutical or biological products; (ii)&nbsp;the Clinical
Laboratory Improvement Amendments of 1988; (iii)&nbsp;the Health Insurance Portability and Accountability Act of 1996, the Health
Information and Technology for Economic and Clinical Health Act, and the regulations promulgated pursuant thereto; (iv)&nbsp;the
U.S. Patient Protection and Affordable Care Act, (v)&nbsp;the Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h); (vi)&nbsp;federal
and state anti-kickback laws (including the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320-7(b))); (vii)&nbsp;the Stark Law
(42 U.S.C. &sect; 1395nn); (viii)&nbsp;Legal Requirements governing the development, conduct, monitoring, patient informed consent,
auditing, analysis and reporting of clinical trials (including the Good Clinical Practice regulations and guidance of the FDA);
(ix)&nbsp;Legal Requirements governing data gathering activities relating to the detection, assessment, and understanding of adverse
events (including pharmacovigilance and adverse event regulations and guidance of FDA and ICH); (x)&nbsp;the federal Medicare and
Medicaid statutes, as applicable; (xi)&nbsp;any Legal Requirement the violation of which is cause for exclusion from any federal
health care program; and (xii)&nbsp;all comparable state, federal or foreign Legal Requirements relating to any of the foregoing,
including but not limited to Regulation (EC) No&nbsp;726/2004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>HIPAA</B>. &ldquo;<U>HIPAA</U>&rdquo;
is defined in <U>Section&nbsp;3.13(h)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>HITECH</B>. &ldquo;<U>HITECH</U>&rdquo;
is defined in <U>Section&nbsp;3.13(h)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>HSR Act</B>. &ldquo;<U>HSR Act</U>&rdquo;
shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>In-bound License</B>. &ldquo;<U>In-bound
License</U>&rdquo; shall mean any and all Contracts to which the Company is a party, or by which it is bound, as of the date of
this Agreement, the primary or a material subject of which is the licensing, assignment or other conveyance or grant of Intellectual
Property Rights, pursuant to which the Company is granted an express license, non-assert, option, or other rights to (including
rights to use, register, or enforce), or expressly assigned, sold, conveyed or otherwise transferred any rights in, to or under,
any material Intellectual Property Rights, and that remains in effect as of the date of this Agreement. Notwithstanding the foregoing,
 &ldquo;In-bound License&rdquo; excludes agreements entered into in the ordinary course of business consistent with past practice,
such as personnel agreements, commercially available off-the-shelf software agreements, clinical trial agreements and material
transfer agreements, in each case pursuant to standard form agreements or that are not otherwise material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Indebtedness</B>. &ldquo;<U>Indebtedness</U>&rdquo;
shall mean (i)&nbsp;any indebtedness for borrowed money (including the issuance of any debt security) to any Person, including
all liabilities under any lease which has been recorded as a capital lease, (ii)&nbsp;any obligations evidenced by notes, bonds,
debentures or similar Contracts to any Person other than the Company, (iii)&nbsp;any obligations in respect of letters of credit
(including standby and commercial) and bankers&rsquo; acceptances (other than letters of credit used as security for leases), bank
guarantees, surety bonds and similar instruments, in each case to the extent drawn upon, including the principal, interest and
fees owing thereon, (iv)&nbsp;all indebtedness created or arising under any conditional sale or other title retention agreement
with respect to property acquired or deferred purchase price of property or services (other than trade accounts payable in the
ordinary course), (v)&nbsp;net obligations of any interest rate, swap, currency swap, forward currency or interest rate Contracts
or other interest rate or currency hedging arrangements, or (vi)&nbsp;any guaranty of any such obligations described in <U>clauses
(i)</U>&nbsp;through <U>(v)</U>&nbsp;of any Person other than the Company (other than, in any case, accounts payable to trade creditors
and accrued expenses, in each case, arising in the ordinary course of business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Indemnified Persons</B>. &ldquo;<U>Indemnified
Persons</U>&rdquo; is defined in <U>Section&nbsp;6.5(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Initial Expiration Date</B>. &ldquo;<U>Initial
Expiration Date</U>&rdquo; is defined in <U>Section&nbsp;1.1(c)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Intellectual Property Rights</B>. &ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall mean all intellectual property and industrial property rights and rights in confidential information
of every kind and description throughout the world, including all U.S. and foreign (i)&nbsp;patents, patent applications, invention
disclosures, and all related continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions
thereof (&ldquo;<U>Patents</U>&rdquo;), and inventions (ii)&nbsp;trademarks, service marks, names, corporate names, trade names,
domain names, URLs, social media addresses, logos, slogans, trade dress, design rights, and other similar designations of source
or origin, together with the goodwill symbolized by any of the foregoing (&ldquo;<U>Trademarks</U>&rdquo;), (iii)&nbsp;copyrights
and copyrightable subject matter (&ldquo;<U>Copyrights</U>&rdquo;), (iv)&nbsp;rights in computer programs (whether in source code,
object code, or other form), algorithms, databases, compilations and data, technology supporting the foregoing, and all documentation,
including user manuals and training materials, related to any of the foregoing, (v)&nbsp;trade secrets and all other confidential
information, including such ideas, know-how, proprietary processes, protocols, specifications, techniques, data, results, plans,
formulae, formulations, compositions, models, and methodologies (&ldquo;<U>Trade Secrets</U>&rdquo;), (vi)&nbsp;all rights in the
foregoing and in other similar intangible assets, and (vii)&nbsp;all applications and registrations for the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Intervening Event</B>. &ldquo;<U>Intervening
Event</U>&rdquo; shall mean an event, occurrence, fact or change that materially affects the business, assets or operations of
the Company (other than any event, occurrence, fact or change resulting from a breach of this Agreement by the Company) occurring
or arising after the date hereof that was not known or reasonably foreseeable to the Board of Directors as of the date hereof,
which event, occurrence, fact or change becomes known to the Board of Directors prior to the Offer Acceptance Time, other than
(i)&nbsp;changes in the Company Common Stock price, in and of itself (however, the underlying reasons for such changes may constitute
an Intervening Event), (ii)&nbsp;any Acquisition Proposal or (iii)&nbsp;the fact that, in and of itself, the Company exceeds any
internal or published projections, estimates or expectations of the Company&rsquo;s revenue, earnings or other financial performance
or results of operations for any period, in and of itself (however, the underlying reasons for such events may constitute an Intervening
Event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IRS</B>. &ldquo;<U>IRS</U>&rdquo; shall
mean the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>knowledge</B>. &ldquo;<U>knowledge</U>&rdquo;
with respect to an Entity shall mean with respect to any matter in question the actual knowledge of such Entity&rsquo;s executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Leased Real Property</B>. &ldquo;<U>Leased
Real Property</U>&rdquo; is defined in <U>Section&nbsp;3.8(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Legal Proceeding</B>. &ldquo;<U>Legal
Proceeding</U>&rdquo; shall mean any action, suit, complaint, litigation, arbitration or any administrative proceeding (including
any civil, criminal, administrative, investigative or appellate proceeding) commenced, brought, conducted or heard by or before,
or otherwise involving, any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 8 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Legal Requirement</B>. &ldquo;<U>Legal
Requirement</U>&rdquo; shall mean any federal, state, local, municipal, foreign, international, multinational, supranational, or
other law, statute, constitution, resolution, ordinance, common law, code, edict, decree, rule, regulation, ruling, treaty, order
or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any
Governmental Body (or under the authority of NASDAQ or other stock exchange).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Licensed Registered IP</B>. &ldquo;<U>Licensed
Registered IP</U>&rdquo; shall mean all Registered IP licensed, or to which rights are otherwise granted, to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Material Adverse Effect</B>. &ldquo;<U>Material
Adverse Effect</U>&rdquo; shall mean any change, circumstance, condition, development, effect, event, occurrence or state of facts
which, individually or when taken together with all other events, occurrences, circumstances, changes, conditions, states of facts,
developments or effects that have occurred in the applicable determination period for a Material Adverse Effect, has had or would
reasonably be expected to have a material adverse effect on (a)&nbsp;the ability of the Company to consummate the Offer and the
Merger on or before the End Date or (b)&nbsp;the business, assets, financial condition or results of operations of the Company,
taken as a whole; <I>provided</I>, <I>however</I>, that none of the following shall be deemed to constitute or be taken into account
in determining whether there is, or would reasonably be expected to be, a Material Adverse Effect for purposes of <U>clause (b)</U>&nbsp;above:
(i)&nbsp;any change in the market price or trading volume of the Company&rsquo;s stock or change in the Company&rsquo;s credit
ratings; <I>provided</I> that the underlying causes of any such change may be considered in determining whether a Material Adverse
Effect has occurred to the extent not otherwise excluded by another exception herein; (ii)&nbsp;any event, occurrence, circumstance,
change or effect resulting from the announcement, pendency or performance of the Transactions (other than for purposes of any representation
or warranty contained in <U>Section&nbsp;3.22</U> and the condition set forth in <U>clause (b)(iv)</U>&nbsp;of <U>Annex I</U> solely
as such condition relates to <U>Section&nbsp;3.22</U>, but in any event subject to the disclosures set forth the Company Disclosure
Schedule); (iii)&nbsp;any event, occurrence, circumstance, change or effect generally affecting the industries in which the Company
operates, or in the economy generally or other general business, financial or market conditions; (iv)&nbsp;any event, occurrence,
circumstance, change or effect arising directly or indirectly from or otherwise relating to fluctuations in the value of any currency
or interest rates; (v)&nbsp;any change, circumstance, condition, development, effect, event, occurrence or state of facts arising
directly or indirectly from or otherwise relating to any act of terrorism, war, national or international calamity, natural disaster,
epidemic or any other similar event; (vi)&nbsp;the failure of the Company to meet internal or analysts&rsquo; expectations or projections;
<I>provided</I> that the underlying causes of such failure may be considered in determining whether a Material Adverse Effect has
occurred to the extent not otherwise excluded by another exception herein; (vii)&nbsp;any adverse effect arising directly from
or otherwise directly relating to any action taken by the Company at the written direction of Parent or any action omitted to be
taken in accordance with <U>Section&nbsp;5.2(b)</U>&nbsp;where the Company has requested Parent&rsquo;s consent and Parent has
unreasonably withheld, conditioned or delayed such consent; (viii)&nbsp;any change, circumstance, condition, development, effect,
event, occurrence or state of facts arising directly or indirectly from or otherwise relating to a change in, or action taken required
to comply with any change in any Legal Requirement or GAAP; or (ix)&nbsp;any regulatory, clinical or manufacturing events, occurrences,
circumstances, changes, effects or developments relating to any Product Candidate or with respect to any product of any competitor
of the Company (including, for the avoidance of doubt, with respect to any pre-clinical or clinical studies, tests or results or
announcements thereof, any increased incidence or severity of any previously identified side effects, adverse effects, adverse
events or safety observations or reports of new side effects, adverse events or safety observations); <I>provided</I> that the
underlying causes of any such change may be considered in determining whether a Material Adverse Effect has occurred to the extent
not otherwise excluded by another exception herein; <I>provided</I> that any change, circumstance, condition, development, effect,
event, occurrence or state of facts referred to in the foregoing <U>clauses (iii)</U>, <U>(iv)</U>, <U>(v)</U>&nbsp;and <U>(viii)</U>&nbsp;may
be taken into account in determining whether there is, or would be reasonably expected to be, a Material Adverse Effect to the
extent such change, circumstance, condition, development, effect, event, occurrence or state of facts materially disproportionately
affects the Company relative to other participants in the industries in which the Company operates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Material Contract</B>. &ldquo;<U>Material
Contract</U>&rdquo; is defined in <U>Section&nbsp;3.10(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Maximum Amount</B>. &ldquo;<U>Maximum
Amount</U>&rdquo; is defined in <U>Section&nbsp;6.5(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Merger</B>. &ldquo;<U>Merger</U>&rdquo;
is defined in <U>Recital (B)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Merger Consideration</B>. &ldquo;<U>Merger
Consideration</U>&rdquo; is defined in <U>Section&nbsp;2.5(a)(iii)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Minimum Condition</B>. &ldquo;<U>Minimum
Condition</U>&rdquo; is defined in <U>Annex I</U> to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>NASDAQ</B>. &ldquo;<U>NASDAQ</U>&rdquo;
shall mean The NASDAQ Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer</B>. &ldquo;<U>Offer</U>&rdquo;
is defined in <U>Recital (A)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer Acceptance Time</B>. &ldquo;<U>Offer
Acceptance Time</U>&rdquo; is defined in <U>Section&nbsp;1.1(h)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer Commencement Date</B>. &ldquo;<U>Offer
Commencement Date</U>&rdquo; shall mean the date on which Purchaser commences the Offer, within the meaning of Rule&nbsp;14d-2
under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer Conditions</B>. &ldquo;<U>Offer
Conditions</U>&rdquo; is defined in <U>Section&nbsp;1.1(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer Documents</B>. &ldquo;<U>Offer
Documents</U>&rdquo; is defined in <U>Section&nbsp;1.1(e)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer Price</B>. &ldquo;<U>Offer Price</U>&rdquo;
is defined in <U>Recital (A)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Offer to Purchase</B>. &ldquo;<U>Offer
to Purchase</U>&rdquo; is defined in <U>Section&nbsp;1.1(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Out-bound License</B>. &ldquo;<U>Out-bound
License</U>&rdquo; shall mean any and all Contracts to which the Company is a party, or by which it is bound, as of the date of
this Agreement, pursuant to which the Company grants an express license, non-assert, option, or other rights (including rights
to use, register, or enforce) to, or expressly assigned, sold, conveyed or otherwise transferred any rights in, to or under, any
material Company IP, to any third party, and that remains in effect as of the date of this Agreement. Notwithstanding the foregoing,
 &ldquo;Out-bound License&rdquo; excludes agreements entered into in the ordinary course of business consistent with past practice,
such as clinical trial agreements, contract service agreements and material transfer agreements, in each case pursuant to standard
form agreements entered into in the ordinary course of business consistent with past practice or that are not otherwise material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Owned Registered IP</B>. &ldquo;<U>Owned
Registered IP</U>&rdquo; shall mean all Registered IP owned or purported to be owned by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Parent</B>. &ldquo;<U>Parent</U>&rdquo;
is defined in the preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Parent 401(k)&nbsp;Plan</B>. &ldquo;<U>Parent
401(k)&nbsp;Plan</U>&rdquo; is defined in <U>Section&nbsp;6.13</U> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Parent Material Adverse Effect</B>. &ldquo;<U>Parent
Material Adverse Effect</U>&rdquo; shall mean any change, circumstance, condition, development, effect, event, occurrence or state
of facts which, individually or when taken together with all other events, occurrences, circumstances, changes, conditions, states
of facts, developments or effects that have occurred in the applicable determination period for a Parent Material Adverse Effect,
would or would reasonably be expected to materially impair, prevent or materially delay Parent&rsquo;s or Purchaser&rsquo;s ability
to consummate the Transactions in a timely manner on the terms set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Parent Related Parties</B>. &ldquo;<U>Parent
Related Parties</U>&rdquo; is defined in <U>Section&nbsp;8.3(c)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Parties</B>. &ldquo;<U>Parties</U>&rdquo;
shall mean Parent, Purchaser, and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Patents</B>. &ldquo;<U>Patents</U>&rdquo;
is defined in the definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Paying Agent</B>. &ldquo;<U>Paying Agent</U>&rdquo;
is defined in <U>Section&nbsp;2.6(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Payment Fund</B>. &ldquo;<U>Payment Fund</U>&rdquo;
is defined in <U>Section&nbsp;2.6(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Permitted Encumbrance</B>. &ldquo;<U>Permitted
Encumbrance</U>&rdquo; shall mean (a)&nbsp;any Encumbrance for Taxes (i)&nbsp;that are not due and payable or (ii)&nbsp;the validity
of which is being contested in good faith by appropriate proceedings and for which adequate reserves have been established in accordance
with GAAP in the Company&rsquo;s latest financial statements included in the Company SEC Documents, (b)&nbsp;mechanics&rsquo;,
materialmen&rsquo;s, carriers&rsquo;, workmen&rsquo;s, warehouseman&rsquo;s, repairmen&rsquo;s, landlords&rsquo; and similar liens
granted or which arise in the ordinary course of business consistent with past practice, (c)&nbsp;in the case of real property,
Encumbrances that are easements, rights-of-way, encroachments, restrictions, conditions and other similar Encumbrances incurred
or suffered in the ordinary course of business consistent with past practice and which, individually or in the aggregate, do not
and would not materially impair the use (or contemplated use), utility or value of the applicable real property or otherwise materially
impair the present or contemplated business operations at such location, or zoning, entitlement, building and other land use regulations
imposed by Governmental Bodies having jurisdiction over such real property or that are otherwise set forth on a title report, (d)&nbsp;in
the case of Intellectual Property Rights, licenses granted to use such Intellectual Property Rights and (e)&nbsp;in the case of
any Contract, Encumbrances that are restrictions against the transfer or assignment thereof that are included in the terms of such
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Person</B>. &ldquo;<U>Person</U>&rdquo;
shall mean any individual, Entity or Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Pre-Closing Period</B>. &ldquo;<U>Pre-Closing
Period</U>&rdquo; is defined in <U>Section&nbsp;5.1(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Product Candidates</B>. &ldquo;<U>Product
Candidates</U>&rdquo; shall mean all drug or biological product candidates being developed, tested, labeled, manufactured or stored
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Purchaser</B>. &ldquo;<U>Purchaser</U>&rdquo;
is defined in the preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Registered IP</B>. &ldquo;<U>Registered
IP</U>&rdquo; shall mean all Patents, Trademarks (including, for clarity, domain names), Copyrights and other Intellectual Property
Rights that are registered, filed or issued under the authority of, with or by any Governmental Body or other intellectual property
registrar, and all applications for any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Release</B>. &ldquo;<U>Release</U>&rdquo;
shall mean any presence, emission, spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring, emptying, dumping,
disposal, migration, or release of Hazardous Materials from any source into or upon the environment, including the air, soil, improvements,
surface water, groundwater, the sewer, septic system, storm drain, publicly owned treatment works, or waste treatment, storage,
or disposal systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Representatives</B>. &ldquo;<U>Representatives</U>&rdquo;
shall mean officers, directors, employees, attorneys, accountants, investment bankers, consultants, agents, financial advisors,
other advisors and other representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Restricted Shares</B>. &ldquo;<U>Restricted
Shares</U>&rdquo; is defined in <U>Section&nbsp;2.5(a)(iii)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Sarbanes-Oxley Act</B>. &ldquo;<U>Sarbanes-Oxley
Act</U>&rdquo; is defined in <U>Section&nbsp;3.5(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Schedule 14D-9</B>. &ldquo;<U>Schedule
14D-9</U>&rdquo; is defined in <U>Section&nbsp;1.2(a)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SEC</B>. &ldquo;<U>SEC</U>&rdquo; shall
mean the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Securities Act</B>. &ldquo;<U>Securities
Act</U>&rdquo; shall mean the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Shares</B>. &ldquo;<U>Shares</U>&rdquo;
is defined in <U>Recital (A)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Specified Agreement</B>. &ldquo;<U>Specified
Agreement</U>&rdquo; is defined in <U>Section&nbsp;8.1(e)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Specified Governmental Bodies</B>. &ldquo;<U>Specified
Governmental Bodies</U>&rdquo; is defined in <U>Section&nbsp;3.13(a)</U>&nbsp;of the Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Stockholder List Date</B>. &ldquo;<U>Stockholder
List Date</U>&rdquo; is defined in <U>Section&nbsp;1.2(b)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Subsidiary</B>. An Entity shall be deemed
to be a &ldquo;<U>Subsidiary</U>&rdquo; of another Person if such Person directly or indirectly owns, beneficially or of record,
(i)&nbsp;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at
least a majority of the members of such Entity&rsquo;s board of directors or other governing body, or (ii)&nbsp;at least 50% of
the outstanding equity or financial interests of such Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Superior Offer</B>. &ldquo;<U>Superior
Offer</U>&rdquo; shall mean a <I>bona fide</I> written Acquisition Proposal not solicited in violation of this Agreement that the
Board of Directors determines, in its good faith judgment, after consultation with outside legal counsel and its financial advisor,
is reasonably likely to be consummated in accordance with its terms, taking into account all legal, regulatory and financing aspects
of the proposal and the Person making the proposal and other aspects of the Acquisition Proposal that the Board of Directors deems
relevant, and if consummated, would result in a transaction more favorable to the Company&rsquo;s stockholders (solely in their
capacity as such) from a financial point of view than the Transactions (including after giving effect to proposals, if any, made
by Parent pursuant to <U>Section&nbsp;6.1(b)(i)</U>); <I>provided</I> that for purposes of the definition of &ldquo;Superior Offer,&rdquo;
the references to &ldquo;20%&rdquo; in the definition of Acquisition Proposal shall be deemed to be references to &ldquo;50%.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Surviving Corporation</B>. &ldquo;<U>Surviving
Corporation</U>&rdquo; is defined in <U>Recital (B)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Takeover Laws</B>. &ldquo;<U>Takeover
Laws</U>&rdquo; shall mean any &ldquo;moratorium,&rdquo; &ldquo;control share acquisition,&rdquo; &ldquo;fair price,&rdquo; &ldquo;supermajority,&rdquo;
 &ldquo;affiliate transactions,&rdquo; or &ldquo;business combination statute or regulation&rdquo; or other similar state anti-takeover
laws and regulations (including Section&nbsp;203 of the DGCL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Tax</B>. &ldquo;<U>Tax</U>&rdquo; shall
mean any tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated
tax, unemployment tax, national health insurance tax, excise tax, premium, alternative or minimum tax, ad valorem tax, transfer
tax, stamp tax, sales tax, use tax, property tax, business tax, escheat or unclaimed property, withholding tax or payroll tax,
or other tax of any kind whatsoever (including any levy, assessment, tariff, impost, imposition, or duty (including any customs
duty) in the nature of a tax), and including any penalty, interest or other additions thereto, imposed, assessed or collected by
or under the authority of any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Tax Return</B>. &ldquo;<U>Tax Return</U>&rdquo;
shall mean any return (including any information return), report, statement, declaration, estimate, schedule, form, election, certificate
or other document or information filed with or supplied to, or required to be filed with or supplied to, any Governmental Body
in connection with the determination, assessment, reporting, withholding, collection or payment of any Tax and any attachments
thereto or amendments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Termination Condition</B>. &ldquo;<U>Termination
Condition</U>&rdquo; is defined in <U>Annex I</U> to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Termination Fee</B>. &ldquo;<U>Termination
Fee</U>&rdquo; is defined in <U>Section&nbsp;8.3(c)</U>&nbsp;of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Trademarks</B>. &ldquo;<U>Trademarks</U>&rdquo;
is defined in the definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Trade Secrets</B>. &ldquo;<U>Trade Secrets</U>&rdquo;
is defined in the definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Transactions</B>. &ldquo;<U>Transactions</U>&rdquo;
shall mean (i)&nbsp;the execution and delivery of the Agreement and (ii)&nbsp;all of the transactions contemplated by the Agreement,
including the Offer and the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Treasury Regulations</B>. &ldquo;<U>Treasury
Regulations</U>&rdquo; shall mean the regulations promulgated under the Code by the U.S. Department of the Treasury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDITIONS TO THE OFFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligation of Purchaser to accept for
payment, and pay for, Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction
of the conditions set forth in <U>clauses (a)</U>&nbsp;through <U>(h)</U>&nbsp;below. Accordingly, notwithstanding any other provision
of the Offer or the Agreement to the contrary, Purchaser shall not be required to accept for payment or (subject to any applicable
rules&nbsp;and regulations of the SEC, including Rule&nbsp;14e-1(c)&nbsp;under the Exchange Act) pay for, and may delay the acceptance
for payment of, or (subject to any such rules&nbsp;and regulations) the payment for, any tendered Shares, and, to the extent permitted
by the Agreement, may terminate the Offer: (i)&nbsp;upon termination of the Agreement; and (ii)&nbsp;at any scheduled Expiration
Date (subject to any extensions of the Offer pursuant to <U>Section&nbsp;1.1(c)</U>&nbsp;of the Agreement), if: (A)&nbsp;the Minimum
Condition, the Termination Condition and conditions set forth in <U>clauses (e)</U>&nbsp;and <U>(g)</U>&nbsp;shall not be satisfied
by one minute after 11:59 p.m.&nbsp;Eastern Time on the Expiration Date; or (B)&nbsp;any of the additional conditions set forth
below shall not be satisfied or waived in writing by Parent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">there
shall have been validly tendered and not validly withdrawn Shares that, considered together with all other Shares (if any) beneficially
owned by Parent and its Affiliates, represent one more Share than 50% of the sum of (x)&nbsp;the total number of Shares outstanding
at the time of the expiration of the Offer, plus (y)&nbsp;the total number of Shares that the Company would be required to issue
upon conversion, settlement, exchange or exercise of all options, warrants, rights or securities vested and outstanding at the
time of the expiration of the Offer that are convertible, exchangeable or exercisable into Shares (whether then outstanding or
for which the conversion, settlement, exchange or exercise date has already occurred, but in any event without duplication) (the
 &ldquo;<U>Minimum Condition</U>&rdquo;); <I>provided</I>, <I>however</I>, that for purposes of determining whether the Minimum
Condition has been satisfied, the Parties shall exclude Shares tendered in the Offer pursuant to guaranteed delivery procedures
that have not yet been &ldquo;received&rdquo; (as such term is defined in Section&nbsp;251(h)(6)(f)&nbsp;of the DGCL);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;the
representations and warranties of the Company set forth in the first sentence of <U>Section&nbsp;3.1(a)</U>&nbsp;(Due Organization;
Subsidiaries, Etc.), <U>Section&nbsp;3.2</U> (Certificate of Incorporation and Bylaws), <U>Section&nbsp;3.4</U> (Authority; Binding
Nature of Agreement), <U>Section&nbsp;3.21</U> (Takeover Laws), <U>Section&nbsp;3.23</U> (Opinion of Financial Advisor) and <U>Section&nbsp;3.24</U>
(Brokers and Other Advisors) of the Agreement shall be true and correct in all material respects as of the date of the Agreement
and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time (except to the extent any such representation
or warranty expressly relates to an earlier date or period, in which case as of such date or period);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
representations and warranties of the Company set forth in the first sentence of <U>Section&nbsp;3.3(a)</U>, <U>clauses (i)&nbsp;&ndash;
(ii)</U>&nbsp;of <U>Section&nbsp;3.3</U></FONT><U><FONT STYLE="font-size: 1pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">(b)</FONT></U><FONT STYLE="font-size: 10pt">&nbsp;solely
as such representations relate to the Company, <U>clauses (i)&nbsp;&ndash; (iii)</U>&nbsp;of <U>Section&nbsp;3.3(c)</U>&nbsp;and
<U>Section&nbsp;3.3(d)</U>&nbsp;(Capitalization, Etc.) of the Agreement shall be true and correct (except for <I>de minimis </I>inaccuracies)
in all respects as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance
Time (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as
of such date or period);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
representation and warranty of the Company set forth in <U>Section&nbsp;3.6(b)</U>&nbsp;(No Material Adverse Effect) of the Agreement
shall be true and correct in all respects as of the date of the Agreement and at and as of the Offer Acceptance Time as if made
at and as of the Offer Acceptance Time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
representations and warranties of the Company set forth in the Agreement (other than those referred to in <U>clauses (i)</U>&nbsp;through
<U>(iii)</U>&nbsp;above) shall be true and correct (disregarding for this purpose all &ldquo;Material Adverse Effect&rdquo; and
 &ldquo;materiality&rdquo; qualifications contained in such representations and warranties) as of the date of the Agreement and
at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time (except to the extent any such representation
or warranty expressly relates to an earlier date or period, in which case as of such date or period), except where the failure
of such representations and warranties to be so true and correct has not had, and would not reasonably be expected to have a Material
Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company shall have complied with or performed in all material respects the obligations, covenants and agreements it is required
to comply with or perform at or prior to the Offer Acceptance Time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">since
the date of the Agreement, there shall not have occurred any change, circumstance, condition, development, effect, event, occurrence
or state of facts which, individually or in the aggregate, has had, or would reasonably be expected to have, a Material Adverse
Effect that is continuing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
waiting period (or any extension thereof) applicable to the Offer under the HSR Act shall have expired or been terminated;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Parent
and Purchaser shall have received a certificate executed on behalf of the Company by the Company&rsquo;s Chief Executive Officer
and Chief Financial Officer confirming that the conditions set forth in <U>clauses (b)</U>, <U>(c)</U>&nbsp;and <U>(d)</U>&nbsp;of
this <U>Annex I</U> have been satisfied;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">there
shall not have been issued by any Governmental Body of competent jurisdiction in any jurisdiction in which Parent or the Company
has material business operations, and remain in effect, any judgment, temporary restraining order, preliminary or permanent injunction
or other order, decree or ruling restraining, enjoining or otherwise preventing the acquisition of or payment for Shares pursuant
to the Offer or the consummation of the Offer or the Merger, nor shall any Legal Requirement have been promulgated, enacted, issued
or deemed applicable to the Offer or the Merger by any Governmental Body in any jurisdiction in which Parent or the Company has
material business operations, which prohibits or makes illegal the acquisition of or payment for Shares pursuant to the Offer or
the consummation of the Merger; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Agreement shall not have been terminated in accordance with its terms (the &ldquo;<U>Termination Condition</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing conditions shall be in addition to, and not a
limitation of, the rights of Parent and Purchaser to extend, terminate or modify the Offer pursuant to the terms of the Agreement.
The foregoing conditions are for the sole benefit of Parent and Purchaser, may be asserted by Parent or Purchaser regardless of
the circumstances giving rise to any such conditions (including any action or inaction by Parent or Purchaser) and (except for
the Minimum Condition) may be waived by Parent and Purchaser, in whole or in part, at any time and from time to time, in the sole
and absolute discretion of Parent and Purchaser. The failure by Parent or Purchaser at any time to exercise any of the foregoing
rights shall not be deemed a waiver of any such right and each such right shall be deemed an ongoing right which may be asserted
at any time and from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORTY SEVEN, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>FIRST</U>: The name of the Corporation
is Forty Seven, Inc. (the &ldquo;Corporation&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>SECOND</U>: The address of the registered
office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, Delaware, 19801. The
name of its registered agent at that address is The Corporation Service Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>THIRD</U>: The purpose of the Corporation
is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State
of Delaware as set forth in Title 8 of the Delaware Code (the &ldquo;DGCL&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>FOURTH</U>: The total number of shares
of stock which the Corporation shall have authority to issue is 100 shares of Common Stock, each having a par value of $0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>FIFTH</U>: The following provisions are
inserted for the management of the business and the conduct of the affairs of the Corporation, and for further definition, limitation
and regulation of the powers of the Corporation and of its directors and stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(1) The business and affairs of the Corporation shall be
managed by or under the direction of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(2) The directors shall have concurrent power with the stockholders
to make, alter, amend, change, add to or repeal the By-Laws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(3) The number of directors of the Corporation shall be
as from time to time fixed by, or in the manner provided in, the By-Laws of the Corporation. Election of directors need not be
by written ballot unless the By-Laws so provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(4) In addition to the powers and authority hereinbefore
or by statute expressly conferred upon them, the directors are hereby empowered to exercise all such powers and do all such acts
and things as may be exercised or done by the Corporation, subject, nevertheless, to the provisions of the DGCL, this Amended and
Restated Certificate of Incorporation, and any By-Laws adopted by the stockholders; provided, however, that no By-Laws hereafter
adopted by the stockholders shall invalidate any prior act of the directors which would have been valid if such By-Laws had not
been adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>SIXTH</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(1) The liability of the directors for monetary damages
shall be eliminated to the fullest extent under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(2) To the fullest extent permitted by applicable law, the
Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the
Corporation (and any other persons to which applicable law permits the Corporation to provide indemnification) through By-Law provisions,
agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification
and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of
this Article SIXTH to authorize corporate action further eliminating or limiting the personal liability of directors, then the
liability of a director to the Corporation shall be eliminated or limited to the fullest extent permitted by applicable law as
so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">(3) Any repeal or modification of this Article SIXTH shall
only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article
SIXTH in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>SEVENTH</U>: Meetings of stockholders may
be held within or without the State of Delaware, as the By-Laws may provide. The books of the Corporation may be kept (subject
to any provision contained in the DGCL) outside the State of Delaware at such place or places as may be designated from time to
time by the Board of Directors or in the By-Laws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>EIGHTH</U>: The Corporation reserves the
right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the
manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the Corporation has caused
this Amended and Restated Certificate of Incorporation to be executed on its behalf this [<FONT STYLE="font-family: Symbol">&middot;</FONT>]
day of [<FONT STYLE="font-family: Symbol">&middot;</FONT>], 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Forty Seven, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Amended and Restated Certificate of Incorporation
of Forty Seven, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2011253d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><IMG SRC="tm2011253d2_ex99-1img01.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="tm2011253d2_ex99-1img02.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CONTACTS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 73%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Gilead Sciences, Inc.</TD><TD STYLE="width: 2%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 25%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Forty Seven, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Douglas Maffei, PhD, Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Hannah Deresiewicz, Investors</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(650) 522-2739</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(212) 362-1200</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Amy Flood, Media</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Ann Rhoads, Investors</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(650) 522-5643</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(650) 352-4853</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; padding-left: 4in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Sarah Plumridge, Media</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(312) 506-5200</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9
BILLION<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&ndash; Gilead Gains Forty Seven&rsquo;s
Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid
Leukemia and Diffuse Large B-Cell Lymphoma &ndash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&ndash; Transaction Supports
Gilead&rsquo;s Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline &ndash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Foster City, Calif. and Menlo Park,
Calif. </B>-- <B>March 2, 2020 </B>-- Gilead Sciences, Inc.<FONT STYLE="color: #212529; background-color: white">&nbsp;(</FONT>Nasdaq:
GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant
to which Gilead will acquire Forty Seven for&nbsp;$95.50 per share in cash. The transaction, which values Forty Seven at approximately&nbsp;$4.9
billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the
second quarter of 2020, subject to regulatory approvals and other customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through the addition of Forty Seven&rsquo;s
investigational lead product candidate, magrolimab, the acquisition will strengthen Gilead&rsquo;s immuno-oncology research and
development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which
new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse
large B-cell lymphoma (DLBCL). The investigational therapy targets CD47, a &ldquo;do not eat me&rdquo; signal that allows cancer
cells to avoid destruction thereby permitting the patient&rsquo;s own innate immune system to engulf and eradicate those cancer
cells. Forty Seven presented promising results of a Phase 1b study of magrolimab in patients with MDS and AML at the American Society
of Hematology meeting in December 2019. Magrolimab has the potential to be a first-in-class therapy.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This agreement builds on Gilead&rsquo;s
presence in immuno-oncology and adds significant potential to our clinical pipeline,&rdquo; said Daniel O&rsquo;Day, Chairman and
Chief Executive Officer of Gilead Sciences. &ldquo;Magrolimab complements our existing work in hematology, adding a non-cell therapy
program that complements Kite&rsquo;s pipeline of cell therapies for hematological cancers. With a profile that lends itself to
combination therapies, magrolimab could potentially have transformative benefits for a range of tumor types. We are looking forward
to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif">March 2, 2020</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 49%; font: 10pt Times New Roman, Times, Serif">Page 2</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This is an exciting day for patients
who may one day benefit from future anti-CD47 therapies and other immuno-oncology treatments based on our research and an exciting
time for Forty Seven as this allows us to achieve our vision of helping patients defeat their cancer,&rdquo; commented Mark McCamish,
MD, PhD, President and Chief Executive Officer of Forty Seven. &ldquo;We are pleased to join Gilead and believe that by combining
our scientific expertise with Gilead&rsquo;s strength in developing treatments that modify the immune system, we will be able to
more rapidly advance our therapies.&rdquo;

</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Magrolimab</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U></U></B>
Forty Seven is initially studying magrolimab in patients with MDS and AML. Additional studies are ongoing in non-Hodgkin lymphoma
(NHL) and solid tumors. Magrolimab has been granted Fast Track designation by the&nbsp;U.S. Food and Drug Administration (FDA)&nbsp;for
the treatment of MDS and AML, and for the treatment of relapsed or refractory DLBCL and follicular lymphoma, two forms of B-cell
NHL. Magrolimab has also been granted Orphan Drug designation by the&nbsp;FDA for the treatment of MDS and AML and&nbsp;by the
European Medicines Agency&nbsp;for the treatment of AML.<BR>
<BR>
More than 400 patients have received the compound to date through clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>
Ongoing Phase 1b Clinical Trial
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, Forty Seven presented promising results of a Phase 1b trial evaluating magrolimab in combination with azacitidine
in untreated patients with higher risk MDS and untreated patients with AML, who are ineligible for induction chemotherapy.&nbsp;This
has led to the initiation of a potential registrational cohort in MDS. All patients received a 1 mg/kg priming dose of magrolimab,
coupled with intrapatient dose escalation to mitigate on-target anemia. Patients were then treated with full doses of azacitidine
and magrolimab maintenance doses of 30 mg/kg weekly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of the data cutoff of November 18, 2019, 62 patients had been treated with the combination in the Phase 1b portion of the trial,
including 35 patients with MDS and 27 patients with AML.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>
Clinical Activity Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the data cutoff, 46 patients were
evaluable for response assessment, including 24 patients with untreated higher-risk MDS and 22 patients with untreated AML, who
were ineligible for induction chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#9679;</TD><TD>In
higher-risk MDS, the overall response rate (ORR) was 92 percent, with 12 patients (50 percent) achieving a complete response (CR),
eight patients (33 percent) achieving a marrow CR and two patients (8 percent) achieving hematologic improvement.&nbsp;Two patients
(8 percent) had stable disease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#9679;</TD><TD STYLE="text-align: justify">In
untreated AML, the ORR was 64 percent, with nine patients (41 percent) achieving a CR, three patients (14 percent) achieving a
CR with complete blood count recovery (CRi) and one patient (5 percent) achieving a morphologic leukemia-free state (MLFS). Seven
patients (32 percent) had stable disease and one patient (5 percent) had progressive disease.</TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#9679;</TD><TD>The
median time to response among MDS and AML patients treated with the combination was 1.9 months.</TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#9679;</TD><TD>Median
duration of response and median overall survival have not been reached for either MDS or AML patients, with a median follow-up
of 6.4 months (range 2.0 to 14.4 months) for MDS and 8.8 months (range 1.9 to 16.9 months) for AML.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%">March 2, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 49%">Page 3</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><B>Safety Data</B>
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the data cutoff, the combination of magrolimab and azacitidine was well-tolerated, with no evidence of increased toxicities
compared to azacitidine alone.&nbsp; Adverse events (AEs) were consistent with prior clinical experience.&nbsp; No deaths were
observed in the first 60 days on combination treatment and only one patient out of 62 (1.6 percent) discontinued treatment due
to a treatment-related AE.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Additional Programs<BR>

</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beyond magrolimab, Forty Seven is preparing
to advance two additional investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in
combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation
conditioning regimens. FSI-189, an anti-SIRP&alpha; antibody, is being developed for the treatment of cancer, as well as certain
non-oncology settings, including transplantation conditioning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>
Terms of the Transaction </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all
of the outstanding shares of Forty Seven&rsquo;s common stock at a price of $95.50 per share in cash. Following successful completion
of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same
price as in the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consummation of the tender offer is subject
to a minimum tender of at least a majority of outstanding Forty Seven shares plus Forty Seven shares underlying vested options,
the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gilead plans to pay all cash consideration
for the transaction. The tender offer is not subject to a financing condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citi and J.P. Morgan are acting as joint
financial advisors to Gilead. Centerview Partners LLC is acting as the exclusive financial advisor to Forty Seven. Skadden, Arps,
Slate, Meagher &amp; Flom LLP is serving as legal counsel to Gilead and Cooley LLP is serving as legal counsel to Forty Seven.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #212529">At&nbsp;8:00
a.m. Eastern Time&nbsp;today, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction.
</FONT>A live webcast of the call can be accessed at Gilead&rsquo;s Investors page at <U>http://investors.gilead.com</U>. Please
connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download that
may be required. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8479332
to access the call.<BR>
<BR>
Telephone replay will be available approximately two hours after the call through 8:30 a.m. Eastern Time, March 4, 2020. To access
the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 8479332. The webcast will
be archived on <U>www.gilead.com</U> for one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%">March 2, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 49%">Page 4</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>
<BR>
About Gilead Sciences</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Gilead Sciences,
Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world.
Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information
on Gilead Sciences, please visit the company&rsquo;s website at <U>www.gilead.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>About Forty
Seven </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forty Seven, Inc.&nbsp;is a clinical-stage
immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches
based on technology licensed from&nbsp;Stanford University. Forty Seven&rsquo;s lead program, magrolimab, is a monoclonal antibody
against the CD47 receptor, a &ldquo;don&rsquo;t eat me&rdquo; signal that cancer cells commandeer to avoid being ingested by macrophages.
This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid
leukemia, non-Hodgkin lymphoma, and solid tumors. For more information on Forty Seven, please visit the company&rsquo;s website
at www.fortyseveninc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>
Forward-Looking Statements </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication contains forward-looking
statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the
acquisition of Forty Seven by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements
of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent,
belief or current expectation of the companies&rsquo; and members of their senior management team. Forward-looking statements include,
without limitation, statements regarding the business combination and related matters, prospective performance and opportunities,
post-closing operations and the outlook for the companies&rsquo; businesses, including, without limitation, the ability of Gilead
to advance Forty Seven&rsquo;s product pipeline, including magrolimab, FSI-174 and FSI-189; regulatory approval of magrolimab,
FSI-174 and FSI-189 on a timely basis; the anticipated timing of clinical data; the possibility of unfavorable results from clinical
trials; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability
to complete the transaction considering the various closing conditions; difficulties or unanticipated expenses in connection with
integrating the companies; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance
on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks
and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking
statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Forty Seven&rsquo;s
stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various
closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay
or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees,
other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions,
if any; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or
political conditions outside of the companies&rsquo; control; transaction costs; actual or contingent liabilities; and other risks
and uncertainties detailed from time to time in the companies&rsquo; periodic reports filed with the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on
Form 10-K<FONT STYLE="background-color: white">,&nbsp;as well as the Schedule&nbsp;14D-9&nbsp;to be filed by Forty Seven and the
Schedule TO and related tender offer documents to be filed by Gilead and Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead</FONT>.
All forward-looking statements are based on information currently available to Gilead and Forty Seven, and Gilead and Forty Seven
assume no obligation and disclaim any intent to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%">March 2, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 49%">Page 5</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Additional Information and Where
to Find It</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tender offer described in this communication
has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation
of an offer to sell shares of Forty Seven, nor is it a substitute for any tender offer materials that Gilead, its acquisition company
or Forty Seven will file with the SEC. A solicitation and an offer to buy shares of Forty Seven will be made only pursuant to an
offer to purchase and related materials that Gilead intends to file with the SEC. At the time the tender offer is commenced, Gilead
will file a Tender Offer Statement on Schedule TO with the SEC, and Forty Seven will file a Solicitation/Recommendation Statement
on Schedule 14D-9 with the SEC with respect to the tender offer. FORTY SEVEN&rsquo;S STOCKHOLDERS AND OTHER INVESTORS ARE URGED
TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER
DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY
BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain
other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Forty Seven
at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free
at the SEC's web site at www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Forty Seven<I>.</I> Free
copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing
requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Copies of
the documents filed with the SEC by Forty Seven will be available free of charge under the &ldquo;Investors&rdquo; section of Forty
Seven&rsquo;s internet website at ir.fortyseveninc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition to
the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation
Statement, Gilead and Forty Seven file annual, quarterly and current reports, proxy statements and other information with the SEC.
Gilead&rsquo;s and Forty Seven&rsquo;s filings with the SEC are also available for free to the public from commercial document-retrieval
services and at the website maintained by the SEC at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gild-20200301.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWaaCebPtzp5xGekhuWh9bSlKzyMoRivRoSLyF6VGoV4N -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:gild="http://gilead.com/20200301" elementFormDefault="qualified" targetNamespace="http://gilead.com/20200301">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://gilead.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gild-20200301_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gild-20200301_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>gild-20200301_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>gild-20200301_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gilead.com/role/Cover" xlink:href="gild-20200301.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gilead.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2011253d2_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011253d2_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* /@# 2(  A$! Q$!_\0
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M!YQGH1_,#U'YYH =12%@#@YR>< $G [\ ^M&?KR<=#V_#@>YX/:@!:*:64$
MG!)P,Y&3@' )X/7C'4Y Y!P;TZ;AP2#SW&,C/3C(!]SCKQ1UMUWMY .HHHH
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M/$X2$L7C<0G*MBL=#!VP].CA,/']=D&%"$C/3=C&,$8./<_*/3G.,5\<?\%
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M20&60Y&Y@!7]4_\ PW/^QEC_ ).K^ AXZ_\ "T_!QS[\:OC\N*_,?XS_ /!
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MOB7=KHFBRW*O#=0W]MJ+#Y5A3^IW]EC]C+P=^R-^S--^S/\ #'QOXUET0?\
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M25_#5CI5K?V?AC3IKS5-%N;SP;:W4%K#I>I:UI$7FZB=/MUUBYT6&%[N=K
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ML=)U/PQH?BE[6^OM$\-ZC'J,IU+1VT>^,5UJ\]L]]I6IP62FX>*]P7R/NO\
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+$SNQ-%>F44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2011253d2_ex99-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011253d2_ex99-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !# /X# 2(  A$! Q$!_\0
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MH-E\2+R>9@V6UKQI:7>DZOJMY-)F2ZU*ZT][F?*O(A?.?Q<_:$_8A_X*4?\
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MM)2BTVGS$M%5S=0AMI8[N/E"ECR<#( .,G&,^H]10+F$XP6R20!L?/'4XQG
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M\%#M$\3V:3FP^''P=\9:YXBGC23:D.N6L&A6$=PZ\9N[^X 7S3AV! P1BO\
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M4^JWGA76?#.E3^'[KPCX\TN"-M>LM+L9U^TZ;+%!.--U.ZU=+BWMQ.96_O3
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M>PM_#>G?\$>M6T_P_96HT:Q\.VFD>,++1=/T>U7[#!HMOI=OI4=E!I]G9C[
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M;P?PC^*?A3XU^ -&^)7@:YU.Y\*^(7UN#3)[^SELKUGT#7-3\.:@9+20R21
M:GI=T(&\QS<0QI,/ED*M^44?[,G[1\_[7O@WQMXD_P"$OM-/TGXD_"3Q%X#^
M)'@KPGX:U;_A"?@UX3\$VEMXW^"&K>,-;^.?A]O!W@;Q9J,.LZ!XZ\+Z'\(/
M%5SXJN]4T_Q7IMQ=:I90WFG_ #3;_!?7-+^)OPU^!?QA^ ?Q,^-4_AS]B?XK
M>(E^#_P\^*]GX;3P_P"-_$_[5?CBY\!^,Y;-O&'A/2HM<2TU&PA\._$RSU"Y
MU?X47KMK5I%'=Q17]B ?T,:3XNTW5/%/B7PA;KJ@U;PI::#?:LUUH>KVFE-!
MXCAOI=,&E:]=VL>DZW*$TZX.HP:7=W4VER&&/4$MGN8%DZZOP>O_ -D[]M3Q
M%J'@71?B;J'B/QM _B;_ ();)\7O$>E_$Z_TNQ\7:=\&]!^*%O\ M67ZO:ZM
M9:G+IVJZGJ_A^'Q7;0P6<GQ(M+N0W%L;6XN+6PYW5OA+>_"#6OA]X _:&TBQ
M\0?L[>#OBQ^VE<_!KX!ZE^T/X%^'UYH7A*]\<^&/$?[.WQ&TJR\??$3P1;>*
M/"/PO\'R^,O#^@VDWB.XUGX%0:YHM]H.CRV\$(T( _;/XP?%GP5\$? NJ?$;
MX@ZI=Z1X7T>?2;*ZNK'3+_6KR6_U_5K30M%L++2=,@N;^^O=1U?4+*RMK>VA
M9Y9KA$R,\XGPC^.GPZ^-UKXB?P%K.HW6H>#-6BT'QCX;UW0M;\*^+?"6J7-J
MM_8VFO\ AKQ!::?JUB;^Q=;JQO);=[6_MP\EM-*8I@GY;_"OX;_%?X^_\$AO
MV<_"]BOCK5/'7C6T^"GC:34M0\:Z@/B GA9_CCI'CY_%D/Q)UU+/7-8U^T\"
MK'K^D^/)X;;4_%<BVOB.VTZTGU-;>*A^UM^Q9X\T:"7P_P#L_P#PT\0?%&X^
M)%KXM\9^+OC=XX\7ZY\4?C3;_''0= CT#X.,NL^._BUX'T/P3X<\/Z;-?VVC
M^-;;2?%[> ?)$?AGPMI]_JUWK! /UQ\0?$CPEH-U?V=YJUS>ZCIVK^&=%U32
M= TK4O$>KZ->>+WD'A^36-+T:TO+G3;&_2&:4:O>P1V$-M!--<7*1*[UUVJ:
M)INMV$^E:WI5CK&FW:JESI^HVD%]8W0&<":WGC>"5 1N56C(S@@+D ?BA8?L
MD?'70?BU\2/&ND_#?6-.\:_%+4_V%/&_BCXFZ9XJL6AUR^^'VC3:;\?]+US=
MXFBNVU==<2UU>[LXM/.C^);.6:2TG6>2ZBFY+PM^R;^UM8ZI\8KS49/'L/Q<
MU3P3\>-,\4>/="T3P]X<\/?'2\\8:W>GX8+J_P 5+CX^^(_%.LR>$_#TNE+X
M&BLOA3X#N/AW<:=/ID$^GV:Q27V<J:E'D:BJ=VY044XU$^;FA4C-2C*$W+FE
M%JSE=[.Q492A.,Z<I0G3?-3J1E*%:$GK*4:M.4)Q]Y*47&490<*;C)2A=_MI
M:Z3\/_AM90FQTKPOX%L]6U&RTJ)K33]/T2"^U+4)?)T_3@;>",S7%Q-^[M82
MV9'.Q!DBN\"2!@QSPXP6RHW_ '1D?Q*<CIZ<'/(_!#XA_L!_$$IXFT"P^$&H
M>-/A-9WO['?Q<M_ ]Q\0+J_N]?\ B[X'NIM/^.&N:9)K/BFWNQXLU#1S:W&L
MW5[J]MI_BFXMY+FX%YJ169OJG]E+X.?%CX=?M;?%[Q/=_#;Q!!\,/&.@:K>7
M7Q*^*LEA8?%BW\0R^)1<:!X%M-8\%?$WQ5X5^+WP_P!/T0RR^&]6\4> O!_C
M7X>6BQ>&W\0>([&9+/2JA&-.*C3A3II*W[NG3IW3WNH0C'Y\MUW'5J5J]3VM
M:M6K57)3E5K5*E:K.7LW3;G5JSJSFG%[.5D]4D?1)_;N_9L3Q?>>$-0\:ZYH
MHL?',OPUG\9ZWX)\8:3\,1X^M]5&BGPM)\2+C1D\(6NHR:RRZ7$]WJMK97-^
M8]/2Z:ZFCAD^O@9V. 7Y91N97"$,IW'<KXQ@$!TPH<QNHSO5_P 9+WX:_M-:
MM\$OVB/V.]+_ &9]2E;XV?%CXT(WQL\>^*_A_!\&?#'PY^*?C'4M47Q[!I>G
M>(=6\>^(O$/AS2+Y;[1?!MKX3TN74/$D-D)]=T.R2YU2TRM)_9)_:!;]K^RU
MGQM=^+K_ $.U^,9U31?B[X;\'^';VVOOV9K3X8ZOX<G^ GC/QKK_ ,<(-2L/
MA[XFNKN'2_$_PZTKX,WVH3>/4\-_$S1=:DO/#DNLP40?JY\&?C)X=^.'AO6?
M%W@S3?%5OX9L/%OB7PEI.M^)]'?1H/%;^$M7N] U;7/#=O/*;NZ\.'6=/U'3
M]/U2ZM[-M2-D]U#"]O)#-+ZS(7\P;1(0K;@ VU&?RV 5B>#&VX C)"R*K8ZD
M_P W%W^P1^T)X-^#7P@\ 67PVU-_ .D_"7X[Z-;_  Y\$:?8>//$_P ,?VB_
M&/Q:\4ZOX7^-6BWFK_'SX,V?ASQVWPZOO#EK\-_BS#X@\7W7PCU[1;F:#2M(
MMM7N;R^^D=?_ &=/VHM;_:V^&FOZSX+?7]-\(>/?AUX%^(7QI2RT2QO?C9^S
M;+^SCKW@CXFZM\2/$H^(4<":EXL^)=_!>WOP,^'?P<\*^#_#FJ6MGXPMM;US
M588?$9 /U7\8_''P/X+^'=O\4I;K6O%O@R^N+6VL;WX=>'=8\>WE]]LN)+(7
M=IIWAJUO;V:RM[B"8WES#$8;41OO90 3XW\+OVXO@7\9-4^&FE> ;[QYJ$?Q
MA?53\.M<U3X=^*_#F@>);/1_#-YXMO-5TO4=>L=/-]H[:/9330ZC:+/;A@D;
M31LP9^$_X)V? W5?V>/V0/#OP1UCX97/PU\5>#M0\>Z%K>GMJ=KJ^F>)]1_M
M_6%T[QEH.JP:SK+W.@>)=&?1KBS>[_LJ]@F>X@N=(LI8W:7Y@\-_L3>._%_P
M;_X)E_#+XM?#IK_0_@9\+O%.@?''PTWBY;.STC6;CX(WWA/1M-OI-+U,7/B2
MR;Q--;P_9K2^FL]R0WES))#",@'[2,2%) ).. .I/H/3/J3QUSQ7(>'?%VG^
M)Y?$EMI@U82^%?$-QX9U4ZCH6KZ.CZA:VMI>2R:7-J5I FM:?Y-[$L.L:6;C
M3;B42P13M-!,H_!77OV4OVS]<\-?L\:7X]'C[4I?"7P3TCX?>'=4\.6.A_$G
MQU\%/BCX=^)>M&V^(-CX@\1_'WX6V&B^([WX8V_@^Q3XB7]C\2;V>TL-2TS6
M+*YFU"5+[Z8O?V3/C'X_^.>G#XLZ=XF\2_!R']JWXE?$;4X#\0K_ $O2M9\%
M-\'/ ^D>"K_5-#\/ZOI;3:-=?$#2-6U(>#62?2K/4'FGDT];5X@0#] /C%^T
M?\,/@5/X=TSQUK>JW'BCQBUX/!W@7PCX>UGQGX]\3)I<:2:M>:7X4\.V=YJ<
MFFZ4DL;:CJ<\46FV^Y8WN8IW1'[SX5_$SPM\7O!NF>/O!=YJEYX=UD7"VK:S
MH&M>%]4MY[.XDM;RRU#0_$-CIVKV%W9W,<D$J7-HH<KOCDD3:[?'/Q@\'?%+
MX8?M8>&?VI_ _P *-7^.G@^]^"5U\%/%W@WPGJGAZV^(_@":#Q6/%.D^+/ F
MG^+M6\/Z!K&C:T"^C^*-,@URQUB)X;34(6N[=)[1/DO]I/P1^V'\?_B'\._'
M&C?LU7'PLUC0-+\!:O\ #_7;7Q)HOBKX@^$;ZV^(R7GCG2_%'C.+XJZ#X,^&
M/G>#MTTMGX-\!?$#6_%:W<NC7_B^*UA_LR$ _<&BOQA/[(_[05CX_;XM^#AK
MGA;XTZ[^U3^U+-=?$74_'NIZS::3\ /'W@CQ['\,+*\T*?5;S2Y? >G>.1X"
MUVT\#VND8T35+>35[:RBNWO3=><7O[,7Q:N/V?QX8\!?L^_$'X;?$$>._@?J
M_P"UK)XP\4VGQ4LOVJM \,0>/$^(MIH^G)\<O#<GCK[9KNI:#XD\0-K'B'X=
MW/Q#\.&T\'7VH7T.F)HT0!^\M%?CQ\%_V1/B#-X\_8VNOBE8?$+7_A7\'_A_
M^U=XJN/#OB_5;?P=:>"_B1K_ ,:_V<_%_P"S;X<U?X=>$/B7X[L-=TWX;^%/
M#7Q"B^&>G:WXL\90^#[6*2+4+B#59-/C7]AEY52>I SW[>H !_ #Z"@!:***
M "BBB@ HHHH **** "L&WT/13K"^)?[(TO\ X2+^S7T3^WAI]H-9.BB[;4!I
M!U,1"].EK?R/>K8&<VBW3M<+$)6+DHH UY^3"AP5DE*.I (93#,2I![$@?E7
MG_B7X=?#WXGV.G67Q(\!^"O']G8"TU2PM/&GA70?$]K8ZE(LBO>V5OK5A>PV
MERRJ%,MND;XW#.&;)10!W.GJJ0;$542,I'&B*%2.,0QLL:*H"I&A<K&B@)'&
M%CC"QHBK>HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M9Y&BV1=1[XQ^<7'1F8RK?S0%]/A/_@)02P,$%     @ \CAB4+JA.8K7 0
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MM.B@>1,:+[B<6J\YBR'QC.\?1H]BZ<&8A6#O[I5TXH\<P_?,?P!02P,$%
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M]["?"=MA/7;AWR"I83KOUO]H=)G+H%W\S<A'2NU!7PW_R?(+4$L! A0#%
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /(X8E  H2;ZG@(  )0+   8
M          "  ?8(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #R.&)0 NQ/W5@"   "!@  %               @ '*"P  >&PO<VAA
M<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #R.&)0NJ$YBM<!   R!@  #0
M            @ %4#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /(X8E P
M _>^-P$  "("   /              "  580  !X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " #R.&)0_\ F"+T   "% @  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #R.&)0"X_8
M R$!  !7!   $P              @ &O$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "@ * ( "   !%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm2011253d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gild-20200301.xsd" xlink:type="simple"/>
    <context id="From2020-02-29to2020-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-02-29</startDate>
            <endDate>2020-03-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-02-29to2020-03-01">0000882095</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-02-29to2020-03-01">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-02-29to2020-03-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-02-29to2020-03-01">2020-03-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-02-29to2020-03-01">Gilead Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-02-29to2020-03-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-02-29to2020-03-01">0-19731</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-02-29to2020-03-01">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-02-29to2020-03-01">333     Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-02-29to2020-03-01">Foster     City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-02-29to2020-03-01">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-02-29to2020-03-01">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-02-29to2020-03-01">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-02-29to2020-03-01">574-3000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-02-29to2020-03-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-02-29to2020-03-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-02-29to2020-03-01">true</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-02-29to2020-03-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-02-29to2020-03-01">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-02-29to2020-03-01">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-02-29to2020-03-01">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-02-29to2020-03-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6607607824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  01,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gilead
Sciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333
    Lakeside Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster
    City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2011253d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2011253d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20200301_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20200301_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20200301.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "gild",
   "nsuri": "http://gilead.com/20200301",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2011253d2_8k.htm",
      "contextRef": "From2020-02-29to2020-03-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://gilead.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2011253d2_8k.htm",
      "contextRef": "From2020-02-29to2020-03-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-20-027472-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-027472-xbrl.zip
M4$L#!!0    ( /(X8E U'%[:00,  (D,   1    9VEL9"TR,#(P,#,P,2YX
M<V2U5FU3&C$0_MS.]#^D][43CM/Z H*.8T?'$:T#%?W6"7<+9 S)-<D)^NN[
MN1= .!C ED_)[O,\V4UVEVN<34:"O( V7,FF%U2J'@$9JHC+0=-[Z-#SSL7U
MM4?.3K]\)OAK?*647'(049W\4"&]EGUU0N[8".KD"B1H9I4^(5TF$F=1EUR
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M4ZDU%+>C!8\Z$PWV<)!4)B::1;I-$+,;V"Z(@K=#$&NG=%D49A7)+>B,O6D
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MH=&'^;\%*%]<EVO5L>AI\8C%:;S=YIGL684]^#YZ9Y#C!Q0#"J ]INB(" C
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MW+;G>TS#VQIU'ID?NW#PZT V3'+>&)VT8-0);,OF/A71R24]'<Z;$9 8#_
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M!&0$>40%#"Q4Q FYKAC Z]L=B0DE^20332-X?<WS31U+VT1$EL8UH*]"%.A
MC2#>RZXK'EA]GL7WIH7.672X92%Z3 M5KY-,5VG7&)A)FBJ&V3MENV)@6.C
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MMIJURO4E-*C2G[ \F O;L]-:I?RI5<,>?[#/]4:#5:ZO:)KZY0T@I@QMZE>
MHDO9\_.'>N4#:WVX_M2H0F=&*Z\ -LX^-1I_K*^=UJ!M#8#X@U5KE7H+^]1;
M@(IJ#89O?X .K9M:I8W+GT:8++^-KC_1M=Q952XL";LA,'Z'[-)&DQQS"2!;
MJ-I<FM7:V4FWZ6:-R&6H+!OQ8Z#L(1E"-4OG$_P+IGZ(UI6*XRC"&\@5SF&4
MR$A=BNX3 B(V!U&X]7PA" #% _^-*^XP$&$";^(8C\?Y0'3SX/CEF:'ZNMX0
MW0550>QU$)DRI$PCJIKK4-4'*PDP?=3@#%O*D?3A"5FKK*21L5'*-:(-HG,[
M>H_FK2VVP#OH;-N.8?Q.W\VWO;V]OM;@=X+<NZH/_B4&_/$;!O3M^2P0+:.O
MAF>Q!A/]7C0*="@,\_CZ4 -,)K\*#;@KY@X*A=QYO0%DG]O%U1=S>[N%G/YV
M,1U)P4-#=.J3PC$JFR4U(MG.AFSV5,C=,#K(C=21 4^>.Y'EHAHM>"MS='PO
MG9CRK")W$^\+)U<^0NZ4MX@R<LI;TO,85.7+8WYX3N-6&)>G*.\QBB#J\\N!
MB*XJ,O5D%*ZFD_5X1180IJ9+V\_CK2.3 %N"2YD'RG_39PGKL%N*?9*7RSPN
MO-;7YD@O]A+"*]T)U(J;7&[3.R=PDHX\I4L>)@DW-0INF.2;M"CDQ-&N3P$0
MAPIU.#]!E=%)D%GIIM$]'('WVE5) ER\3W6P&F$Y7X2^+3#4%@C_WN[JZ+(4
MC9KV\!HS*>SH1HYH_J2H_!G"F2Z1F%\8JSX_4<A3@?+\SY&_%6B6<:%W?KG0
MJW6AWQ8Y+?&)=?!O6_7SJW+[4[.V4A=W[G0OXDY/7W^J;FN)4O8D.=(_L4'&
M$'YC0RN$Q"< P'F9R&R0.O\IQ:X*:0:P.$Q'R'/%'='G3D^?HB-5K!I@J&*$
MIT]H.#X*^YYO_P"'?64HR-.W45=,,JF#/KDR/W%%][,*\!^]Z/NE:S+C<0%<
M##.]SVS/6V/:)Q3,M])$9:U*O795J;7 ++ZJI!94O>[Z%?9WZ4L%"Q>@\;+\
M&9KX(V@O,OBLT-6+><FU[)2>,?I?L;>KQ\%K;.);@/JOV:U5%"T_MM;3R9%>
MZ+.Q'(G"4B0*ESLS],QB_X6 ;@5;K(K)6(?=Y-FU<F"J?/)7[^?2FN7MLAI^
M8NYHE9SV=]NHA8MA;T]RTF<KCU8"4*7/;:P0(^^\TL>ZT]H#&-)4%G*-12C1
M1:'SOTS\=BU<I,50@.>7. [T8J&MU_YRU;2_OWO,KF7MX1%K\"!\.^[_B^6Q
MESM,L-7QK G1;3\<."=)++8$+)&$('NP'HY9O4J_?"T<G'Z-+K8.),343_SV
M</;M]\+%^%OY8[^V]?%Z\K#;&'[_?!%ZVXW6T#YKW=GW=WR_Y5>OG+OM@^O=
MB^VK!J]/#BXF/SZ,?WSTFO;'+U=6O7O5_SQJC<?[WX=.[=([J$\N=[VVN&L5
MOUST^IV=VN^=AX/O.X?WI=/S+W?G-^T;;R)N?JOL;1=]N_3YHMMOWA3V]PK-
M;W>7IX6[R[-!8^<B=/^\W-MK7E\7OM]5_JSY?UY6/X<%VSFTQG<[AY/?JX?\
M^WUI<L;;K=:'[Y-/N__^.)E\.Z_^6?A]O&5_W_ET\*/P\6/8OZZ?6M?AOZU.
MU[^XY'_VOWR^#\+2WH=_5ZL_^I/6E]OW$B7_"U!+ P04    " #R.&)0>BR(
MOOE" 0#WE@< %0   '1M,C Q,3(U,V0R7V5X,BTQ+FAT;>R]:5/<6+8N_#TC
M\C_H=IS3 1&"!CR47:Y;$1CC*NYQV1R@NM_^J,Q4@MI**5L#./O7OVO:>Z\M
M*0<,3L83T:<,9$I[7..SGO7+[V=_?/JUW_OE]\/]#_#? /_OE[.CLT^'O_[R
M-_XO_/5O\N=?WG_Y\,_@].R?GP[_[U_&>5;]'.SN3*O@+)G$9? YO@I.\DF4
MA?R+,#B-BV3\%_@B?/78?*^*OU5;49J<9S\'17)^4;T+)E%QGL"/.W_Y]9>/
M7SZ?Z5=LE<E_8GX/_/7]KX??+I)!4@5[V[N__.T]C!*_ /\Y;KS&/O-=T'KC
M7W[]:S8HI^\6?.LO'8]<=<9J0O#1[@'\\N>O!U\^?SSZ</CY[&C_TR]_^_/'
MO_#P_SL\^//LZ,OGX.#+\3_U*Z^Q"(NW[SKK^G^VMH*/29R.?@Y.ZC3>.H[.
MXV!KZ]=?/AS]W?_>5I5/:2?EQT%>5?F$?G.5C*H+7*.=__Z+]TU]=J8PR$%>
MC.*"G_0^C89?@SU8JS)/DY']HWDN_WW7_-U-"Y[_J_Q_-?J_><.?._%Y:W,K
MNSR,LRHNZ(;L_W9R>/@'G*M@__.'X/C3_N?@R\?@C\.3WPY/^,K<T@C6-*5H
MDF?G/S^T4<-&?/QR<@;B\O#OAY]#?N?1YX/M\$'N0? A3J.KJ(B#85Y,\R*J
MDCR[O;>N;U-^._H$RBPX/3@Z_'QP>/I(-R:(LM%#FPILSMF7DR\BJ8+3/]\_
MSLUY:+/X$%7Q*(C*(!\'?T3%\(+?NAL&>SM[.S_XY;<\PZ=F?MS6R5*OPQ>]
M@V_]NXZS(4Z/WTJ>PYREV]V;5JW5>ZV69>[,_9DH7Z#KM-A7\'YUO).=")@4
MKV)[U%.8W-:@B*.O6X-XG!?PMBB]BF:E_^S7'<_&2>H!JP75R^F]6>_BC]W
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M."I;()5ELL #QHF2LG'9#O^ [=)^S\5N;>]QEODX;JD*4* .^@DY\6]MRZB
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M)HJ2!%Z[<67XSS.O803WN3ZO(]"]5>Q>^V=&&TB08?K4_@04VS *'0TJ<9S
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M5&*?!Z-B1(>XW*1ZSDP5V_FD.WA"O!/IXH4LDU(D=!6L)GUW( +.R9A6V)R
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M61)!TZBLK)L<-AN;-(> Z@2[3V;B:!OM.X[(U[)=6=T?R7:X<G@*5ZL,:CW
M,!AH+1B@J_DN@U?;>QN#33*)J.H;_F9^);\+W*\NNW[5^;OV+[^U?]/YL<OV
M2+YUO/=;UXN_V3=+9+OP7O=-_8E8OE5?3\[VRWIC U?6- NHK&V36<DAY04M
MN-@T+/P)AG/O1?2*(>?=)Q9R?OT<<M:G3"\AV#S5UFE\/J$SSBOW@E]]_X[W
M_2][(1O3-.4"\3&D="Z'KCBJ$WI^2$CML1)#KW(9I_F4[0E.O<%_+^E'>9)0
M)9>F*=B86.907?AA58KAM..J%Q$W18 _LG99UE[I\01B5S=7?_+-U5]N?'S,
MLQ;'%I!\FR*1^P2QW Z42:J#@+B'U.8+K0YF*^&VWM+ 6Q":6+0C@=@CD*\I
M(G7A: 3'IJGW"=%T; ;</ TLVJ3JY@IK%-6:.F2)+:J.;/9)7M0#&\\3B"%%
MF&-NNAW!%1@4[(IOY ;^%V5(/R<%/OHSFS^\J=N<&[/H CRZD_]F700()S&&
M5\U1?"8[N \-VZ0:$TL19%\>Y7+?97\\S$:4BF'*]@,%T5C&1+:I6]\)/D?M
M2&"9B&,.8A'T4'YH"=Y\ F\1V2J4_HT$W"?^)E['P-U&G7?K$-\@_#WQK1B'
MNX4W"MI^;^T=.3MD=[]G.G*>SL&C=U%^\&@$7L#8=/3[50+=AA^\^/9EDJ<6
M$,9..VF943R.ZK22$#1^A7;0ED)+(J%K<_@ F$$QJ)[\7; .,=_IHA#>2!PT
M +5L!S: S-!XXA(!U/8#$=,N+] Y'H2&N]J409VD(XKFCA-F>_Y/GO'C1[%;
MCU+(1AJ9DZX7^'I?$YZ:=M1^H,!<$(=!>RJ$H&_7I;RU.?FLQ.]$B:NX7[\'
M6P_OW]"W0'JLF[]XD;3QG%S$ G9H(_9/7+W-T;$B<NCWA%#^& 6+%,GQOPW:
M06CNSHH(Q$Q4?/58=(3=R/LD_N8@G\Z8@7_QIS=MO8PF=;1"^0OY)?[@66[)
M!SZ9%LR-"7JL.]O!OL'0^Q]+J#:>HXP+"J"P07?)A-=4S:74)@E;$=%Z7IRR
MHHZRRFC0;)-,0$FZ@#%GY$$2'-E#T8T0FO.O>G1N2G!&\9 T>Z..R.!VFF"*
MVK644"T;!++1Z$AN0'"Y#) <T1+Q^P/0.EA;!6)Y0S'=&A(";UE#*9D@K[+8
M-$?0G%M8=WP!JOXKX0<A!'-A\#R#V/^ ;QT]2B&T9M/V<XX95-@O27-BEP]3
M+HJ[1S(!_Q%_BRS&@*I?8K81AF@=IFG[#QZPT:'I/R%#*UH&\D$_<%# B4\R
MM!2[WM:F">^Z<)MXF^P?.JA<YV$K^[TYQ*^NDP+8*\F$!511#WF1Z%93#W=[
MJZED+^0T1,+V#T8 \Z*\2*:T%G@?^ <VTTB\]7LM^39'JAD+R5Y+*BQT/>B]
M"912V@R/LQQ6E DM!9,U1)KE.#N/1_?_2JV8'7EGNAO\C,\5/6LS)KL_/8F4
MR4]S4R9STA=/(7'RQ'@[0-)( 6=.=>&Q$%MR"T@..K,:%Y)Z*>EDAFC#]<^6
MB^UXB):$K\B;00:";%P_RG#_Y<\#*^S%#:Q+4W91H-E&I!^6=B(>C[D>-K=%
MP*SI\FS,!?B1X4JQ[C@Y $B64!"-!*JNT%EN9$</8O-[AD"VJ>$=QIS1@Z2M
M5>L:ZF"$[4706/??2' *YJ*WY;Y-(E35?P+5.^AZ+/W8TN6J)A]2>G:\^X3@
MT;X36M+O.6R))%FZ4/<15M6-:K G9DQ2-[0&DT;-A=(V)IX,\I&E]\_@R+9=
MM$=YB>Z\0=-;&,*&[X1?JT<3Q;^.4$MB<U>QZP)Q\CO?M9+'W^_-?=F7NO+?
M]B@/QIH+X6Q XFQIM("D1I-6I.F46QF"]#BV6R)&<FMN>3@WQFW@B#R,.:TF
MN0&'#WQDQ]J]PB:0*'9O<.))-D:9C,Q]2:GI ;PB#@X'QTRX:V/:YKNCYI='
MG=\><:/@12EN%P"(;%]'28?XP+UR/@_X"OA-4\5H_:0L;WNL<VOTJ,J*E4V_
M)_D%Z_@:+>3(&:@C&5%$M9VV#<?VL^" Y:W5V Q40$^(,XF3(#85AHJZ530;
ME3R1'XI^:B(P;;_-4&3<R\TNE_I1"I8U5_0M(+!?[> N.RU6<L&9EJM#U!9T
M52EDX]U5.D$=M]54_Q-#TW?=<Q7^:X%N_;O7[ZU^^4P2S&<F;AU_<WHCUR*]
MD7/MNGK-GE!AER1Z ,RFWW$-+M8=D,Q:JTVQL%:$6/2850S<=[8K'.9G@Y-2
M]V)JAMF3[%]UQI$]//X4<^<X>XAQLN*<X7XEW3D3C ^)I3=#XC+"B2.?#)K]
M<56E<CV+.I5CRT>F0<N'/];<4U,AI RCFPWPFU[([)77F(?7G:)43P-X$:^
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M9C'&SL8J@0=V<"T&LGQD*<"\$2B>NPX$\3<[R:8PMT-<L#YAD.;\3;=*QM5
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M?J?-B9 B-&&"(08Q<,J02L1=$MSUKH^H2+<NN*_[B&O/$# TS*>TV=V(;D,
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M@L<W*,N+V#V&SC&[X,M?WJ%MDD*?<(LCE7<M)AXE51%(%+DR[7VP3&T<)68
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M7T!P!G$; K!%!2&WA60"CP+GD;0*.2L^:3 #%@B)7J >%"#B:1:F*,$P*6<
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MW-[2V[;DR]<PLFVZU T<C+\_?[+*(+OYP$/7.,ZM/WGX$^35<V9-J+OE7'2
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MY*RI[/J'L4:/\-]8L<'T;>_&DW(\*[# M* T!-5^-&,7SDZN"LH7)>BSPBR
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MM[@-/U&<Y-H1XUAC-@+H#6!GOL.O/G6F>5OIT1[O*Y!PN4(8%<;)JS8A$3%
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M_<OM[D1%;(+ V@IV[WC\5A?>K93H5M_$@!XVKO#FWA-3R+ZN)<+_2,,D0%>
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MX@:X#VC<&%/%!GL5+TOJ/PA!A&G W^8#(4B?O2(;..0M@OH/FA9DE95=C&A
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MRCK7[@Y;/F+_ZPDFG0.E[00UP4#*#GAKSK(A("UG)QYF'\[*#;,9>Z/]H*K
ME'C.>&$FGQA0$(00:+%(2[]:'SHS3!\A%37;><YZ:60<JCE/@R$*EXEF7\M3
M3'H9/RM;.UBAE;9\U$?%*FGRB(D+N62Q(L(3.F?0#KHHL\-\YF*@0@GO&\LP
MI6AQ\<9/N,BRZ]/P0/G=9>.L5N)G5.C=^MS39CGRI_<M1_[D>XY\6S*<=YSB
MC-38(L*E?G,\A[*;L-\')GQ_T/F; T_7RAQ@HNQ-VE%<U:V1.+YUCCY8\$.$
M9U\O&81IODUH"SY7,FAW9T4VZ'.YA6$R:'WX-( BNLV\2YSNU?3&I.R$0%V
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M'+E082Y19(]8%0?)J)'\S/-:,1$8&&EW_)YW85MU<=%4$^J9KSA7CC5[!%1
MWS2#."OTHGS^]  Z"MJENS/0E;*WP,32(-#;&F[%GM9O#EY708+S] SH4_BV
M^V8\7K9$"^[YN2RI9^Y.E06+Z2$O% B^"5,OI'?=$[_B>$!RB7128F037G>
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M4DXQD23W'7=>G^!\5M0]J029A#CM+/(_+CZ=L0>'=#QNY'ZC)-*5$5YKC./
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M6^%,6UP]@,OA6C@OG9ECUCW[FWVR]$5;QB$E(.,(%XLM(TUG^."B5S/X4I(
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MJ344R*EN,5R(N;5A$E+ACK5B,YCXL>)KR*.M0_3%0OGWU"#B7)#*]&R""J#
M>K:213[8MOO 6478ERCM\9]</TY"!%/M"@,$U![EEB9VI]1CQ(1>3I("I:SR
MMN#^R03R'QNOC3B%]MD-*ZFMK#/ZEY[[)C1M[R3Q NEO(3M+5*.1?$%')@MX
M5#I$C1D-@Q"JF$#U1 .Q@K;XN)-EJ1)5A1!2T1QH#9R'Q[DJ0I!,F$YF@5IY
M8>;5WX[Z_%1:3)]=9#X: B.Z&&<Q*SW]RO %M9>7V6GD=](W" 8?]A-N+S&A
MT>,DK6GN ].2DUHTT<O:U)>QS<5YIGU>'V<+C_[1YQH;S'%':6RY[]YU1I%;
MY6]T1) (MYSL*[]Z.$L9R\"5E'B3O)[X0,O:MJ( UQ-W[4BY/J1OR%@SV'HG
MS.@ S\EY.XO B3$!HZLHY9_6JE#A/)O42ZYTR/O)4@G>D32:FE?3-T(>+8M>
M2C,+=C:;-3.;DE/S:G,, /%\]^$X%_T6\HBR+72H8__F^</'Q-'F/4QJ0;<@
MP ?C684[PJWSBVI6GAJI$N-3S="GTN]L<1_1C7V$'[^$CW PD1UD:*FZP$4X
M"=_YIBKE_J6GY':$OL^?G.'90"MNB=(OBBX=(7YO"ODE:O8M_D:^W* $#G\$
MPZM-M5W8!:?A5YD*SDP@AJVEOB\N[=0,X+Q#(=Y%B/SN!B84)0#7Z;ZKGEZR
MM7O9E4;.8Q8H^9F)4U=A+OW'?'8#JRRZ!'04XIG+J'V2D9)/4[+D\HM::%IX
ML#8>AG?[1AR&EQ)=I83O@I<3!\GIEY& T;D50U!).$"Y8"SG@SHYP ROO&8=
M6J.A!U7%]?4/%4["!NKKX?!5U'=@_ FROOA,I^;=@"?%[8F_Z^;2G7"GDG(V
M74/T=,S< UEK<[HWK=+%^U8. G]B10N.VW(VS=&I,>1%01*$#TZ;[AC;E[
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MA;UN/U?'R[ZEZ(&EOD><548?V:"I N"OU7Q&B9' 2^KCBN/C<_M/K>WON_O
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MI+3DC/LOOA.@L@0F4?\!Y3RAZI/,*AE3\?^W]Z7/;2-)OM\9P?\!T;'S0HJ
MU))\M+L]T[&RCK;VV9:?I-[9B8WY !)%$FT0X "@9,Y?__*J"P=%N2U9I!P3
MTQ:)(E#(RLK*\Y<6Z,:#C'6B;_8A5"")LVVKJVPTTEL&';"O$<CJ%PZXMY"?
MQM;QBNS .C'Y65QX49O%W=JHA0:1H8MLFD#P42=RGL^,]\"EF1,BJ6!IJP9&
M<N/==U^UO;W_@G=\(0D#NVV2')_$TESVE[LO>#I-ST5;.B=OD)+%N,ULHTJ+
M#922KQY62EX)6"W(RNAS32Z>F,92-J*PK,_<P>Y+B]N!F:1R[] DI\-1&P9E
ME"+5YNC^+JMH.J.$%TQ[$ @\ZT6DY,RH"&ANQ''4VP2D+(%DYYDK<5JYQP6O
MOYS R5LVX,1;D)J<AB<#Q..H(Z%*<Q5=K6-4 U0G7="DD;NM^?&A\T/*7(F]
M=F_TIOU>[0T;=V%'I8].,LQUY0P1PBF=SV(#6Y)QOD1!D4M)XZ7GQY)-S"5/
M,(W@@E(ORG8 :>:6#=Q_/S^TEH)J=KF+$G%%A>101F8+TZNU,+5Q&MN=4;K$
M@XO1?6-=<93!2Q2F)6<MJ2V29#5J!X? LP]%TT9_NRHPF4/?/926DISMSO N
M5M,@)4A2>_H] CWWJE>X3-$>,C>YUV:B%&1Y#I^1E318B"RA6U R-R=V8PPO
MX6VNU363MBY922'98Z8ZD":'VEI2>!#=:+-B+P"2+-.DI#HY[%@LS^<4<CYJ
M,30WZ^R2,2# _UE48716A!(KB[:\2!(E%%B$L1N"Y .P'0G#ZZ9,=UG.)TG)
MDV=YV._-)HL2HPXFDPJ)1F^EO[#G.^JDD:@*&::\^R6[ P54 .6VJ)E>MSZ"
M^U[9&SD =2;D[5<7RSMVM#!%7?J7QRNN5@LV[.\]M6C#S]^C#5^3S>B_%&-
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M_[P]>W-VQ8\[O(_(9^V9#_5B1R<7" T?')^<GGTX(PS]QYTCT1XH/JTU.,<
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MM\ U B!R5@;;VB9#TTRV+%55FJYN>H=CX[04YWNP]Q=^C<)VP/:AV2EO%C7
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MI)P/[ <R$='4K:I4W*KV-P)QP#6I6'Z*O87X4II'6$P[! TZ\7XSR#/"@1C
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MA[Q0+LI*34O/2,0M$(.YZ7 PF$]-9>!@?X_8\F!__ROS<:L2P)T8'X2/VY6
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M%EI#G\I]! @#IRX/0AA^+OYG QIMD(6E]3*8-6U\1:AR(K0 =8]6A.O27.'
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MM=\OWI4,I!.EA$X9!5$<HV^"H'GR<8Z7X5]L^25WHLNA5% )$X0.3*56P'F
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M@ OV!&]+*"QP7><(!!A16HT# 3TRV A.<36QH\A?O*>S74:"BPO?)'G\I]9
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M%$KV.N;PER1VAER=P:GSL.<=R"]X\'62S[&NBY-;*%,4)98F95B3$_8+ QB
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M%"GI]\1(#C5" 7X;2G(R Q-@6 X3]=#$W\)1&'745]#\CHOH)MOV(C?VD*+
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M!WCW]W]Y\7,PVYWN\F]/J/-H1@)+HX%9<E(*$W<O?.- J6A$!G$MN^V[G=?
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MF#<ACEVK+-)]X)P.;MR"4#O4I=$-/'!1?US 91\SJA+THMKK?_"LP@'Q_7-
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MU$R)0_K-8@?+9UHH__AI]HQI9N6F@YV_C)&BLNET"4;)9^*MT,DS@'ED&JV
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M?O&$YE>4</S-[<!'I]_^2L+Q-T_9^?9S=$5LI"9-PO%P5\+QLW%EM;CW,XN
M(;J]$SX7A9M[\=[&&U^"-[7#T5U7W=7*,\I#EO$I4NP/(@A J@0"?13?&I>*
M@?WF4[T53 &><&*3>Y\D#A<IU0'%/-%!/G=6'H!=9GP$UO6!!S':=J^MNNX
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M#%WK *HE[)'(S"^34*,1_E8"U[6F16N6"<!OM?TKS5Q$(T^ALD;!CZFQF'7
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M,2YX<V102P$"% ,4    " #R.&)01.3J5/P*  #?AP  %0
M@ %P P  9VEL9"TR,#(P,#,P,5]L86(N>&UL4$L! A0#%     @ \CAB4!IW
MWKE4!P  ,%D  !4              ( !GPX  &=I;&0M,C R,# S,#%?<')E
M+GAM;%!+ 0(4 Q0    ( /(X8E"HPAMVY"4  />W   2              "
M 286  !T;3(P,3$R-3-D,E\X:RYH=&U02P$"% ,4    " #R.&)0>BR(OOE"
M 0#WE@< %0              @ $Z/   =&TR,#$Q,C4S9#)?97@R+3$N:'1M
M4$L! A0#%     @ \CAB4'P($>DQ'P  4(0  !8              ( !9G\!
M '1M,C Q,3(U,V0R7V5X.3DM,2YH=&U02P4&      8 !@", 0  RYX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2011253d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2011253d2_8k.htm">tm2011253d2_8k.htm</File>
    <File>gild-20200301.xsd</File>
    <File>gild-20200301_lab.xml</File>
    <File>gild-20200301_pre.xml</File>
    <File>tm2011253d2_ex2-1.htm</File>
    <File>tm2011253d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
